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To improve our ability to identify HSCs and their localization in vivo we 
compared the gene expression profiles of highly purified hematopoietic stem cells 
(HSCs) and non-self-renewing multipotent progenitors (MPPs).  Cell surface receptors of 
the SLAM family, including CD150 and CD48, were differentially expressed among 
functionally distinct progenitors such that HSCs were highly purified as CD150+CD48- 
cells whereas MPPs were CD150-CD48-.  The ability to purify HSCs based on a simple 
combination of SLAM receptors allowed us to identify HSCs in tissue sections.  Most 
HSCs were associated with sinusoidal endothelium in the spleen and bone marrow.  This 
raised the possibility that HSCs reside in perivascular niches.   
Our data suggesting that HSCs reside perivascularly was in contrast to studies 
which proposed that HSCs identified by the thymidine analogue bromo-deoxyuridine 
(BrdU)-label retention are associated with osteoblasts via N-cadherin-mediated 
homophilic adhesion.  We therefore tested the hypotheses that N-cadherin was important 
for HSC maintenance and that HSCs could be identified by BrdU-label retention.  We did 
not detect N-cadherin expression in HSCs by polymerase chain reaction, using anti-N-
cadherin antibodies, or by ß-galactosidase staining of N-cadherin gene-trap mice.  
Moreover, N-cadherin deficiency did not affect bone marrow cellularity, the numbers of 
colony-forming progenitors, the frequency of HSCs, the ability of HSCs to sustain 
hematopoiesis over time, or their ability to reconstitute irradiated mice.  These results 
xvi 
indicate that HSCs do not depend on N-cadherin-mediated adhesion to osteoblasts for 
their maintenance.  We tested whether HSCs might retain BrdU, either because they 
segregate chromosomes asymmetrically or because they divide slowly, by administering 
BrdU to newborn, cyclophosphamide/G-CSF mobilized, and normal adult mice for 4 to 
10 days, followed by 70-days without BrdU.  In each case, less than 6% of HSCs retained 
BrdU and less than 0.5% of BrdU-retaining hematopoietic cells were HSCs, revealing 
poor specificity and poor sensitivity as an HSC marker. Sequential administration of 
chloro-deoxyuridine (CldU) and iodo-deoxyuridine (IdU) suggested that all HSCs 
segregate their chromosomes randomly. Division of individual HSCs in culture revealed 
no asymmetric segregation of label.  HSCs therefore cannot be identified based on BrdU 














IDENTIFICATION, LOCALIZATION AND CHARACTERIZATION OF 
HEMATOPOIETIC STEM CELLS AND THEIR IN VIVO NICHE1  
 
INTRODUCTION 
Hematopoietic stem cells (HSCs) are the self-renewing, multipotent progenitors 
that give rise to all types of mature blood cells.  HSCs persist throughout life and 
dynamically regulate their numbers after injury by undergoing self-renewing divisions 
that depend upon both cell-intrinsic (Molofsky et al., 2004) and cell-extrinsic (Adams and 
Scadden, 2006) mechanisms. With respect to the cell-extrinsic mechanisms, HSCs are 
thought to reside within specialized microenvironments within hematopoietic tissues 
created by supporting cells that express membrane-bound and secreted factors that 
promote HSC maintenance (survival and self-renewal), and that regulate HSC migration, 
quiescence, and differentiation. The bone marrow is the major site of adult 
hematopoiesis, but HSCs can undergo hematopoiesis in the adult spleen and liver during 
periods of hematopoietic stress (Figure 1.1). Specialized HSC niches have long been 
hypothesized within these hematopoietic tissues (Schofield, 1978), and recent advances 
have begun to characterize the mechanisms of cell-extrinsic regulation of HSCs (Table 
1.1).  
                                                           
1 Originally published in Nature Reviews Immunology 8:290-301, April 2008 under the 
title “Uncertainty in the niches that maintain haematopoietic stem cells” with authors 
listed as MJ Kiel and SJ Morrison. 
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A major question in the field of HSC biology has been to identify the cells that are 
responsible for this cell-extrinsic regulation of HSC maintenance and that comprise the 
HSC niche.  Until recently, this question was too difficult to address adequately due to 
the technical difficulty associated with isolation of HSCs. As a result, much work in this 
regard relied on the use of markers of HSC identity that were either untested or that 
resulted in low HSC purity. This dissertation describes the use of SLAM-family members 
for the improved and simplified isolation of HSCs, the subsequent localization of HSCs 
in tissue sections in a perivascular niche in the bone marrow and spleen, and the 
examination of other previously utilized strategies to identify putative HSCs in vivo 
adjacent to osteoblasts, including N-cadherin expression and bromo-deoxyuridine 
(BrdU)-label retention.       
In the past, many different techniques have been employed to isolate cells with 
the ability to reconstitute the hematopoietic compartment of lethally irradiated recipient 
mice in all lineages for long periods of time (HSCs). These techniques have included 
density separation, differential dye efflux ability and analysis of expression of surface 
antigens by antibody staining. Use of antibodies recognizing surface markers expressed 
only on mature hematopoietic cells provided an effective initial depletion strategy to 
enrich for HSC activity. The use of additional antibodies recognizing HSCs and other 
progenitors, such as Sca-1 and c-kit, or progenitors and not HSCs, such as Flk-2, further 
improved HSC isolation strategies. Other more specific positive markers of HSCs were 
also identified, including CD201 (Balazs et al., 2006) and Endoglin (Chen et al., 2003; 
Chen et al., 2002). Nevertheless, the purification of HSCs still required the use of a 
complex combination of antibodies against these markers and considerable technical 
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expertise to recognize the different immunophenotypic populations.  Importantly, in 
order to localize HSC niches in tissue sections, a simplified strategy was required that 
would be amenable to immunohistochemical analysis without compromising the purity of 
the target population.   
Some of the early attempts to identify the HSC niche localized putative HSCs 
near osteoblasts in the bone marrow. A number of these studies reported that enriched 
populations of HSCs preferentially home to areas of bone marrow that are close to the 
endosteum after being injected into irradiated or non-irradiated mice. It is difficult to 
interpret the results of some of these experiments because the transplanted cells were 
enriched using markers that give low HSC purity, and it remains uncertain whether the 
cells that localized close to the endosteum were HSCs or were other cells. In other cases, 
relatively highly enriched HSCs were infused, and approximately 60% of the cells found 
in bone-marrow sections fifteen hours after infusion were within twelve cell diameters of 
the endosteum (Nilsson et al., 2001a). This supports the idea that HSCs are more likely 
than other bone marrow cells to localize near the endosteal surface. Nonetheless, a 
variety of distinct microenvironments are located within 12 cell diameters of the bone. 
This is particularly true in trabecular bone, where a high proportion of HSCs appear to 
localize (Calvi et al., 2003; Kiel et al., 2005; Zhang et al., 2003) and where many cells 
are close to a bone surface. These results raise the question of whether the endosteal 
surface is itself a niche, or whether endosteal cells instead contribute to the formation of 
niches that are close to, but not at, the endosteal surface. 
One widely discussed current model proposes that HSCs adhere to the surface of 
osteoblasts using N-cadherin-mediated homotypic adhesion and that HSCs are acutely 
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dependent upon this interaction for their maintenance. This inference was based on the 
observation of N-cadherin+ cells at the endosteum that express some HSC markers 
(Wilson et al., 2004; Zhang et al., 2003). However, these studies did not test whether the 
N-cadherin expressing cells had HSC activity or whether N-cadherin was necessary for 
HSC maintenance. As described in Chapter 3 of this dissertation, we have been unable to 
detect N-cadherin expression by cells with HSC activity (Kiel et al., 2007) and have been 
unable to detect any defect in hematopoiesis or HSC function due to loss of N-cadherin in 
hematopoietic cells.   
Similarly, BrdU-label retention assays were postulated to identify HSCs because 
of their relative quiescence as compared to other bone marrow cells.  These assays are 
carried out by administering a short pulse of BrdU to label dividing cells, then removing 
BrdU for a longer chase period to allow cells that are actively dividing to dilute out the 
label through subsequent divisions in the absence of BrdU.  The fraction of cells that 
remains BrdU+ for long chase periods is believed to be enriched for HSCs.  
Using these strategies, previous attempts to localize putative HSCs in tissue 
sections identified a subset of cells in the bone marrow that was distinguished by both N-
cadherin expression and long-term BrdU-label retention adjacent to osteoblasts at the 
endosteum.  Despite the fact that neither the specificity nor the sensitivity of these 
techniques was addressed, these N-cadherin+ BrdU-label retaining cells were postulated 
to be HSCs that reside in direct contact with osteoblasts. 
 For these reasons, many HSCs are believed to reside at, or near, the endosteum in 
the bone marrow.  Endosteal cells are known to secrete factors that promote HSC 
maintenance (Adams and Scadden, 2006; Li and Xie, 2005; Suda et al., 2005). Therefore, 
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the endosteum has an important role in promoting HSC maintenance and regulating HSC 
function. However, other bone marrow cells probably also play important roles in the 
creation of HSC niches.  For instance, many HSCs are now known to reside adjacent to 
sinusoidal blood vessels in the bone marrow (Kiel et al., 2007; Kiel et al., 2005), and 
perivascular cells also secrete factors that regulate HSC maintenance (Sacchetti et al., 
2007; Sugiyama et al., 2006).   
Herein I present evidence suggesting the existence of perivascular niches and 
challenge some of the evidence suggesting the existence of osteoblastic niches. Later I 
will consider the evidence for the involvement of diverse cell types, hematopoietic 
microenvironments, and growth factors in the regulation of HSC maintenance, and finally 
will consider the diverse models of HSC niches that are consistent with currently 
available evidence. 
 
ENDOSTEAL CELLS CONTRIBUTE TO THE MAINTENANCE OF HSCs 
Much of the work pertaining to the characterization of environmental mechanisms 
that regulate HSC maintenance has been focused on the role of the bone-marrow 
endosteum. The endosteum is the inner surface of the bone at the interface of bone and 
bone marrow (Figure 1.1A). The endosteal surface is covered by a protective layer of 
bone-lining cells that can differentiate into bone-forming osteoblasts, but is also marked 
by the presence of bone-resorbing osteoclasts. Osteoblasts and osteoclasts are present in 
dynamic equilibrium under steady-state conditions but can increase or decrease in 
frequency depending on whether new bone is forming or being remodelled (Franz-
Odendaal et al., 2006; Seeman and Delmas, 2006). The endosteal surface interfaces with 
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haematopoietic progenitors in the marrow as well as with a rich supply of arterial blood 
that passes through the endosteum to nourish the bone (De Bruyn et al., 1970). It is likely 
that the interaction of bone cells, haematopoietic cells, and vascular cells at the 
endosteum regulates both haematopoiesis and bone formation. 
The endosteum has long been viewed as having a role in the regulation of 
primitive haematopoietic progenitors. Beginning in the 1970s, it was reported that 
progenitors that can form multilineage colonies in the spleens of irradiated mice (colony-
forming unit-spleen; CFU-S), which were initially regarded as HSCs but which were later 
found to be mainly transiently reconstituting multipotent progenitors (Morrison and 
Weissman, 1994; Spangrude et al., 1995; Wolf et al., 1993), are more enriched near the 
endosteum than within the central bone marrow (Lord et al., 1975). At least some of these 
CFU-S were thought to reside at the endosteal surface (Gong, 1978), though other studies 
questioned this conclusion and observed CFU-S throughout the bone marrow (Maloney 
et al., 1978). Complicating matters further, the CFU-S near the endosteum were more 
rapidly dividing than CFU-S in the central bone marrow (Lord et al., 1975), suggesting 
that the cells near the endosteum might not be quiescent HSCs. Although the implications 
of these observations for HSC localization are uncertain, these studies made the general 
point that primitive haematopoietic progenitors tend to be enriched near the endosteum. 
Important recent studies have shown that factors that regulate HSC maintenance 
are secreted by cells at the endosteum. Genetic manipulations that increase osteoblast 
numbers and trabecular bone in mice also increase the number of HSCs in bone marrow 
(Calvi et al., 2003; Zhang et al., 2003).  Osteoblasts express factors that appear to 
regulate the maintenance or the numbers of HSCs in the bone marrow, including positive 
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regulators such as angiopoietin (Arai et al., 2004) and negative regulators such as 
osteopontin (Nilsson et al., 2005; Stier et al., 2005). Coupled with evidence that at least 
some HSCs reside at or near the endosteum (Arai et al., 2004; Kiel et al., 2007; Kiel et 
al., 2005; Nilsson et al., 2001b; Suzuki et al., 2006; Zhang et al., 2003), these data 
suggest the existence of an endosteal niche for HSCs. Very specific models of this 
endosteal niche have been widely discussed in the literature, though currently available 
data remain compatible with a variety of ways in which endosteal cells could promote 
HSC maintenance (Figure 1.2). 
In addition to N-cadherin, osteoblasts have also been proposed to promote HSC 
maintenance by expressing Jagged, thereby activating Notch expressed by HSCs 
adhering to osteoblasts (Calvi et al., 2003). Notch activation by Jagged does promote 
HSC maintenance in culture (Calvi et al., 2003). However, conditional deletion of both 
Jagged1 and Notch1 from bone marrow cells did not affect HSC maintenance in vivo 
(Mancini et al., 2005). It remains possible that HSCs require Notch signaling under 
certain circumstances but Notch activation does not appear to be a crucial general 
component of the niche. Additionally, we have determined that HSCs do not depend on 
N-cadherin expression for their maintenance based on conditional deletion of N-cadherin 
in HSCs. Nevertheless, if N-cadherin and Notch ligands are not required for HSC 
maintenance, it is possible that endosteal cells promote HSC maintenance by secreting 
diffusible factors that act indirectly or at a distance (Figure 1.2). Additional work will be 
required to determine whether a subset of HSCs adheres to the surface of osteoblasts by 
other mechanisms or whether endosteal cells mainly secrete factors that act on HSCs 
nearby, but not at, the endosteum. 
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Osteoblasts are capable of supporting the maintenance of primitive 
haematopoietic progenitors in culture (Taichman and Emerson, 1994), but it remains 
unclear whether osteoblasts are acutely required for HSC maintenance in vivo. This has 
been tested by ablating osteoblasts from adult Col1a1-TK mice (Visnjic et al., 2004; Zhu 
et al., 2007). These authors did not observe an acute loss of HSCs. Rather they observed 
an acute loss of differentiating cells, particularly B-lineage progenitors, followed by a 
delayed depletion of c-kit+lineage-Sca-1+ cells, which are enriched for HSCs. In fact, the 
frequency of c-kit+lineage-Sca-1+ cells in bone marrow actually increased over time 
after osteoblast ablation (although absolute numbers of such cells declined), whereas B-
lineage progenitors and other differentiating cells were severely depleted in frequency 
and absolute number within days of osteoblast ablation (Visnjic et al., 2004; Zhu et al., 
2007). This suggests that some types of restricted progenitors and differentiating cells 
depend more acutely on osteoblasts than HSCs do. This raises the question of whether 
HSCs were slowly lost as a direct consequence of osteoblast ablation or whether HSCs 
were ultimately depleted as a secondary consequence of the loss of other bone-marrow 
cells. 
Apart from the potential role of non-endosteal bone-marrow cells in the regulation 
of HSCs, even the role of the endosteum itself is likely to be complex (Figure 1.3). 
Osteoclast activity (Kollet et al., 2006) and the calcium ions that are generated by bone 
resorption (Adams et al., 2006) have also been implicated in HSC maintenance and 
localization. Osteoclasts secrete proteases such as matrix metalloproteinase-9 (MMP9) 
and cathepsin K as well as growth factors such as CXCL12 (Kollet et al., 2006) that 
regulate HSC maintenance and localization within the bone marrow (Ara et al., 2003; 
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Peled et al., 1999; Sugiyama et al., 2006; Zou et al., 1998). The proteases are required for 
bone remodeling as well as to release membrane-bound growth factors, such as steel 
factor, that also regulate HSC frequency and localization in the bone marrow (Heissig et 
al., 2002; Kollet et al., 2006). One interpretation of the late disappearance of HSCs from 
the endosteum after osteoblast ablation (Visnjic et al., 2004; Zhu et al., 2007) is that the 
ongoing ability of osteoclasts to resorb bone, to secrete growth factors, and to 
enzymatically enhance the release of growth factors synthesized by other cells, may have 
sustained HSCs for a considerable period of time in the absence of osteoblasts, though 
this remains to be tested. 
 
THE EVOLUTIONARILY CONSERVED ROLE OF VASCULAR CELLS IN HSC 
MAINTENANCE 
 
The vasculature has a crucial role in the formation and expansion of HSCs during 
embryonic development, and probably in the regulation of adult HSCs. Indeed, there are 
vertebrate species in which haematopoiesis never occurs in association with bone. In 
zebrafish, for example, haematopoietic progenitors arise in close association with the 
dorsal aorta and ultimately establish haematopoiesis in the kidney and thymus 
(Murayama et al., 2006). Evolutionarily, bone marrow was first used as a site of 
haematopoiesis in certain amphibian species (Zon, 1995). 
Even in mammals, the ability of HSCs to self-renew and differentiate during fetal 
development, prior to the creation of bone marrow cavities, suggests that HSCs arise and 
are maintained in vascular niches prior to birth. There is a close developmental 
relationship between the haematopoietic and endothelial lineages (Huber et al., 2004; 
Kennedy et al., 1997), and HSCs appear to arise from a perivascular progenitor during 
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embryonic development (Cumano et al., 1996; de Bruijn et al., 2002; Medvinsky and 
Dzierzak, 1996; Mikkola and Orkin, 2006; North et al., 2002; Sanchez et al., 1996). In 
addition to these data demonstrating the presence of perivascular HSCs in the yolk sac, 
aorta-gonad-mesonephros region, and vitelline arteries, HSCs also reside and undergo 
haematopoiesis in association with blood vessels in the placenta (Gekas et al., 2005; 
Ottersbach and Dzierzak, 2005). Since there is no bone or endosteum in any of these 
tissues, the data suggest that HSCs probably reside primarily in perivascular niches 
during embryonic and fetal development. Nonetheless, these niches remain to be 
characterized and could depend on critical contributions by non-vascular cells.  
Furthermore, these niches only transiently contain HSCs raising the possibility that the 
existence of supportive niches in these tissues is only transient or that HSCs are induced 
to migrate from these tissues by signals from subsequent sites of hematopoiesis such as 
the liver and bone marrow.  
 
THE CONTRIBUTION OF THE VASCULATURE TO THE MAINTENANCE OF 
ADULT HSCS 
 
Vascular cells likely contribute to the creation of HSC niches in extramedullary 
tissues. HSCs are present throughout adult life in extramedullary tissues, such as the liver 
and spleen (Taniguchi et al., 1996), and extramedullary haematopoiesis can flourish in 
these tissues for long periods of time despite the absence of bone or endosteum (Johnson 
et al., 1992; Yang et al., 1995). This implies that there are cells other than osteoblasts that 
can create environments that sustain adult HSCs. As described in Chapter 2, most HSCs 
mobilized to the adult spleen localized adjacent to sinusoids (Kiel et al., 2005), 
suggesting that HSCs in extramedullary tissues may reside within perivascular niches. 
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Sinusoids are specialized blood vessels that are present only in haematopoietic tissues 
and that carry venous circulation. The walls of sinusoids are fenestrated endothelium 
through which haematopoietic cells can enter and exit the circulation. The case for 
extramedullary vascular niches remains circumstantial as we are not aware of any data 
that directly demonstrate that perivascular cells in extramedullary tissues can promote the 
maintenance of HSCs. 
As described in Chapters 2 and 3, many HSCs in adult bone marrow can also be 
found around sinusoids. When the localization of HSCs in bone marrow was examined 
using SLAM-family markers about 60% of bone-marrow HSCs were adjacent to 
sinusoids and up to 20% of HSCs localized to the endosteum (Kiel et al., 2007; Kiel et 
al., 2005). The remaining HSCs were scattered throughout the bone marrow, and were 
not located adjacent to sinusoids or endosteum. HSCs were thus significantly more likely 
than other bone marrow cells to localize to sinusoids or the endosteal surface, consistent 
with the idea that there might be niches in these locations (Kiel et al., 2007). Virtually all 
HSCs were within 5 cell diameters of a sinusoid in the bone marrow (Kiel et al., 2007), 
raising the possibility that even the HSCs that are near the endosteum may be influenced 
by perivascular cells. 
The observation that substantial numbers of HSCs localize to sinusoids in the 
bone marrow makes sense, given that HSCs can be mobilized within minutes of 
administering interleukin (IL)-8 to mice (Laterveer et al., 1995). Furthermore, HSCs 
deficient for Rac1 and Rac2 (genes that encode proteins that control cell migration) are 
highly defective in their ability to migrate and yet conditional deletion of Rac1 and Rac2 
from adult haematopoietic cells (Gu et al., 2003) or administration of a RAC inhibitor 
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leads to the mobilization of HSCs into circulation within hours (Cancelas et al., 2005). 
This rapid mobilization of HSCs that lack the ability to migrate normally supports the 
idea that significant numbers of HSCs are present on sinusoids, poised to enter the 
circulation. All of these data raise the question of whether endothelial cells or other 
perivascular cells actually create a perivascular niche that helps to maintain HSCs (Kiel 
et al., 2005; Kopp et al., 2005) (Figure 1.4A,C) or whether HSCs transiently migrate 
through perivascular sites on their way in and out of circulation (Wright et al., 2001) 
(Figure 1.4B). 
Similar to osteoblasts, endothelial cells can promote the maintenance of HSCs in 
culture (Li et al., 2004; Ohneda et al., 1998) and normal endothelial cell function is 
required for haematopoiesis in vivo (Yao et al., 2005). When the gene encoding the 
common cytokine receptor subunit, GP130, was conditionally deleted from endothelial 
cells, the postnatal bone marrow became hypocellular, mice became anemic by 
adulthood, and died by 1 year of age (Yao et al., 2005). In this study, a floxed allele of 
GP130 was conditionally deleted using Tie2-Cre, a transgene in which Cre-recombinase 
is expressed in HSCs and in endothelial cells (Koni et al., 2001), making it possible to 
conditionally delete floxed genes from these cell types. The authors reported that 
cellularity around sinusoids in the bone marrow markedly declined, whereas cellularity at 
the endosteum remained normal. The defects were not attributable to a loss of GP130 in 
HSCs as GP130-deficient bone-marrow cells were able to reconstitute irradiated wild-
type recipients, but wild-type bone marrow cells remained unable to reconstitute GP130-
deficient mice. These data provide strong genetic evidence of the importance of 
endothelial cells to haematopoiesis in vivo, though it remains unclear from these data 
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whether endothelial cells are required for the maintenance of HSCs or just for their 
differentiation, and whether the endothelial cells act directly or indirectly on HSCs. 
Similar to the endosteum, the perivascular environment also contains multiple cell 
types that may regulate HSCs (Figure 1.3B). Sugiyama and colleagues found that 
perivascular reticular cells in bone marrow express very high levels of CXCL12, a factor 
required for the maintenance of HSCs (Sugiyama et al., 2006). They also confirmed that 
a high proportion of HSCs localize perivascularly, and that the subset of HSCs that 
localizes to the endosteum or elsewhere is also consistently in contact with CXCL12-
expressing reticular cells. The presence of CXCL12-secreting reticular cells in both the 
perivascular and endosteal environments provides a potential unifying mechanism for the 
maintenance of HSCs in both sites, and reminds us that the most morphologically 
recognizable cell types in a particular environment (such as osteoblasts and endothelial 
cells) need not be the cells that are most functionally important for the creation of a 
niche. Nonetheless, there are no genetic data confirming that these reticular cells are a 
more functionally important source of CXCL12 for the maintenance of HSCs than 
osteoblasts or osteoclasts, so the argument that they create a niche for HSCs is not yet 
conclusive. Indeed, endothelial cells themselves internalize circulating CXCL12 and 
resecrete it into the bone marrow (Dar et al., 2005), raising the possibility that endothelial 
cells could also be an important source of CXCL12 for HSCs. 
Taken together, these data highlight the potential complexity of the cell types and 
factors responsible for the cell-extrinsic regulation of HSCs.  Both perivascular cells and 
endosteal cells are likely to be important contributors to the extrinsic regulation of HSCs. 
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Table 1.1: Cell-extrinsic factors genetically necessary for normal HSC maintenance 
in vivo. 
 
Factor Genetic evidence for regulation of HSCs in vivo 
Angiopoietin 
(Ang-1) 
Combined loss of Tie2 (the receptor for Ang-1) as well as Tie1, leads 
to defects in postnatal HSCs (Puri and Bernstein, 2003).  Ang-1 
appears to promote the maintenance of quiescent HSCs (Arai et al., 
2004) 
Calcium ions Deletion of the calcium sensing receptor leads to reduced bone 
marrow cellularity and HSC content with increased progenitor cell 
mobilization into the circulation and spleen (Adams et al., 2006) 
CXCL12  Mice deficient in the chemokine CXCL12 or its receptor CXCR4 
show disrupted colonization of the bone marrow while conditional 
deletion of CXCL4 in adult mice leads to reductions in HSC number 
in the bone marrow and reduced HSC activity upon transplantation 
(Ara et al., 2003; Nagasawa et al., 1996; Sugiyama et al., 2006; Zou et 
al., 1998) 
Hedgehog (Hh) Patched (the Hh receptor) heterozygous HSCs have reduced long-term 
reconstituting activity, suggesting that a member of the Hh family of 
ligands can negatively regulate HSC self-renewal, at least when the 
pathway is over-activated (Trowbridge et al., 2006) 
Osteopontin 
(OPN) 
The matrix glycoprotein OPN is expressed at the endosteum by bone-
lining cells and negatively regulates HSC numbers. OPN deficient 
mice have moderately increased HSC numbers in the marrow (Nilsson 
et al., 2005; Stier et al., 2005) 
Stem cell factor 
(SCF, Sl, Steel 
Factor) 
Mice with mutations in SCF (Sl/Sld, steel-Dickie mutants) or in its 
receptor c-kit (W/Wv, dominant spotting mutants) have fewer HSCs 
and exhibit less HSC function (Barker, 1994; McCarthy et al., 1977) 
Thrombopoietin 
(Tpo) 
Tpo is synthesized in the liver and is transported into the bone marrow 
through the blood.  Mice deficient in Tpo or the Tpo receptor c-Mpl 
have profound reductions in HSC numbers (Kaushansky, 2003; Solar 
et al., 1998) 
 
In addition to these factors that are genetically necessary for the maintenance of normal 
numbers of HSCs in the bone marrow, there are additional factors that are likely to 
regulate to regulate HSC maintenance based on over-expression experiments or 
experiments performed in culture, but which have not yet been fully tested for necessity 
in vivo.  









Figure 1.1: Anatomy of the adult haematopoietic organs, bone marrow and spleen.  
A) Haematopoietic stem cells (HSCs) reside primarily within bone marrow during 
adulthood. Bone marrow is a complex organ containing many different haematopoietic 
and non-haematopoietic cell types. Haematopoiesis occurs within the medullary cavity, 
surrounded by a shell of vascularized and innervated cancellous bone. Minute projections 
of bone (trabeculae) are found throughout the trabecular zone of bone, such that many 
cells in this region are close to bone surface. The interface of bone and bone marrow is 
known as the endosteum, which is covered by bone-lining cells that can differentiate into 
bone-forming osteoblasts. Bone-resorbing osteoclasts are also present at the endosteum. 
Arteries carry oxygen, nutrients, and haematopoietic growth factors such as 
thrombopoietin (Kaushansky and Drachman, 2002; Wolber and Jelkmann, 2002) into the 
bone marrow, before feeding into capillaries and then sinusoids, which coalesce to form 
the venous circulation. Sinusoids are specialized venuoles that form a reticular network 
of fenestrated vessels that allow cells to pass in and out of circulation.  B) HSCs can 
also be found at low levels in extramedullary tissues like the spleen (shown) and liver 
throughout adult life. When bone marrow haematopoiesis is impaired by age, cancer, or 
myeloablation, expanded numbers of HSCs can engage in extramedullary haematopoiesis 
in the spleen. HSCs reside around sinusoids in the red pulp of the spleen (Kiel et al., 
2005), but not within the white pulp, which contains lymphocytes and antigen-presenting 
cells. 
      
























Figure 1.2: Possible mechanisms by which endosteal cells contribute to the 
formation of HSC niches.  Genetic manipulations that increase osteoblast numbers also 
increase haematopoietic stem cell (HSC) numbers (Calvi et al., 2003; Zhang et al., 2003), 
and endosteal cells release a variety of factors that are thought to regulate HSC 
maintenance and localization (Adams et al., 2006; Adams and Scadden, 2006; Arai et al., 
2004; Kollet et al., 2006). Existing data are compatible with a variety of ways in which 
endosteal cells could contribute to HSC niches:  A) One possibility is that the 
endosteum itself is a niche, with HSCs that reside in direct contact with osteoblasts 
(Adams and Scadden, 2006; Li and Xie, 2005; Suda et al., 2005). This possibility has 
been favoured based on the idea that HSCs are regulated by N-cadherin and Notch 
signals from osteoblasts, though more recent studies have questioned whether N-cadherin 
(Kiel et al., 2007) or Notch (Mancini et al., 2005) regulate HSC maintenance under 
steady-state conditions.  B) An alternative possibility is that factors secreted from 
endosteal cells diffuse, or are actively transported, to regulate HSC niches that are close 
to, but not at, the endosteum.  C) A third possibility is that endosteal cells promote HSC 
maintenance by regulating the function of third-party (or intermediate) cells that in turn 
create HSC niches away from the endosteum. For example, osteoblasts are known to 
regulate the recruitment of vasculature to bone marrow (Street et al., 2002; Tombran-
Tink and Barnstable, 2004). 


























Figure 1.3: Many different cell types may contribute to formation of HSC niches 
near the endosteum and around sinusoids.  A) Osteoblasts and osteoclasts secrete a 
variety of factors that have been implicated in the regulation of haematopoietic stem cells 
(HSCs) (Adams and Scadden, 2006; Kollet et al., 2006). Furthermore, bone remodelling 
by these cell types elevates the concentration of calcium ions locally and in circulation, 
influencing HSC localization and maintenance through the calcium-sensing receptor 
(Adams et al., 2006). Sympathetic-nervous-system activity also regulates HSC 
localization in the bone marrow, perhaps by innervating the endosteum (Katayama et al., 
2006). The endosteal surface is also heavily vascularized by arteries that nourish bone in 
some locations and by the pervasive presence of sinusoids. Vascular and perivascular 
cells might contribute to the formation of HSC niches at or near the endosteum (Ara et 
al., 2003; Sugiyama et al., 2006). As yet unidentified cells could also contribute to these 
niches.  B) Perivascular sites are likely to maintain fetal HSCs in placenta, spleen, and 
liver. During adulthood, the presence of HSCs around sinusoids throughout 
haematopoietic tissues (Kiel et al., 2005), the ability of endothelial cells to promote HSC 
maintenance in culture (Li et al., 2004; Ohneda et al., 1998), and the secretion of HSC 
regulatory factors by perivascular reticular cells and mesenchymal progenitors (Li et al., 
2001; Sacchetti et al., 2007; Sugiyama et al., 2006), raises the possibility of perivascular 
niches for HSCs (Kopp et al., 2005) in the bone marrow and in extramedullary tissues 
such as the spleen. If such niches exist, a wide variety of perivascular cells could 
conceivably contribute to such niches, including endothelial cells, megakaryocytes, 
perivascular reticular cells, mesenchymal progenitors, and other cell types. 
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Figure 1.4: Possible reasons for the observation of HSCs in perivascular sites.  
When the localization of HSCs (blue) is systematically examined using validated markers 
in bone marrow and in extramedullary tissues, many HSCs are found adjacent to 
sinusoids (Kiel et al., 2005). Possible reasons for perisinusoidal localization include:  A) 
HSCs may reside in perivascular niches (Kopp et al., 2005; Sugiyama et al., 2006).  B) 
HSCs may reside in endosteal niches but their frequent migration through circulation 
(Wright et al., 2001) means that they are often observed in perivascular sites on their way 
in or out of the circulation.  C) HSCs may reside in spatially distinct endosteal and 
perivascular niches, that are either functionally redundant or that have different roles in 
the regulation of HSCs. 
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CHAPTER 2 
DIFFERENTIAL EXPRESSION OF SLAM FAMILY MEMBERS 
DISTINGUISHES STEM AND PROGENITOR CELLS IN THE 




To improve our ability to identify HSCs and their localization in vivo we 
compared the gene expression profiles of highly purified hematopoietic stem cells 
(HSCs) and non-self-renewing multipotent hematopoietic progenitors (MPPs).  Cell 
surface receptors of the SLAM family, including CD150, CD244, and CD48, were 
differentially expressed among functionally distinct progenitors.  HSCs were highly 
purified as CD150+CD244-CD48- cells while MPPs were CD244+CD150-CD48- and 
most restricted progenitors were CD48+CD244+CD150-. The primitiveness of 
hematopoietic progenitors could thus be predicted based on the combination of SLAM 
family members they expressed. This is the first family of receptors whose combinatorial 
expression precisely distinguishes stem and progenitor cells.  The ability to purify HSCs 
based on a simple combination of SLAM receptors allowed us to identify HSCs in tissue 
sections. Many HSCs were associated with sinusoidal endothelium in spleen and bone 
                                                
1 Originally published in Cell 121:1109-21, July 2005 with authors listed as MJ Kiel, OH 
Yilmaz, T Iwashita, OH Yilmaz, C Terhorst and SJ Morrison. 
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marrow, though some HSCs were associated with endosteum. HSCs thus occupy multiple 
niches, including sinusoidal endothelium in diverse tissues. 
 
INTRODUCTION 
Two central and related questions in stem cell biology involve the identification 
of markers that distinguish stem cells from other progenitors, and the identification of 
microenvironments (‘niches’) in which stem cells reside (Morrison et al., 1997a; 
Spradling et al., 2001).  These issues have been studied extensively in the hematopoietic 
system (Hackney et al., 2002; Ivanova et al., 2002; Lemischka, 1997; Phillips et al., 
2000; Ramalho-Santos et al., 2002), but our inability to rigorously identify HSCs using 
simple combinations of markers has compromised our ability to study HSC 
microenvironments in vivo. 
The locations and identities of differentiated cells are often defined by the 
differential expression of individual families of cell surface receptors.  The locations and 
identities of olfactory sensory neurons and chemosensory neurons are distinguished by 
their differential expression of olfactory receptors (Buck and Axel, 1991), and Mrg 
family receptors (Dong et al., 2001) respectively.  Although the gene expression profiles 
of multiple stem cell populations have been described (Easterday et al., 2003; Evsikov 
and Solter, 2003; Fortunel et al., 2003; Ivanova et al., 2002; Iwashita et al., 2003; 
Ramalho-Santos et al., 2002), no single family of cell surface receptors has yet been 
found in which members are differentially expressed in a way that correlates with 
primitiveness or developmental potential. 
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In the absence of simple combinations of markers that reliably purify HSCs, it has 
been necessary to use complex combinations of markers.  HSCs have been highly 
enriched as Thy-1loSca-1+Lineage-c-kit+ cells or CD34-Sca-1+Lineage-c-kit+ cells 
using combinations of 10 to 12 surface markers (Morrison and Weissman, 1994; Osawa 
et al., 1996; Spangrude et al., 1988).  But even using these complicated sets of markers, 
only 20% of intravenously injected cells gave long-term multilineage reconstitution in 
most studies (Morrison et al., 1995; Osawa et al., 1996; Spangrude et al., 1995; Wagers et 
al., 2002). By gating more restrictively on existing HSC markers, or by combining these 
with Hoechst exclusion, nearly homogeneous subsets of bone marrow HSCs have been 
isolated (Matsuzaki et al., 2004; Takano et al., 2004; Uchida et al., 2003) but these 
markers remain too complex for the identification of HSCs in tissue sections. 
Studies of various transgenic mice have demonstrated the functional importance 
of osteoblasts in regulating bone marrow HSCs (Calvi et al., 2003; Visnjic et al., 2004; 
Zhang et al., 2003).   Immunofluorescence studies with markers of primitive 
hematopoietic progenitors have suggested that HSCs interact with osteoblasts at the 
endosteum of bone marrow (Arai et al., 2004; Wilson et al., 2004; Zhang et al., 2003).  
However, not all HSCs can be associated with osteoblasts. The ability of cytokines to 
mobilize HSCs into circulation within minutes (Laterveer et al., 1995) has suggested that 
a subset of HSCs must be closely associated with blood vessels in the bone marrow 
(Heissig et al., 2002). Moreover, there are no osteoblasts in sites of extramedullary 
hematopoiesis, like the liver and spleen, where HSCs are maintained throughout adult life 
(Taniguchi et al., 1996). These observations indicate that the endosteum/osteoblast 
microenvironment is unlikely to be the sole supportive niche for HSCs.  
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Endothelial cells also regulate HSC function and could contribute to the creation 
of HSC niches. Endothelial cells are capable of maintaining HSCs in culture (Cardier and 
Barbera-Guillem, 1997; Li et al., 2004; Ohneda et al., 1998), and ablation of endothelial 
cells in vivo by administration of anti-VE-cadherin antibody leads to hematopoietic 
failure (Avecilla et al., 2004). Endothelial cells also create stem cell niches in other 
tissues such as the nervous system (Capela and Temple, 2002; Louissaint et al., 2002; 
Palmer et al., 2000; Shen et al., 2004).  Simple combinations of markers that identify 
HSCs with high reliability would make it possible to test whether HSCs interact with 
endothelial cells in vivo. 
We have found that SLAM family receptors are differentially expressed among 
hematopoietic progenitors in a way that correlates with progenitor primitiveness. The 
SLAM family is a group of 10 to 11 cell surface receptors that are tandemly arrayed at a 
single locus on chromosome 1 (Engel et al., 2003; Sidorenko and Clark, 2003). SLAM 
family members regulate the proliferation and activation of lymphocytes (Howie et al., 
2002; Wang et al., 2004) but were not known to be expressed by hematopoietic 
progenitors.  Our ability to purify HSCs using simple combinations of SLAM family 
members made it possible to image HSCs in tissue sections using markers that had been 
validated as yielding high HSC purity in functional assays.  Many HSCs within the bone 
marrow and spleen were associated with sinusoidal endothelium.  This indicates that 
HSC niches are heterogeneous and reveals the importance of sinusoidal endothelial cells 





The purity of cells used for gene expression profiling 
To identify genes that are tightly associated with HSC identity we have compared 
the gene expression profiles of highly enriched populations of HSCs and transiently 
reconstituting multipotent progenitors (MPPs) (Morrison et al., 1997b; Morrison and 
Weissman, 1994). HSCs were isolated as Thy-1loSca-1+Lineage-c-kit+ cells. One out of 
every 4.9±2.5 (20%) intravenously injected Thy-1loSca-1+Lineage-c-kit+ cells long-term 
multilineage reconstituted irradiated mice in limit dilution competitive reconstitution 
assays (Table 2.3). 
Thy-1loSca-1+Lineage-c-kit+ HSCs give rise to non-self-renewing Thy-1loSca-
1+Mac-1loCD4lo MPPs in vivo (Morrison et al., 1997b). We have enhanced the purity of 
this cell population by further selecting the B220- subset of Thy-1loSca-1+Mac-
1loCD4lo cells (Table 2.4). 1 out of every 4.0 intravenously injected Thy-1loSca-1+Mac-
1loCD4loB220- cells (25%) reconstituted irradiated mice in competitive reconstitution 
assays, usually giving transient multilineage reconstitution (Table 2.4). Thy-1loSca-
1+Mac-1loCD4loB220- cells are more highly enriched for MPPs than any previously 
characterized cell population. 
 
Genes that are tightly linked to HSC identity 
 We isolated 3 independent 5,000 cell aliquots of HSCs or MPPs or 8,000 CD45+ 
bone marrow cells (which include nearly all hematopoietic cells; more of these cells were 
used because they have a lower RNA content), and independently extracted and 
amplified RNA from each aliquot for gene expression profiling (Iwashita et al., 2003).  
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The gene expression profiles were compared using Affymetrix oligonucleotide arrays 
(Table 2.5). Variability was low among samples of the same type: Pearson correlation 
coefficient, R2=0.988 to 0.991 for untransformed data (Table 2.5).  However, the 
variability between samples of different types (HSC versus MPP, R2=0.798±0.024; HSC 
versus CD45+, R2=0.558±0.009) was significantly higher (P<0.0005). Transcript 
expression was detected (present calls) at 46% of probe sets for HSCs, 46% of probe sets 
for MPPs, and 41% of probe sets for CD45+ cells. 
We identified genes for which signal intensities were at least 3-fold higher in 
HSCs, the difference was statistically significant (P<0.05), and signals were significantly 
above background in at least one HSC sample (non-zero present call).  We identified 
1151 probe sets that satisfied these criteria for being upregulated in HSCs as compared to 
CD45+ cells, and 46 probe sets in HSCs as compared to MPPs (out of 36,701 probe sets 
total).  Twenty-seven of these 46 probe sets were expressed at higher levels in HSCs as 
compared to both MPPs and CD45+ cells (Table 2.1).  To further evaluate these genes, 
we compared their expression by quantitative (real-time) RT-PCR in at least two 
independent samples of HSCs, MPPs, and whole bone marrow cells.  Of the 25 genes 
against which qPCR primers could be designed, all were confirmed as being expressed at 
>1.9-fold higher levels in HSCs as compared to MPPs and CD45+ cells (Table 2.1). 
 
CD150 (SLAM) is expressed by HSCs but not by MPPs 
One of these genes encodes the homotypic cell surface receptor CD150 (SLAM), 
which was not previously identified as being expressed in stem cells or other 
hematopoietic progenitors. CD150 is the founding member of the SLAM family of cell 
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surface receptors (Engel et al., 2003; Sidorenko and Clark, 2003).  CD150 appeared to be 
4 to 17-fold upregulated in HSCs as compared to MPPs and CD45+ bone marrow cells 
by microarray analysis and qPCR (Table 2.1). Only 6.6±1.7% of whole bone marrow 
cells were CD150+ by flow-cytometry (Figure 2.1A). Consistent with the trends observed 
at the RNA level (Table 2.1), CD150 was expressed by 46±12% of cells within the Thy-
1loSca-1+Lineage-c-kit+ HSC population but by only 0.9±0.5% of cells in the Thy-
1loSca-1+Mac-1loCD4loB220- MPP population (Figure 2.1B,C).  
To test whether CD150+ cells include HSCs, we performed competitive 
reconstitution assays in which CD150+ or CD150- donor bone marrow cells were 
transplanted into lethally irradiated recipient mice along with a radioprotective dose of 
recipient-type whole bone marrow cells (Figure 2.1D). In each of two independent 
experiments, recipients of the CD150+ cells were long-term multilineage reconstituted by 
donor cells (6/6 mice) while recipients of CD150- cells almost always (8/9 mice) 
exhibited transient multilineage reconstitution (1/9 mice was long-term multilineage 
reconstituted). These data indicate that HSCs are enriched in the CD150+ fraction and 
depleted in the CD150- fraction of bone marrow cells. Recipients of CD150+ bone 
marrow cells were always able to transfer long-term multilineage donor cell 
reconstitution to secondary recipients, while recipients of CD150- cells were not able to 
transfer donor cell reconstitution to secondary recipients (data not shown).  These results 





CD244 is expressed by transiently reconstituting MPPs but not by HSCs 
 To test whether other SLAM family members might be differentially expressed 
between hematopoietic progenitors we examined the SLAM family member CD244 
which was not detected in HSCs by microarray analysis (Table 2.1).  At the protein level, 
only 8.9±0.6% of bone marrow cells expressed CD244 by flow-cytometry (Figure 2.2A).  
Little or no CD244 staining was detected among Thy-1loSca-1+Lineage-c-kit+ HSCs 
(Figure 2.2B) but 33±10% of cells in the Thy-1loSca-1+Mac-1loCD4lo MPP population 
were CD244+ (Fig. 1.2C).  This suggested that at least some MPPs expressed CD244. 
 We performed two independent competitive reconstitution assays in which 
CD244+ or CD244- donor bone marrow cells were transplanted into lethally irradiated 
recipient mice along with a radioprotective dose of recipient-type whole bone marrow 
cells (Figure 2.2D).  Recipients of the CD244- cells were always long-term multilineage 
reconstituted by donor cells (8/8 mice) while recipients of the CD244+ cells were always 
transiently multilineage reconstituted (8/8 mice). Consistent with this, recipients of 
CD244- cells were always able to transfer long-term multilineage reconstitution to 
secondary recipients, while recipients of CD244+ cells were never able to transfer donor 
cell reconstitution to secondary recipients (data not shown; transplants were performed 
16 weeks after reconstitution of primary recipients). These data indicate that HSCs are 
contained within the CD244- fraction, while at least some transiently reconstituting MPPs 





CD48 is expressed by restricted progenitors but not by HSCs or MPPs 
By microarray analysis, the SLAM family member CD48 was expressed at 
significantly higher levels on CD45+ cells as compared to HSCs or MPPs (fold 
change>3). CD48 is a ligand for CD244 (Engel et al., 2003).  To test whether CD48+ 
cells were depleted of HSC activity, we performed competitive reconstitution assays in 
which CD48+ or CD48- donor bone marrow cells were transplanted into lethally 
irradiated recipient mice along with a radioprotective dose of recipient-type whole bone 
marrow cells (Figure 1.3).  Recipients of the CD48- cells were always long-term 
multilineage reconstituted by donor cells (5/5 mice) while recipients of the CD48+ cells 
were always reconstituted by B cells (6/6 mice), but never by myeloid cells (0/6) and 
rarely by T cells (1/6). These data indicate that CD48+ cells include restricted B cell 
progenitors, but that all HSCs and MPPs are CD48-. 
Although CD48 was not expressed by multipotent progenitors, it was expressed 
by most progenitors that formed myeloerythroid colonies in culture in addition to B 
lineage progenitors (Figure 2.3D, E).  83.4±3.7% of all colony-forming progenitors from 
bone marrow fell within the CD48+CD244+CD150- population, which accounts for only 
5.1±0.4% of bone marrow cells (Figure 2.3E).  Some additional erythroid (BFU-E) and 
megakaryocyte (CFU-Meg) progenitors fell within the CD48+CD244+CD150- 
population (Figure 2.3E). While CD150 is expressed by HSCs, and CD244 is expressed 
by transiently reconstituting MPPs, most colony-forming progenitors express CD48. 




A SLAM code for hematopoietic stem cells 
 These results raised the possibility that HSCs and other progenitors could be 
isolated based on combinations of SLAM family members (SLAM codes). HSC activity 
was contained in the CD150+ but rarely in the CD150- fraction (Figure 2.1D), the 
CD244- but not the CD244+ fraction (Figure 2.2D), and the CD48- but not the CD48+ 
fraction (Figure 2.3D). The CD150+CD48-CD244- fraction of bone marrow cells 
represented only 0.0084±0.0028% of whole bone marrow cells.  Since CD150+CD48- 
cells were uniformly CD244- (Figure 2.4A,B), we tested the reconstituting potential of 
CD150+CD48- cells. On average, 1 out of every 4.8±2.7 (21%) injected cells engrafted 
and yielded long-term multilineage reconstitution (Figure 1.4C; Table 1.6).  These results 
are similar to those obtained with Thy-1loSca-1+Lineage-c-kit+ cells (1 in 4.9±2.5 
engrafted and yielded long-term multilineage reconstitution; Table 2.3), indicating that 
the simple combination of CD150 and CD48 can highly enrich HSCs. 
To test whether the combination of CD150 and CD48 with other markers might 
yield an even more highly enriched population of HSCs we competitively reconstituted 
irradiated mice with single CD150+CD48-Sca-1+Lineage-c-kit+ cells in five independent 
experiments (Table 2.2). Only 0.0058±0.0012% of bone marrow cells were 
CD150+CD48-Sca-1+Lineage-c-kit+.  One CD150+CD48-Sca-1+Lineage-c-kit+ cell 
was sorted per well and then the contents of each well were individually injected into the 
recipient mice.  We visually confirmed the presence of a single cell per well prior to 
injection, and functionally confirmed the presence of a single cell per well in control 
studies (Figure 2.8).  1 out of every 2.1 CD150+CD48-Sca-1+Lineage-c-kit+ cells (47%) 
engrafted and gave long-term multilineage reconstitution. In contrast, the CD150- subset 
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of Thy-1loSca-1+Lineage-c-kit+ cells (Figure 2.1B) did not give long-term multilineage 
reconstitution (data not shown). The combination of CD150 and CD48 with previously 
identified HSC markers significantly increased HSC purity. 
 
The HSC SLAM code is conserved among mouse strains 
One impediment in the identification of HSCs is that some of the best markers, 
including Thy-1 and Sca-1, are not conserved among mouse strains (Spangrude and 
Brooks, 1992, 1993). To test whether the HSC SLAM markers are conserved among 
mouse strains, we isolated CD150+CD48- cells from the bone marrow of Balb/c and 
DBA/2 mice, which arise from distinct breeding lineages as compared to C57BL mice 
(Laboratory, 1997). CD150+CD48- cells were also rare in Balb/c and DBA/2 mice, 
representing 0.016±0.002% or 0.028±0.007% of bone marrow cells respectively (Figure 
2.5 A, B).  While Balb/c mice have a similar frequency of HSCs in their bone marrow as 
C57BL mice, DBA/2 mice have a 2 to 3 fold increase in HSC frequency (deHaan et al., 
1997). 
Ten male CD150+CD48- cells from either strain were injected into lethally 
irradiated female recipients, along with a radioprotective dose of 200,000 female bone 
marrow cells.  Blood chimerism was tested by quantitative (real-time) PCR using primers 
that amplify SRY, a Y-chromosome (donor) marker. Sixteen weeks after transplantation, 
11 out of 16 Balb/c recipients were reconstituted (>1.5%) by male cells, averaging 
10.8±14.3% of blood cells (Figure 2.5E).  Seven out of 15 DBA/2 recipients were clearly 
reconstituted (>0.6%) by male cells, averaging 3.5±3.8% of blood cells (Figure 2.5F). 
Lower levels of DBA/2 reconstitution were expected given that DBA/2 mice have more 
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competing HSCs in co-transplanted female bone marrow.  Two additional DBA/2 mice 
exhibited very low levels of male cells (~0.2%) and were not considered HSC 
reconstituted. 
To confirm that these mice exhibited multilineage reconstitution, 3 reconstituted 
mice and 1 unreconstituted mouse from each strain were sacrificed and myeloid (Mac-
1+B220-CD3-), B (B220+CD3-Mac-1-), and T (CD3+Mac-1-B220-) cells were isolated 
from their spleens.  In each case, the reconstituted mice had male cells in all 3 lineages 
while the unreconstituted mice did not (Figure 2.5E,F). These results correspond to 1 out 
of 9.1 Balb/c CD150+CD48- cells (11%) and 1 out of 16.4 DBA CD150+CD48- cells 
(6%) giving long-term multilineage reconstitution.  HSCs from Balb/c and DBA/2 mice 
are also highly enriched within the CD150+CD48- population. 
 
Identifying HSCs using simple markers that yield high purity in functional assays 
1 out of 4.8 (21%) CD150+CD48- cells from C57BL mice gave long-term 
multilineage reconstitution (Figure 2.4, Table 2.6).  This raised the possibility of 
identifying HSCs in tissue sections using a simple two-color stain. Initial studies revealed 
that a subset of megakaryocytes also appeared CD150+CD48- in sections (data not 
shown), partially explaining why not every CD150+CD48- cell gave long-term 
multilineage reconstitution.  To enhance our ability to reliably identify HSCs in tissue 
sections, we sought an additional marker that would distinguish HSCs from 
megakaryocytes.  CD41 is a commonly used marker of megakaryocyte lineage cells (Na 
Nakorn et al., 2003; Phillips et al., 1988).  Although CD41 is expressed by primitive 
HSCs, CD41 is downregulated by HSCs during the transition to definitive hematopoiesis 
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and most adult HSCs do not express CD41 (Ferkowicz et al., 2003; Mikkola et al., 2003).  
By flow-cytometry, 37±5% of CD150+CD48- cells were CD41+ (Figure 2.6A), and 
megakaryocytes (which can be recognized by their unique size and morphology) were 
excluded when sections were examined for CD150+CD48-CD41- cells (Figure 2.7C).  
The exclusion of CD41+ cells thus further enhances the purity of CD150+CD48- HSCs. 
To confirm that adult HSCs were CD41-, even in extramedullary tissues, we 
sorted CD41+ and CD41- cells from the spleen after cyclophosphamide/G-CSF treatment 
(Figure 2.6B). Cyclophosphamide/G-CSF treatment leads to the mobilization of HSCs 
from the bone marrow, increasing the frequency of HSCs in the spleen (Morrison et al., 
1997c). While CD41- cells always (5/5) gave long-term multilineage reconstitution in 
recipient mice, we never (0/5) detected reconstitution from CD41+ cells (Figure 1.6C).  
Adult HSCs do not express detectable CD41 in mobilized spleen, consistent with 
previous studies of adult bone marrow.   
To test the purity of CD150+CD48-CD41- cells, we isolated this population from 
normal bone marrow (where they represented 0.0065±0.0009% of cells) and mobilized 
spleen (where they represented 0.0063±0.0005% of cells), and injected single cells into 
irradiated mice in competitive reconstitution assays. 1 out of every 2.2 bone marrow 
CD150+CD48-CD41- cells (45 %) gave long-term multilineage reconstitution (Table 
2.2).  1 out of every 3 CD150+CD48-CD41- cells from mobilized spleen (33%; 4/12 
mice) gave long-term multilineage reconstitution (Table 2.2), a dramatic increase in 
purity relative to mobilized Thy-1loSca-1+Lineage-c-kit+ cells (Morrison et al., 1997c).  
This two-color stain thus simplifies and improves HSC isolation. 
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Extramedullary HSCs associate with sinusoidal endothelium  
Prior studies have imaged the interaction of primitive hematopoietic progenitors 
with osteoblasts in the endosteum of bone marrow (Arai et al., 2004; Wilson et al., 2004; 
Zhang et al., 2003) (see Figure 2.9 for schematic of bone marrow and spleen architecture) 
but HSCs have not been imaged in sites of extramedullary hematopoiesis. To address this 
we have examined the spleens of cyclophosphamide/G-CSF mobilized mice. 
CD150+CD48-CD41- cells were mainly associated with sinusoidal endothelium in 
parafollicular areas (red pulp) of the mobilized spleen.  To be sure that rare differentiated 
cells could not appear to be CD150+CD48-CD41- by immunohistochemistry we further 
stained these cells with lineage markers (Gr-1, Mac-1, B220, CD2, CD3, CD4, and CD8) 
to exclude myeloid, B, and T cells.  Only 0.0059±0.005% of cells in sections were 
CD150+CD48-CD41-Lineage- (identified by scanning 633,000 cells in sections from 3 
independent spleens; a frequency comparable to the frequency detected by flow-
cytometry) and all of these were found in the parafollicular red pulp.  Moreover, these 
cells expressed Sca-1 and CD45, just like the CD150+CD48-CD41- cells identified by 
flow-cytometry (Figure 2.10). Of the 37 CD150+CD48-CD41-Lineage- cells that were 
observed, 23 (62%) were in contact with sinusoidal endothelial cells (Figure 2.7A).  
Another 14 CD150+CD48-CD41-Lineage- cells (38%) were not visibly in contact with 
endothelium, though they were always near (<10 cell diameters) sinusoids in the red pulp 
(Figure 2.7B).  Compared to other cells in red pulp, CD150+CD48-CD41-Lineage- cells 
were more than 3-fold more likely to be in contact with sinusoids, as 18.2±2.2% of all 
nucleated cells in the red pulp were in contact with sinusoids.  The proportion of cells 
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associated with sinusoids in white pulp was much lower.  These data suggest that most 
HSCs within the mobilized spleen are associated with sinusoidal endothelium. 
 
Bone marrow HSCs associate with sinusoidal endothelium in addition to endosteum 
We observed a total of 35 CD150+CD48-CD41-Lineage- cells in sections from 
three femurs.  These cells represented 0.0067±0.0016% of cells in the sections (identified 
by scanning 522,000 cells in sections from 3 independent bones; a frequency comparable 
to the frequency detected by flow-cytometry).  Like in the spleen, the CD150+CD48-
CD41-Lineage- cells identified in sections also expressed Sca-1 and CD45 (Figure 2.10). 
Most of these cells (20/35; 57%) were located in the trabecular zone, and the remaining 
cells were distributed throughout the diaphysis (shaft).  Five of the cells (14%) were 
associated with endosteum, consistent with prior studies (Arai et al., 2004; Wilson et al., 
2004; Zhang et al., 2003) and another 9 cells were not associated with recognizable cell 
types. Most of the CD150+CD48-CD41-Lineage- cells that we observed (21 of 35; 60%) 
were in contact with sinusoidal endothelium (Figure 2.7C). Only 10.1±1.4% of all 
nucleated bone marrow cells were in contact with sinusoids, indicating that 
CD150+CD48-CD41-Lineage- cells were 6-fold more likely to be located in contact with 
sinusoids. These data may underestimate the fraction of HSCs near endosteum because 
some bone fragments peeled away from slides after sectioning, raising the possibility that 






By comparing the gene expression profiles of highly purified Thy-1loSca-
1+Lineage-c-kit+ HSCs (Table 2.3), Thy-1loSca-1+Mac-1loCD4lo MPPs (Table 2.4), 
and CD45+ bone marrow cells we found that SLAM family receptors were differentially 
expressed among hematopoietic stem and progenitor cells.  CD150 was expressed by 
HSCs but not by MPPs, and not by restricted hematopoietic progenitors (Figures 2.1, 
2.3). CD244 was expressed by MPPs and by some restricted progenitors but not by HSCs 
(Figure 2.2). CD48 was expressed by restricted B lineage and myeloerythroid lineage 
progenitors, but not by multipotent progenitors (Figure 2.3).  This demonstrates that 
SLAM family members are differentially expressed among hematopoietic progenitors in 
a way that correlates with primitiveness.  This is the first example of a single family of 
cell surface receptors that is precisely differentially expressed among stem and progenitor 
cells in a way that predicts developmental potential. 
 
Improving HSC purification 
 SLAM family members are so precisely differentially expressed that HSCs are 
very highly enriched within the CD150+CD48- cell population, which represents only 
0.0084±0.0028% of C57BL bone marrow cells (Figure 2.4). 21% of CD150+CD48- cells 
(1 in 4.8) that were intravenously injected into irradiated mice gave long-term 
multilineage reconstitution in limit dilution reconstitution assays (Table 2.6).  This 
demonstrates that two SLAM family markers yield HSC enrichments that are comparable 
to much more complex combinations of markers (Benveniste et al., 2003; Chen et al., 
2003; Morrison et al., 1995; Osawa et al., 1996; Spangrude et al., 1995; Wagers et al., 
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2002).  Moreover, 47% of single CD150+CD48-Sca-1+Lineage-c-kit+cells (1 in 2.1) and 
45% of single CD150+CD48-CD41- cells (1 in 2.2) yield long-term multilineage 
reconstitution in irradiated mice (Table 2.2). SLAM family markers simplify and enhance 
HSC purification, and are conserved among mouse strains (Figure 2.5). 
Most of the best protocols for HSC isolation yield populations from which 20% of 
intravenously injected cells engraft and give long-term multilineage reconstitution 
(Benveniste et al., 2003; Chen et al., 2003; Morrison et al., 1995; Osawa et al., 1996; 
Spangrude et al., 1995; Wagers et al., 2002).  This raised the question of whether the 
maximum efficiency with which HSCs are able to engraft after intravenous 
transplantation is only around 20% (1 in 5), or whether available markers only yield 
populations of HSCs that are 20% pure (Benveniste et al., 2003).  Recently, HSC purities 
of 40 to 96% were achieved by gating more restrictively on previously identified markers 
(Matsuzaki et al., 2004; Takano et al., 2004).  However, many HSCs are excluded from 
these very restrictive gates, raising the possibility that highly efficient engraftment is a 
property of only a subset of HSCs (Christopherson et al., 2004).  The fact that we have 
been able to achieve 47% functional HSC purity using new markers that include most or 
all bone marrow HSCs (this study and (Uchida and Weissman, 1992)) suggests that 
highly efficient engraftment is a property of nearly all HSCs in young adult bone marrow. 
The ability of SLAM family members to improve HSC purity is even more 
dramatic in the mobilized spleen.  Only 1% of Thy-1loSca-1+Lin-c-kit+ cells (1 in 100) 
from cyclophosphamide/G-CSF mobilized spleen give long-term multilineage 
reconstitution, raising the possibility that mobilized HSCs might engraft less efficiently 
than HSCs from normal bone marrow (Morrison et al., 1997c).  The fact that 33% of 
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CD150+CD48-CD41- cells (1 in 3.0) from the mobilized spleen were able to give long-
term multilineage reconstitution indicates that even mobilized HSCs are able to 
reconstitute with high efficiency. 
We have not yet detected an HSC defect in CD150-deficient mice (Wang et al., 
2004).  Hematopoiesis appeared normal in CD150-/- mice as the cellularity and 
composition of the bone marrow, blood, spleen, and thymus were grossly normal (Figure 
2.11).  We did not observe any differences between CD150-/- mice and littermate controls 
in terms of complete blood cell counts (data not shown) or the frequency of colony 
forming progenitors in the bone marrow (Figure 2.11).  We also did not detect any 
difference in HSC frequency or reconstituting potential upon transplantation into 
irradiated mice (Figure 2.11C, D).  Thus CD150 is not required for HSC maintenance or 
function in young adult mice, but could regulate more subtle aspects of HSC biology. 
The mechanism by which the tandemly arrayed genes at the SLAM locus are 
differentially expressed among primitive hematopoietic progenitors is uncertain.  Loss of 
CD150 did not detectably affect the expression pattern of CD48 or CD244 on HSCs or on 
bone marrow as a whole (data not shown).  Thus signaling by CD150 did not appear to 
repress CD48 or CD244. Understanding the mechanisms responsible for the differential 
expression of SLAM genes might provide important insights into the determination of 
stem cell identity given that SLAM receptors are differentially expressed in a way that 





Identifying HSC niches in tissue sections 
 The identification of a simple combination of markers that includes most HSCs 
made it possible for the first time to examine HSC localization in bone marrow and in 
extramedullary tissues using markers that were validated in functional assays to yield 
high HSC purity.  Many HSCs appeared to be in contact with sinusoidal endothelium in 
bone marrow, while other HSCs appeared to be associated with endosteum (Figure 2.7C).  
The precise proportion of bone marrow HSCs in each location is uncertain given that half 
of CD150+CD48-CD41- cells failed to give long-term multilineage reconstitution in 
irradiated mice.  HSCs that localized to endosteum were presumably associated with 
osteoblasts, consistent with prior studies (Arai et al., 2004; Calvi et al., 2003; Visnjic et 
al., 2004; Zhang et al., 2003).  Since bone marrow cells intravasate into circulation 
through sinusoids, the fact that many HSCs were associated with sinusoidal endothelium 
explains how HSCs could be mobilized into circulation within minutes of treatment with 
certain cytokines (Laterveer et al., 1995). Bone marrow HSCs appear to localize to at 
least two distinct niches, defined by the association of HSCs with sinusoidal endothelial 
cells and osteoblasts in different locations within the bone marrow. 
 We found no heterogeneity within the CD150+CD48-CD41- HSC population that 
correlated with the difference in localization.  For example, only 3.8% of CD150+CD48-
CD41- cells in normal bone marrow were in S/G2/M phases of the cell cycle (Figure 
2.12), consistent with previous studies reporting that HSCs are mainly quiescent 
(Cheshier et al., 1999; Morrison and Weissman, 1994).  This means that the vast majority 
of CD150+CD48-CD41- cells associated with both sinusoids and endosteum must be in 
G0/G1 phase of the cell cycle. 
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 HSCs in the spleens of mice treated with cyclophosphamide/G-CSF appeared to 
usually associate with sinusoidal endothelium as well (Figure 2.7A).  However, since 
two-thirds of single CD150+CD48-CD41- cells failed to give long-term multilineage 
reconstitution in irradiated mice, it is not possible to infer the precise proportion of HSCs 
associated with sinusoids as compared to other sites. These results suggest that sinusoidal 
endothelial cells create a niche that sustains HSCs in extramedullary tissues. These HSCs 
are unlikely to be migrating into circulation because the number of HSCs in the spleen 
continues to increase for several days after the onset of mobilization (Morrison et al., 
1997c).  Moreover, most of the CD150+CD48-CD41-Lineage- cells we observed in 
normal adult bone marrow were also in contact with endothelial cells.  The association of 
many HSCs with sinusoidal endothelium during steady state hematopoiesis suggests that 
this is not a transient interaction. 
 The observation that HSCs interact with sinusoidal endothelial cells in bone 
marrow and extramedullary tissues is consistent with observations that endothelial cells 
express factors that regulate HSC maintenance and function.  Definitive HSCs first arise 
during embryonic development among endothelial cells in the dorsal aorta, and have a 
very close developmental relationship with the endothelial lineage (Kennedy et al., 1997; 
Kubo and Alitalo, 2003; North et al., 2002; Oberlin et al., 2002).  Co-culture of HSCs 
with vascular endothelial cells from a variety of hematopoietic and non-hematopoietic 
tissues maintains the repopulating capacity of HSCs under conditions in which HSCs 
would otherwise differentiate or die (Cardier and Barbera-Guillem, 1997; Li et al., 2004; 
Ohneda et al., 1998).  This indicates that endothelial cells express factors that promote 
the maintenance of HSCs.  Endothelial cells appear to regulate the function of primitive 
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hematopoietic progenitors via multiple mechanisms in vivo (Avecilla et al., 2004; Heissig 
et al., 2002).  These observations suggest that endothelial cells create a niche in 
hematopoietic tissues that sustains a substantial fraction of the HSC pool. 
 Neural stem cells are also thought to localize to vascular niches (Capela and 
Temple, 2002; Louissaint et al., 2002; Palmer et al., 2000), and endothelial cells can 
support the self-renewal of neural stem cells in culture (Shen et al., 2004).  This raises the 
possibility that endothelial cells are generally important in the construction of 
mammalian stem cell niches and that sinusoidal endothelium represents a specialization 
adapted for the maintenance of HSCs. 
SLAM family markers represent an important new resource for studying HSC 
biology.  The fact that a single family of tandemly arrayed receptors can be differentially 
expressed among progenitors in a way that correlates with primitiveness supports the idea 
that stem cell identity is partially determined at the level of transcriptional regulation.  
SLAM family markers simplify and enhance HSC purification, demonstrating that even 
mobilized HSCs are able to engraft mice with high efficiency.   The ability to reliably 
identify HSCs using a two-color stain made it possible to identify HSCs in tissue sections 
using functionally validated markers.  This analysis revealed that a subset of HSCs 
associate with sinusoidal endothelial cells in bone marrow and mobilized spleen.  The use 
of SLAM markers in future studies should refine our understanding of stem cell identity 





MATERIALS AND METHODS 
All mice used in this study were housed in the Unit for Laboratory Animal 
Medicine at the University of Michigan.  Donor hematopoietic cells were obtained from 
adult (6-8 week-old) C57BL/Ka-CD45.2:Thy-1.1 mice.  Recipient mice in reconstitution 
assays were adult C57BL/Ka-CD45.1:Thy-1.2 mice. 
 
Flow-cytometric isolation of stem and progenitor cells  
Bone marrow cells were flushed from the long bones with Hank’s Buffered Salt 
Solution without calcium or magnesium, supplemented with 2% heat-inactivated calf 
serum (Gibco, Grand Island NY; HBSS+). Cells were triturated and filtered through nylon 
screen (45um, Sefar America, Kansas City MO) to obtain a single cell suspension. 
Thy-1loSca-1+Lineage-c-kit+ HSC and Thy-1loSca-1+Mac-1loCD4loB220- 
MPPs were isolated as previously described (Morrison et al., 1997b; Morrison and 
Weissman, 1994). For isolation of Thy-1loSca-1+Lineage-c-kit+ cells, whole bone 
marrow cells were incubated with unconjugated monoclonal antibodies to lineage 
markers including B220 (6B2), CD3 (KT31.1), CD5 (53-7.3), CD8 (53-6.7), Gr-1 (8C5) 
and Ter119.  Following dilution, pelleted cells were resuspended in anti-rat IgG specific 
F(ab)2 conjugated to phycoerythrin (PE; Jackson ImmunoResearch, West Grove PA).  
Cells were then stained with directly conjugated antibodies to Sca-1 (Ly6A/E-APC), c-kit 
(2B8-biotin), Thy-1.1 (19XE5-FITC), Mac-1 (M1/70-PE) and CD4 (GK1.5-PE).    
Progenitors were often enriched by pre-selecting for Sca-1+ or c-kit+ cells using 
paramagnetic microbeads (Miltenyi Biotec, Auburn CA) and autoMACS.  For isolation 
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of Thy-1loSca-1+Mac-1loCD4loB220- MPPs the directly conjugated antibodies 
described above were combined with anti-B220-Tricolor (6B2, Caltag Burlingame CA).  
Cells sorted based on CD150 expression were incubated with unconjugated 
antibody to CD150 (26D12; DNAX, Palo Alto CA), and subsequently stained with goat 
anti-rat IgG F(ab)2 fragment conjugated to FITC, PE or APC (Jackson ImmunoResearch). 
When CD150 was combined with lineage markers, directly conjugated antibodies were 
used to stain lineage markers. Cells sorted according to CD41, CD48 or CD244 
expression were stained with directly conjugated anti-CD41 (MWReg30-FITC), anti-
CD48 (HH48-1-FITC or PE) or with directly conjugated CD244.2 (2B4-FITC).  Cells 
were resuspended in 2µg/ml 7-AAD (Molecular Probes) or DAPI to discriminate live 
from dead cells. All flow-cytometry was performed on a FACS Vantage dual laser flow-
cytometer (Becton-Dickinson, San Jose CA). 
 
Long-term competitive reconstitution assays 
Adult recipient mice were irradiated with an Orthovoltage x-ray source delivering 
approximately 300 rads/min. C57BL and DBA/2 recipient mice received two doses of 
550-570rad, delivered at least two hours apart.  Balb/c recipients received two doses of 
495rad.  When HSCs/MPPs were tested for reconstituting potential the donor (CD45.2+) 
population was sorted, and the number of cells to be injected per mouse were re-sorted 
into individual wells of a 96-well plate containing 200,000 CD45.1+ whole bone marrow 
cells in HBSS+. The contents of individual wells were injected into the retro-orbital 
venous sinus of individual lethally irradiated CD45.1+ recipients.  For at least 16 weeks 
after transplantation, blood was obtained from the tail veins of recipient mice, subjected 
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to ammonium-chloride potassium red cell lysis (Morrison and Weissman, 1994), and 
stained with directly conjugated antibodies to CD45.2 (104, FITC), B220 (6B2), Mac-1 
(M1/70), CD3 (KT31.1) and Gr-1 (8C5) to monitor engraftment. 
 
Immunofluorescence analysis of hematopoietic tissue sections 
Femurs from 6-12 week old wild-type mice were embedded in 8% gelatin 
(Sigma) in phosphate buffer and snap frozen in -80oC N-methylbutane chilled in a slurry 
of ethanol and dry ice.  7 um sections were generated using the CryoJane system 
(Instrumedics, Hackensack NJ) with coated slides and a tungsten carbide blade.  Details 
of the staining procedure can be found in Supplemental Methods.  To obtain spleens from 
cyclophosphamide/G-CSF mobilized mice, mice were injected intra-peritoneally with 
4mg of cyclophosphamide (~200 mg/kg; Bristol-Myers Squibb) and then on successive 
days with 5µg of human G-CSF by subcutaneous injection (~250 µg/kg per day; Amgen 
Biologicals). Mice were sacrificed after four days of G-CSF treatment, and their spleens 
were dissected, sectioned, and fixed. 
 
RNA amplification for microarray analysis 
RNA extraction, amplification, and microarray analysis were performed as 
described (Iwashita et al., 2003).  
 
Methylcellulose culture 
Unfractionated bone marrow cells, or single resorted hematopoietic progenitors 
were plated in wells of 96-well plates (Corning, Corning NY) containing 100µl 1.0% 
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methylcellulose (Stem Cell Technologies, Vancouver BC) as previously described 
(Morrison et al., 1996).  The methylcellulose was supplemented with 20% charcoal 
absorbed fetal bovine serum (Cocalico, Reamstown PA), 1% BSA (Sigma), 1% 
penicillin/streptomycin (Gibco) 50ng/ml stem cell factor (SCF), 10ng/ml interleukin-3 
(IL-3), 10ng/ml interleukin-6 (IL-6), 3U/ml erythropoietin (Epo), 10ng/ml Flt-3 and 
10ng/ml thrombopoietin (Tpo).  All cytokines were obtained from R&D Systems 
(Minneapolis MN).  Colonies were maintained at 37oC in humidified chambers 
containing 6% CO2.  Colony formation was scored after 10-14 days of culture. 
 
RNA amplification for microarray analysis 
Methods for RNA extraction, amplification, and microarray analysis were as 
described (Iwashita et al., 2003).  Briefly, total RNA was extracted from 3 independent, 
freshly isolated aliquots of 5,000 Thy-1loSca-1+Lineage-c-kit+ cells, 5,000 Thy-1loSca-
1+Mac-1loCD4loB220- cells, or 8,000 CD45+ cells using Trizol with 250µg/ml 
glycogen (Roche Diagnostic Corporation, Indianapolis IN). The extracted RNA (30µl 
volume) was treated for 20min at 37°C with 2µl of RNase-free DNaseI (2U/µl; Ambion, 
Austin TX) in the presence of 2µl of RNase inhibitor (10U/µl) (Invitrogen). The RNA 
was then purified with RNeasy Mini Kit (Qiagen, Valencia CA) according to the 
manufacturer's instructions and washed 3 times with 500µl of RNase-free water in a 
Microcon YM-100 (Millipore, Bedford MA). After adding 0.025µg T7-d(T)24 primer 
(containing a T7 RNA polymerase binding sequence; 5'-
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG(T)24,; Proligo, 
Boulder CO), the RNA was dried down to 2.5µl.  RNA was amplified through two 
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consecutive rounds of amplification using a modified version of the method of Baugh et 
al. (Baugh et al., 2001). To make cDNA, first strand was synthesized using T7-d(T)24 
primer.  After second strand synthesis, complementary RNA (cRNA) was generated by 
T7 RNA polymerase (Promega, Madison WI).  For the second round of amplification, 
first strand cDNA was synthesized using random hexamers and second strand was 
synthesized using the T7-d(T)24 primer. The double stranded cDNA was resuspended 
with 22µl RNase-free water and transcribed to cRNA with the biotin labeling kit 
(BioArray Highyield RNA transcript labeling kit (T7), Enzo Diagnostics, Farmingdale 
NY) for 12 hours.  cRNA was purified using the RNeasy Mini Kit. 60µg of biotinylated 
cRNA were obtained from two rounds of RNA amplification from 5,000 cells. 
 
Hybridization and data analysis 
After fragmentation, 15µg of HSC cRNA were hybridized per chip to Mouse 
Genome U74 Arrays (version 2 Chips A, B and C; Affymetrix). The chips were 
hybridized and scanned according to the manufacturer's instructions. Signal intensities 
were analyzed as described previously (Iwashita et al., 2003).  To measure fold changes, 
all values less than 100 were set to 100. The significance of differences in signal intensity 
for each probe set was evaluated by T-test using the log10 transformed values from 3 
independent replicates per cell type. 
 
Quantitative real time-PCR (qPCR) 
2,000 to 10,000 cells were directly sorted into 400ul Trizol (Ambion, Austin TX) 
containing 250ug/ml glycogen (Roche, Indianapolis IN).  RNA was extracted according 
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to manufacturer’s instructions.  The extracted RNA (30ul volume) was treated for 20 
minutes at 37oC with 2ul RNase-free DNase-1 (2U/ul; Ambion) in the presence of 2ul 
RNase inhibitor (10U/ul; Invitrogen).  The RNA was then purified using an RNeasy Mini 
Kit (Qiagen, Valencia CA) according to manufacturer’s instructions and washed three 
times with 500ul RNase-free water.  The RNA was used for making cDNA by reverse 
transcription with 1ug random hexamer.  The cDNA was extracted with phenol-
chloroform and precipitated with 20ug glycogen.  After dissolving the cDNA with 
RNase-free water, cDNA equivalent to 200 cells was used for each PCR reaction.  qPCR 
was performed using at least two independent cell samples.  Primers were designed to 
have a Tm of ~59oC and to generate short amplicons (100-150bp).  The PCR reactions 
were performed using a LightCycler (Roche Diagnostic Corporation) according to the 
manufacturer’s instructions.  The RNA content of samples compared by qPCR was 
normalized based on the amplification of hypoxanthine phosphoribosyl transferase 
(HPRT).  In addition to confirming the specificity of the qPCR reactions by examining 
the melting curves of the products, qPCR products were separated in 2% agarose gels to 
confirm the presence of a single band of the expected size.  To estimate the difference in 
the expression levels of individual RNAs between samples, we assumed that one cycle 
difference in the timing of amplification by qPCR was equivalent to a 1.9-fold difference 
in expression level (90% amplification efficiency), a typical value (Fink et al., 1998).   
Experiments to examine the engraftment of female Balb/c and DBA/2 mice by 
male HSCs involved quantitative PCR of extracted genomic DNA rather than cDNA but 
otherwise similar methods as described above were employed.  Genomic DNA was 
extracted from blood cells or splenocytes and resuspended at 10-50ng/ul.  The level of 
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male cell chimerism was tested by qPCR using primers that amplified genomic SRY and 
ß-actin (to normalize DNA content).  Known dilutions of male DNA into female DNA 
were used to establish standards.  Individual samples were normalized to the 100% male 
reference standard according to the following formula: 1.9 exp (CT SRY100% - CT 
SRY)/1.9 exp(CT actin100%- CT actin), where CT SRY100% represents the SRY crossing 
point for the reference sample and CT actin100% the ß-actin crossing point for the 
reference sample.  Level of chimerism in experimental animals was estimated by linear 




CD150-deficient mice (Wang et al., 2004) were backcrossed for more than ten 
generations onto the C57BL/6 background.  Genotyping was performed using the 
primers: CD150+/+-F (5’CAC CCC AGG CAC TTC ACC AAG TCC CAG AGC) and 
CD150+/+-R (5’GCT GGC TGT GAA CTC CCA TCC CAT CCT TG); CD150-/--
F(5’GAA AAT TGG GTC AGG AAG TAA ACG CAG) and CD150-/--R(5’GGG CCA 
GCT CAT TCC TCC CAC). 
Immunofluorescence analysis of HSC localization in tissue sections 
Freshly dissected undecalcified femurs from 6-12 week old wild-type mice or 
spleens from 6-12 week old mice treated with CY/G-CSF were embedded in 8% gelatin 
(Sigma) in 0.1M phosphate buffer pH7.4 and snap-frozen in N-methylbutane chilled in a 
slurry of ethanol and dry ice.  Sections were generated using the CryoJane tape transfer 
system (Instrumedics, Hackensack NJ) with methacrylate coated slides, a tungsten 
carbide blade (Diamond Knives, Wilmington DE) and Bright Cryostat at -24oC.  The 
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7um sections were air-dried overnight at room temperature and subsequently fixed in -
20oC acetone for 15 minutes.  Slides were then blocked with 20% goat serum in 0.1M 
phosphate buffer (pH 7.4) for 40 minutes prior to antibody staining.  Slides were first 
incubated in 0.03ug/ul 26D12 anti-CD150 antibody (DNAX, Palo Alto CA) for 1 hour 
and rinsed.  Goat anti-rat IgG conjugated to Alexa555 (Molecular Probes) was added at 
1/200 dilution and rinsed.  Slides were then incubated in 0.1ug/ul rat IgG (Sigma-
Aldrich) for 10min and rinsed. To avoid the problem of other cells in the tissue sections 
appearing to be CD150+CD48-CD41- in a way that was not detected by flow-cytometry 
we included the additional panel of lineage markers in the tissue immunofluorescence 
stains.  By themselves these lineage markers should exclude differentiated cells, 
providing redundancy within the panel of markers for the exclusion of non-HSCs.  
Unconjugated anti-CD48 and FITC-conjugated anti-CD41 antibodies (each 1/100 
dilution) as well as FITC-conjugated lineage markers including anti-B220 (stains B 
cells), CD2 (T cells), CD4 (T cells), CD8a (T cells), Gr-1 (myeloid cells) and CD11b 
(myeloid cells) antibodies (each 1/200 dilution), and biotinylated pan-endothelial cell 
antigen (MECA-32) at a 1/25 dilution were then incubated for 1hr in 0.1ug/ul rat IgG and 
rinsed. CD48 was visualized by incubation with FITC-conjugated goat anti-Armenian 
hamster (Jackson ImmunoResearch) at a 1/200 dilution for 30min.  Pan-endothelial cell 
antigen was visualized with Alexa647-conjugated streptavidin (Molecular Probes) at a 
1/200 dilution.  Finally, slides were rinsed twice for 5 minutes each and mounted without 
drying using Antifade (Molecular Probes).  To ensure the accuracy of antibody labeling 
of HSCs, control slides were separately stained as above without addition of CD150 
primary antibody.  All antibody incubations took place in blocking buffer.  All rinse steps 
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were 2 times for 3 minutes each with blocking buffer unless otherwise indicated.  All 
antibodies were purchased from Becton Dickinson unless otherwise noted.  Microscopy 
was performed using an Olympus BX51 florescence microscope or an Olympus FV-500 
confocal microscope. 
 
Controls to ensure that the CD150+CD48-CD41-Lineage- cells identified in tissue 
sections were the same as the CD150+CD48-CD41- cells isolated by flow-cytometry 
and functionally characterized 
 
We performed a number of controls to confirm that the CD150+CD48-CD41-
Lineage- cells identified by immunofluorescence in tissue sections were the same as the 
CD150+CD48-CD41- HSCs isolated by flow-cytometry.  If non-stem cells were included 
in the CD150+CD48-CD41-Lineage- population identified in sections, then the 
frequency of these cells in sections should be higher than the frequency of 
CD150+CD48-CD41- cells identified by flow-cytometry.  The CD150+CD48-CD41- 
population in mobilized spleen by flow-cytometry was 0.0063±0.0005% whereas the 
frequency of CD150+CD48-CD41-Lineage- cells in spleen sections was 0.0059%. The 
frequency of CD150+CD48-CD41- cells in bone marrow by flow-cytometry 
(0.0065±0.0009%) also did not differ from the frequency of CD150+CD48-CD41-
Lineage- cells identified within bone marrow sections (0.0067±0.0016%). These results 
demonstrate that the frequency of CD150+CD48-CD41-Lineage- cells in sections was 
not higher than the frequency of CD150+CD48-CD41- cells identified by flow-
cytometry. 
To test whether the CD150+CD48-CD41- cells identified by flow-cytometry 
represent the same population identified in tissue sections as CD150+CD48-CD41-
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Lineage- cells we examined two independent markers of HSC, Sca-1 and CD45.  The 
HSC activity within the CD150+CD48- population was also Sca-1+Lineage-c-kit+ (Table 
2.2), consistent with prior studies of HSC marker expression.  By flow-cytometry, we 
found that 88±3% of CD150+CD48-CD41- cells were Sca-1+ and in tissue sections we 
found that 71% of CD150+CD48-CD41-Lineage- cells were detectably Sca-1+ (Figure 
2.10).  This may underestimate the true frequency of Sca-1+ cells in tissue sections since 
the flow-cytometer is more sensitive than the eye to lower levels of staining, and the Sca-
1 stain that we were forced to use in this multi-color analysis was dim. Furthermore, 
essentially all of the CD150+CD48-CD41- cells identified by flow-cytometry as well as 
the CD150+CD48-CD41-Lineage- cells identified in tissue sections were CD45+ (Figure 
2.10).  This demonstrates that most of the cells identified in tissue sections expressed two 
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Table 2.1:  Genes that were expressed at higher levels in HSCs as compared 
to MPPs and CD45+ cells by both microarray analysis and quantitative PCR. 
cRNA from Thy-1loSca-1+Lineage-c-kit+ HSCs, Thy-1loSca-1+Mac-
1loCD4loB220- MPPs, or CD45+ bone marrow cells were hybridized to 
oligonucleotide arrays.  The average untransformed probe intensities from three 
independent samples were used to calculate fold-change (HSC/MPP; 
HSC/CD45+). The table lists all of the genes that were expressed at significantly 
higher levels in HSCs as compared to MPPs and CD45+ cells by both microarray 




































Table 2.1:  Genes that were expressed at higher levels in HSCs as compared 
to MPPs and CD45+ cells by both microarray analysis and quantitative PCR. 
 
 
   Microarray qPCR 
Gene 
symbol 










Clca1 chloride channel calcium 
activated 1 AF047838 8.3 9.1 32.8 3.3 
Cpne8 Copine VIII AV240111 7.0 11.0 3.8 29.9 
Sdpr serum deprivation response  AI839175 7.0 7.0 116.7 40.3 
Catnal1 catenin alpha-like 1 AI152317 6.9 8.8 4.0 26.2 
Prkcm Protein kinase C mu AV297026 6.4 7.0 ND ND 
Vwf Von Willebrand factor 
homolog AI843063 6.2 17.2 5.2 4.2 
Est RIKEN full-length library, 
clone:E330020H17 AI853427 5.7 5.7 4.9 2.8 
Mjd Machado-Joseph disease 
homolog AV262417 5.2 5.9 1.9 2.3 
Ly64 lymphocyte antigen 64 AV204260 4.8 13.7 9.0 53.8 
D10Ertd
755e 
DNA segment, Chr 10, 




C530008M17 gene AI851362 4.7 7.4 15.3 2.9 
Est Mus musculus transcribed 
sequences AI666656 4.1 10.7 1.9 2.8 
Slam signaling lymphocyte 
activation molecule AI120008 4.0 4.0 5.8 17.0 
Est Mus musculus transcribed 
sequences  AV236645 3.6 9.7 5.6 7.0 
Rnf125 ring finger protein 125 AV361188 3.6 6.0 2.4 2.9 
Peg12 paternally expressed 12 AI413890 3.6 3.8 9.2 22.9 
Bgn biglycan AV016619 3.5 64.1 7.7 52.6 
Exosc1 exosome component 1 AI592141 3.4 7.8 2.5 2.6 
Stub1 STIP1 homology and U-box 
containing protein 1 AW046544 3.4 5.0 2.5 2.2 
Gemin4 gem (nuclear organelle) 
associated protein 4 AV341751 3.4 5.4 2.8 5.9 
Tfpi tissue factor pathway 
inhibitor AI480514 3.2 4.9 4.6 9.2 
Est Mus musculus transcribed 
sequences AI482323 3.2 16.9 3.4 10.2 
pbx1 Pre B-cell leukemia 
transcription factor 1 AI845678 3.1 4.3 3.5 15.6 
Sdsl serine dehydratase-like AI504310 3.1 14.7 7.0 6.1 
Ppap2b phosphatidic acid 
phosphatase type 2B AV346092 3.1 3.7 2.5 2.9 
Armcx1 armadillo repeat containing, 
X-linked 1 AI846227 3.0 3.1 5.6 34.0 
Phactr2 phosphatase and actin 
regulator 2 AW123926 3.0 4.0 1.9 3.0 
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Table 2.2: Competitive reconstitution of irradiated mice with single cells 
from various HSC populations reveals that diverse HSC populations are able 
to engraft with high efficiency in lethally irradiated mice. 
 









1 67% (10/15) 70% (7/10) 47% (7/15) BM CD150+CD48- 
Sca-1+Lineage- c-kit+ 2 67% (6/9) 66% (4/6) 44% (4/9) 
 3 44% (8/18) 88% (7/8) 39% (7/18) 
 4 53% (8/15) 88% (7/8) 47% (7/15) 
 5 58% (7/12) 100% (7/7) 58% (7/12) 
 Mean±SD 58±10% 82±14% 47±7% (1 in 2.1) 
BM CD150+CD48-CD41- 1 30% (3/10) 100% (3/3) 30% (3/10) 
 2 100% (5/5) 60% (3/5) 60% (3/5) 
 Mean±SD 65% 80% 45% (1 in 2.2) 
Mobilized spleen 
CD150+CD48-CD41- 
1 42% (5/12) 80% (4/5) 33% (1 in 3) 
 
Single cells were sorted into different wells of 96 well plates, and the wells were 
visually inspected to confirm that only a single cell was sorted (see Figure 2.8).  
Then the contents of each well were individually injected along with 300,000 













Table 2.3: Thy-1loSca-1+Lineage-c-kit+ cells are highly enriched for long-






The indicated number of donor-type (CD45.2+) Thy-1loSca-1+Lineage-c-kit+ 
cells was transplanted intravenously into lethally irradiated recipients (CD45.1+) 
along with 200,000 recipient-type (CD45.1+) whole bone marrow cells for 
radioprotection.  Recipients were considered engrafted by donor cells if any 
CD45.2+ cells were detected in their peripheral blood (above background: >0.1-
0.3% of myeloid cells or >0.1-0.15% of lymphoid cells).  The frequency of cells 
that engrafted was calculated based on limit-dilution (Poisson) statistics (Smith et 
al., 1991).  Mice were considered long-term multilineage reconstituted if donor-




















10 24/28 1 in 5.7 88% (21/24) 1 in 7.7 (21/28) 
5 13/15 1 in 3.0 100% (13/13) 1 in 3.0 (13/15) 
4 25/34 1 in 3.5 92% (23/25) 1 in 4.1 (23/34) 
Mean±SD 82±7% 1 in 4.1±1.4 93±6% 1 in 4.9±2.5 (20%) 
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Table 2.4: Thy-1loSca-1+ Mac-1loCD4loB220- cells are highly enriched for 

























4 69% (11/16) 1 in 4.0 64% (7/11) 27% (3/11) 9% (1/11) 
 
In previous studies, only 26% of Thy-1loSca-1+Mac-1loCD4lo cells formed 
myeloerythroid colonies in methylcellulose cultures, and many clones gave rise to 
only B lineage reconstitution in vivo (Morrison et al., 1997b; Morrison and 
Weissman, 1994).  This raised the question of whether this population contained 
multipotent progenitors, or a mixture of multipotent and lymphoid committed 
progenitors.  To resolve this question we searched for sources of heterogeneity 
within the Thy-1loSca-1+Mac-1loCD4lo population, and found that 55±14% of 
these cells expressed the B cell marker B220.  The B220+ subset of Thy-1loSca-
1+Mac-1loCD4lo cells lacked the ability to form colonies in methylcellulose or to 
give multilineage reconstitution in vivo (data not shown), while the B220- subset 









Table 2.5: Summary of the microarray analyses of Thy-1loSca-1+Lineage- 
c-kit+ HSCs, Thy-1loSca-1+Mac-1loCD4lo MPPs, and CD45+ bone marrow 
cells. 
 
A. Genes that were differentially expressed among HSCs, MPPs, and CD45+ cells 
based on an analysis of oligonucleotide arrays containing 36,701 probe sets 
Probe sets with fold change>3, P<0.05, non zero present call 
HSC>MPP 47 probe sets 
HSC<MPP 236 probe sets 
HSC>CD45+ 1151 probe sets 
HSC<CD45+ 835 probe sets 
 
B. Squared Pearson correlation coefficients (R2 values) between similar or different samples 
 Mean±SD  
Among replicate HSC samples, N=3 log transformed 0.894±0.012  
 non-log transformed 0.991±0.002  
 
Among replicate MPP samples, N=3 log transformed 0.894±0.003  
 non-log transformed 0.988±0.003  
 
Among replicate CD45+ samples, N=3 log transformed 0.859±0.012  
 non-log transformed 0.991±0.0004  
 
Between HSCs and MPPs, N=9 log transformed 0.851±0.011  
 non-log transformed 0.798±0.024  
 
Between HSCs and CD45+ samples, N=9 log transformed 0.686±0.013  
 non-log transformed 0.558±0.009  
 
To calculate the squared Pearson's correlation coefficient between two groups, we 
transformed each value to the base 10 logarithm (log10). Log10 transformation is 
statistically preferred because the Pearson’s correlation coefficient should be 




Table 2.6:  CD150+CD48- bone marrow cells are highly enriched for long-
term self-renewing, multipotent HSCs based on the ability of 3 or 5 


















5 14/15 1 in 2.4 93% (13/14) 1 in 3.1 (13/15) 
3 4/6 1 in 3.2 50% (2/4) 1 in 7.9 (2/6) 
3 9/14 1 in 3.4 100% (9/9) 1 in 3.4 (9/14) 

























Figure 2.1: CD150+ cells are enriched for HSCs while CD150- cells include 
transiently reconstituting MPPs.  Only 6.6% of bone marrow cells express 
CD150 (A). CD150 expression was detected among Thy-1lowSca-1+Lineage-c-
kit+ HSCs (B) but not among Thy-1lowSca-1+Mac-1loCD4loB220- MPPs (C). 
20,000 CD150+ bone marrow cells gave rise to long-term multilineage 
reconstitution in all recipients (D, blue lines), while 180,000 CD150- bone 
marrow cells gave transient multilineage reconstitution (D, red lines). Cell doses 
were based on the fraction of 200,000 whole bone marrow cells that were 
CD150+ or CD150- as in prior HSC marker studies (Morrison et al., 1995; 
Uchida and Weissman, 1992). The black line at 0.3% represents the background 
threshold, meaning that reconstitution could not be detected in mice falling below 
this line.  Data are from one of two independent experiments that gave similar 
results. Each line represents the frequency of donor-derived myeloid, B, or T cells 





Figure 2.2: HSCs are CD244- while transiently reconstituting multipotent 
progenitors are CD244+.  Only 8.9% of bone marrow cells express CD244 (A). 
CD244 expression was not detected within the Thy-1lowSca-1+Lineage-c-kit+ 
HSC population (B) but was detected on approximately 33% of Thy-1lowSca-
1+Mac-1loCD4loB220- MPPs (C). Note that the black histogram represents 
background fluorescence while the blue histogram represents staining with the 
directly conjugated anti-CD244 antibody.  20,000 CD244+ bone marrow cells 
gave transient multilineage reconstitution in all recipients (blue lines), while 
180,000 CD244- bone marrow cells gave long-term multilineage reconstitution in 
all recipients (red lines). The data are from one of two independent experiments 


































Figure 2.3: HSCs and MPPs are contained within the CD48- fraction while colony-
forming progenitors are mainly in the CD48+ fraction of bone marrow cells. 43% of 
bone marrow cells express CD48 (A). CD48 expression was detected in the Thy-1loSca-
1+Lineage-c-kit+ HSC population (B) but not in Thy-1loSca-1+Mac-1loCD4loB220- 
MPPs (C).  All multilineage reconstituting activity was contained within the CD48- cell 
fraction (D).  80,000 CD48+ bone marrow cells gave rise only to B cells in all recipients 
(blue lines), while 120,000 CD48- bone marrow cells gave long-term multilineage 
reconstitution in all recipients (red lines). CD48-c-kit+ cells are highly enriched HSC 
activity but are not visible in panel A because they represent only 0.1% of bone marrow 
cells. The vast majority of bone marrow cells that formed myeloerythroid colonies in 
methylcellulose were CD48+CD244+CD150- (E). Each bar represents the percentage of 
total colony forming progenitors from unfractionated bone marrow that are contained in 
each cell population. For example, 83.4% of all colonies (CFU-C, white bar) formed by 




























Figure 2.4: CD150+CD48-CD244- cells are highly enriched for long-term 
reconstituting HSCs.  CD150+CD48- cells represent only 0.0084% of bone marrow 
cells (A), and these cells were uniformly negative for CD244 expression (B). Injection of 
3 donor-type CD150+CD48- cells into lethally irradiated recipient mice in a competitive 
reconstitution assay lead to long-term multilineage reconstitution by donor cells in nine 









































Figure 2.5: Balb/c and DBA/2 HSCs are enriched in the CD150+CD48- population.  
CD150+CD48- cells are rare in Balb/c (A) and DBA/2 (B) bone marrow.  Ten 
CD150+CD48- cells from male donors were injected into lethally irradiated female 
recipients in competitive reconstitution assays.  At week 16, DNA from peripheral 
leukocytes was extracted and subjected to quantitative PCR using primers specific for 
genomic SRY to determine the relative contribution of male cells to the peripheral blood 
of female recipients.  Control DNA from untreated male mice was diluted into control 
DNA from untreated female mice as indicated (C and D) to construct a standard curve.  
DNA content in each sample was normalized based on genomic ß-actin amplification 
(C), and the level of male DNA (SRY) in each sample was determined by qPCR (D). To 
be considered reconstituted, the male contribution to peripheral blood had to be clearly 
detectable by qPCR, and the amplified product had to be specific based on melting curve 
analysis, and electrophoresis. Eleven out of 16 Balb/c recipients were clearly 
reconstituted by male cells (E; only 14 mice are shown). Seven out of 15 DBA/2 
recipients were cleary reconstituted by male cells (F; only 14 mice are shown). Splenic 
myeloid (Mac-1+B220-CD3-), B (B220+CD3-Mac-1-), and T (CD3+Mac-1-B220-) cells 
were isolated and examined for donor cell chimerism in 3 reconstituted mice and 1 









































Figure 2.6: Excluding CD41+ cells increases the purity of HSCs in the 
CD150+CD48- fraction. (A) 37±5% of CD150+CD48- bone marrow cells express 
CD41.  (B) Only 4.3% of splenocytes in cyclophosphamide/G-CSF mobilized mice 
express CD41. (C) 10,000 CD41+ mobilized splenocytes gave no detectable 
reconstitution in any recipients (0 of 5 mice, blue), while 200,000 CD41- mobilized 







Figure 2.7:  HSCs are associated with sinusoidal endothelial cells in the spleen (A, 
arrows) and bone marrow (C; arrow). In the cyclophosphamide/G-CSF mobilized 
spleen, CD150+CD48-CD41-Lineage- cells represented 0.0059±0.005 of cells in 
sections.  62% (23/37) of these cells were in contact with sinusoidal endothelial cells (A, 
arrows; * indicates the lumen of the sinusoids). Another 38% (14/37) of CD150+CD48-
CD41-Lineage- cells were located in parafollicular regions that were often near sinusoids 
but not visibly in contact (B, arrow).  It is unclear whether these cells are migrating 
to/from sinusoids or whether there are multiple niches within the spleen.  In normal bone 
marrow, CD150+CD48-CD41-Lineage- cells represented 0.0067±0.0016% of cells in 
sections.  Some of these cells were closely associated with endosteum (not shown).  
However, most of these cells contacted sinusoidal endothelium (C, arrow).  Note the 
large megakaryocyte that was also associated with the sinusoid (C, arrowhead).  Each of 
these images represents a single optical section, but a series of images through each cell 
is shown in Figure 2.13. 
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Figure 2.8: Visualization of single HSCs prior to transplantation.  Single 
CD150+Sca-1+Lineage-CD48-c-kit+ HSCs were sorted and then resorted by flow-
cytometry (FACSVantage SE) on counter mode using doublet discrimination (A). Single 
cells were deposited into 100ul of sterile HBSS buffer containing 2.5ug/ml Hoechst 
33342 (Sigma) and 5.0ug/ml verapamil (Sigma) in individual wells of a 96-well plate 
(B).  After the presence of a single cell was assessed using light microscopy (i) and 
confirmed using UV florescence microscopy (ii), the contents of each well were injected 
into lethally irradiated recipients along with a radioprotective dose of 300,000 recipient-
type CD150- bone marrow cells. In none of more than 150 wells inspected was more than 
one cell seen.  In control studies to functionally test whether there was only a single cell 
per well, the contents of each well were divided into five equal volumes and plated into 
separate wells of methylcellulose and allowed to form colonies (C). In three separate 
experiments, 90.0±10.0% of the sets of five methylcellulose wells contained a single 
hematopoietic colony and in no circumstance (0/48) was more than one colony observed. 
When single cells were directly plated into methylcellulose, 93.3±7.6% of single cells 
formed hematopoietic colonies.  There was thus no difference between the clonogenicity 
of directly plated HSCs or of diluted HSCs (p=0.67).  The contents of a representative set 
of five methylcellulose cultures is shown in the inset (i-v).  These results confirm that 









































Figure 2.9: HSC localization in the bone marrow and spleen.   
HSCs were associated with sinusoidal endothelial cells in the bone marrow (A) and in the 
parafollicular red pulp of the spleen (B).  A subset of HSCs in the bone marrow also 
localized to the interface of bone and bone marrow (A, the endosteum) where osteoblasts 









Figure 2.10: CD150+CD48-CD41- cells express CD45 and Sca-1 in tissue sections 
and by flow-cytometry.  CD150+CD48-CD41- cells isolated by flow-cytometry were 
highly enriched for long-term multilineage reconstituting HSCs, and were present at very 
similar frequencies as CD150+CD48-CD41-Lineage- cells identified in tissue sections. 
Bone marrow CD150+CD48-CD41- cells isolated by flow-cytometry expressed both 
CD45 (98% CD45+) and Sca-1 (89±3.5% Sca-1+). CD150+CD48-CD41-Lineage- cells 
identified in bone marrow sections also expressed CD45 (100% CD45+; A) and Sca-1 
(71% Sca-1+; B). CD150+CD48-CD41-Lineage- cells identified in spleen sections also 
expressed CD45 (100% CD45+) and Sca-1 (80% Sca-1+) (data not shown).  The co-
expression of these additional HSC markers on both the flow-cytometrically isolated cells 
and on the cells identified in tissue sections strongly supports the conclusion that this is 
































Figure 2.11: CD150-deficient mice exhibit normal hematopoiesis, colony-forming 
(CFU-C) progenitor activity, and HSC frequency and function.  
(A) No statistically significant differences were observed in overall cellularity or in the 
frequencies of myeloid, B, T, or erythroid populations in the bone marrow or spleens of 
adult CD150-deficient mice. There was also no difference in the overall cellularity or 
frequency of progenitor populations within the thymus (data not shown). Each statistic 
represents mean ± standard deviation for five mice per genotype. (B) Colony forming 
assays reveal no differences between CD150+/+ and CD150-/- littermates in the frequency 
of restricted hematopoietic progenitors in the bone marrow (4 independent experiments).  
(C) No statistically significant difference in the frequency of Thy-1loSca-1+lin-c-
kit+CD48- HSCs in CD150+/+ (black bars), CD150+/- (grey bars), and CD150-/- (white 
bars) littermates (n=5 to 7 for each genotype).  (D) 200,000 CD150+/+ or CD150-/- donor 
type bone marrow cells were transplanted into irradiated recipient mice along with 
200,000 recipient-type bone marrow cells.  No statistically significant differences were 
observed at 16 weeks post-transplantation in the level of donor-type CD45, myeloid, B-




















Figure 2.12: Few CD150+CD48-CD41- cells are in cycle.   
Only 3.8% of bone marrow CD150+CD48-CD41- cells were in S/G2/M phases of the 
cell cycle based on Hoechst 33342 staining of DNA content.  This is consistent with prior 
studies that found most adult bone marrow HSCs are quiescent (Cheshier et al., 1999; 


















Figure 2.13: Serial optical sections through the cells shown in Figure 2.7.   A series of 
optical sections through the images from Figures 2.7A-C are shown such that each row 
represents a single optical section. White arrows point to the CD150+CD48-CD41-
Lineage- cells in each image.  The spleen contains a higher frequency of CD150+ cells 
than the bone marrow as some lymphocytes, in addition to HSCs, express CD150.  Each 
image, particularly from the spleen, contained 2 to 4 µm particles lacking nuclei that 
stained for both CD150 (red) and CD41 (green).  These appear to be platelets, which are 
CD150+CD41+ and are present throughout hematopoietic tissues, particularly in the 
spleen.  Note that HSCs in the bone marrow were sometimes adjacent to clusters of cells 
that failed to stain with lineage markers (* in C), presumably reflecting clusters of other 
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LACK OF EVIDENCE THAT HEMATOPOIETIC STEM CELLS DEPEND ON 
N-CADHERIN-MEDIATED ADHESION TO OSTEOBLASTS FOR THEIR 
MAINTENANCE1 
 
SUMMARY   
Recent studies have proposed that bone marrow hematopoietic stem cells (HSCs) 
are maintained via N-cadherin-mediated homophilic adhesion with osteoblasts. However, 
there is not yet any evidence that N-cadherin expressing cells have HSC activity or that 
osteoblasts are required for HSC maintenance. We were unable to detect N-cadherin 
expression in highly purified HSCs by polymerase chain reaction, using commercial anti-
N-cadherin antibodies, or by ß-galactosidase staining of N-cadherin gene-trap mice. Only 
N-cadherin negative bone marrow cells exhibited HSC activity in irradiated mice. 
Finally, biglycan-deficient mice had significant reductions in trabecular bone and 
osteoblasts but showed no defects in hematopoiesis, HSC frequency or function. Thus 
reductions in osteoblasts do not necessarily lead to reductions in HSCs. Most bone 
marrow HSCs in wild-type and biglycan-deficient mice localized to sinusoids and few 
localized within 5 cell diameters of the endosteum. These results question whether 
significant numbers of HSCs depend on N-cadherin-mediated adhesion to osteoblasts. 
                                                
1 Originally published in Cell Stem Cell 1:204-17, August 2007 with authors listed as MJ 
Kiel, GL Radice and SJ Morrison. 
 





Hematopoietic stem cells (HSCs) persist throughout adult life in the bone marrow 
where they continuously produce new blood cells. HSC maintenance is hypothesized to 
depend on the localization of HSCs to specialized microenvironments (niches) within the 
bone marrow that support the maintenance of HSCs (Adams and Scadden, 2006; Moore 
and Lemischka, 2006; Wilson and Trumpp, 2006). The identification of these niches has 
been a major goal of the field. 
Osteoblasts are capable of influencing bone marrow HSC frequency. Osteoblasts 
secrete factors that regulate HSC maintenance and function (Arai et al., 2004; Nilsson et 
al., 2005; Stier et al., 2005; Taichman et al., 1996; Zhu et al., 2007) and genetic 
manipulations that increase osteoblast numbers in mice also increase the number of HSCs 
(Calvi et al., 2003; Zhang et al., 2003). Osteoclast function (Kollet et al., 2006), and the 
high levels of calcium thought to be generated from bone resorption (Adams et al., 2006), 
also regulate HSC migration and maintenance. These observations indicate that 
osteoblasts and the endosteum (the interface of bone and marrow where osteoblasts and 
osteoclasts localize) regulate HSC function and raise the question of whether HSCs 
localize to the endosteum itself, or whether they are influenced at a distance (directly or 
indirectly) by extracellular factors that diffuse from the endosteum. 
HSCs have been suggested to reside in direct contact with osteoblasts via 
homophilic adhesion between N-cadherin-expressing HSCs and N-cadherin-expressing 
osteoblasts (Wilson et al., 2004; Zhang et al., 2003). Ten percent of mouse c-kit+lineage-
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Sca-1+ cells stained with a commercial anti-N-cadherin antibody, and BrdU label-
retaining, N-cadherin+ bone marrow cells were observed in contact with osteoblasts 
(Zhang et al., 2003). However, it has not yet been tested whether these N-cadherin+ cells 
are HSCs or other cells that express similar markers. It also has not yet been tested 
whether N-cadherin is genetically required for HSC maintenance. 
Two laboratories have published microarray analyses of highly purified HSCs that 
include data on N-cadherin (Ivanova et al., 2002; Kiel et al., 2005). Neither detected N-
cadherin expression by HSCs, yet both detected N-cadherin expression by neural stem 
cells and embryonic stem cells using the same microarray platform (Ivanova et al., 2002; 
Molofsky et al., 2003). These studies raise the question of whether N-cadherin is 
expressed by HSCs. 
Apart from the role of N-cadherin is the more general question of where HSCs 
reside in bone marrow. We systematically examined the localization of HSCs in the bone 
marrow using SLAM family receptors and found that most HSCs reside on the surface of 
sinusoidal blood vessels (Kiel et al., 2005). SLAM family markers simplify and enhance 
the identification of HSCs as 45% of single CD150+CD48-CD41- bone marrow cells 
give long-term multilineage reconstitution in irradiated mice (Kiel et al., 2005). Almost 
all of these cells are c-kit+, Sca-1+, and lineage-, so these markers can be used in 
conjunction with SLAM markers to purify the same population of HSCs, though they add 
little additional purity (Kiel et al., 2005).  This ‘SLAM-code’ for HSCs has held up in 
every context of definitive hematopoiesis that we have examined (Kim et al., 2006; 
Yilmaz et al., 2006a). In our analysis, 60% of HSCs localized to sinusoids in the bone 
marrow, while 14% of HSCs localized to the endosteum (Kiel et al., 2005). Remaining 
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HSCs were in other locations. This raised the possibility that most HSCs reside in 
sinusoidal vascular niches - a possibility that was further supported by the recent 
discovery that CXCL12-expressing reticular cells also reside adjacent to these sinusoids 
(Sugiyama et al., 2006). 
It is unclear whether osteoblasts are physiologically required for HSC 
maintenance. To test this it would be necessary to deplete osteoblasts in vivo to test 
whether they are not only sufficient to increase HSC numbers (Calvi et al., 2003; Zhang 
et al., 2003), but also necessary for HSC maintenance. This has been done by ablating 
osteoblasts from adult Col1a1-TK mice (Visnjic et al., 2004; Zhu et al., 2007). The 
authors did not observe an acute loss of HSCs. Rather they observed an acute loss of 
differentiating cells, particularly B lineage progenitors. The frequency of c-kit+lineage-
Sca-1+ cells in bone marrow actually increased over time after osteoblast ablation 
(Visnjic et al., 2004; Zhu et al., 2007). HSCs depletion was not observed until weeks 
later, after bone marrow cellularity was severely reduced. This raises the question of 
whether HSCs are slowly lost as a direct consequence of osteoblast ablation or whether 
HSCs do not depend directly on osteoblasts but rather are ultimately depleted as a 
consequence of the loss of other cells. To resolve this question, the ideal approach would 
be to chronically deplete osteoblasts in vivo without inducing hematopoietic failure, to 
test whether this depletes HSCs. 
In this study we have been unable to detect N-cadherin expression in highly 
purified HSCs by a variety of phenotypic and functional approaches.  Thus, N-cadherin is 
unlikely to mediate homophilic adhesion between HSCs and osteoblasts.  Reductions in 
trabecular bone and osteoblasts in biglycan-deficient mice had no effect on 
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hematopoiesis, HSC frequency, or HSC function. We also confirmed that most HSCs 
localize to sinusoids within the bone marrow, and that almost all HSCs are found within 5 
cell diameters of a sinusoid. In contrast, only 8 to 21% of HSCs were within 5 cell 
diameters of endosteum. These data suggest that most HSCs do not acutely depend on 
contact with osteoblasts for their maintenance, though it remains possible that a subset of 
HSCs is maintained at or near the endosteum by mechanisms other than N-cadherin 
mediated adhesion. These results raise the question of whether the endosteum influences 
HSC localization and maintenance directly, by affecting a subset of HSCs that is present 
at the endosteum, or indirectly by the secretion of diffusible factors that influence the 




N-cadherin is not detectable in highly purified HSCs   
We examined N-cadherin expression by a variety of approaches in highly purified 
HSCs. First we tested whether HSCs expressed N-cadherin at the mRNA level by 
attempting to amplify N-cadherin from cDNA isolated from highly purified 
CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs. CD150+CD48-CD41-c-kit+Sca-
1+lineage- cells represented 0.0076±0.0021% of bone marrow cells in these experiments. 
This population contains all of the HSC activity from C57BL mouse bone marrow and 
47% of single cells within this population give long-term multilineage reconstitution in 
irradiated mice (Kiel et al., 2005). We were readily able to amplify N-cadherin from 
neonatal forebrain cells, which are known to express N-cadherin (Redies and Takeichi, 
1993) (Figure 3.1A,B). However, we were never able to amplify N-cadherin from 
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aliquots of CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs (Figure 3.1A,B). We were 
also unable to amplify N-cadherin from aliquots of c-kit+Sca-1+lineage-Flk2- HSCs 
(Figure 3.1A,B), which represented 0.021±0.001% of bone marrow cells and which are 
also highly enriched for HSCs (Christensen and Weissman, 2001; Kiel et al., 2005). In 
contrast, we were able to amplify similar amounts of hypoxanthine 
phosphoribosyltransferase (HPRT) from all of the samples (Figure 3.1B). Thus we were 
unable to detect N-cadherin transcripts in highly purified HSCs. 
To test N-cadherin expression at the protein level, we stained highly purified 
HSCs with two commercially available anti-N-cadherin antibodies and examined the 
staining by flow-cytometry. These antibodies included the YS polyclonal anti-N-cadherin 
antibody that has been used previously to stain bone marrow (Wilson et al., 2004; Zhang 
et al., 2003), and the GC-4 monoclonal anti-N-cadherin antibody that has been used 
previously to characterize N-cadherin expression by epithelial progenitors (Hayashi et al., 
2006). Both antibodies were able to stain neonatal forebrain cells by flow-cytometry 
(Figure 3.1C).  In contrast, neither antibody showed any staining above background on 
either CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs or c-kit+Sca-1+lineage-Flk2- 
HSCs (Figure 3.1D). Thus we were unable to detect N-cadherin expression on the surface 
of highly purified HSCs using commercially available antibodies. 
If a subset of HSCs adheres to the endosteum, it is possible that these cells might 
be depleted within marrow samples that are obtained by flushing the marrow cavity with 
medium. To test whether this approach leaves behind significant numbers of HSCs, we 
used a bone burr (a drill, see Methods) to remove any cells remaining in the flushed 
marrow cavity.  Representative images of sections through the marrow cavity from 
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unmanipulated bone, flushed bone, and burred bone are shown in Figure 3.2 (A-C).  The 
vast majority of bone marrow cells were removed by simply flushing the bone marrow 
cavity: we did not observe residual bone marrow cells on most endosteal surfaces after 
flushing (Figure 3.2B). Nonetheless, there were some locations where residual bone 
marrow cells were present (Figure 3.2Bii). After scoring the endosteal surface with the 
bone burr these residual cells were effectively removed (Figure 3.2C). We did not detect 
any difference in overall viability or in the frequency of CD150+CD48-CD41-c-kit+Sca-
1+lineage- HSCs in the burred fraction of bone marrow cells as compared to the flushed 
fraction of cells (Figure 3.2D). Moreover, the total number of bone marrow cells isolated 
in the burred fraction was only 1.6% of the bone marrow cells recovered by flushing. 
Combining these statistics means that 98.5% of all HSCs in the bone marrow were 
removed by flushing: 6750±2280 HSCs were isolated from the long bones (2 femurs and 
2 tibias) by flushing and only an additional 106±52 were recovered using the bone burr. 
This suggests that significant numbers of HSCs are not left behind when the marrow is 
carefully flushed out of the long bones. 
To test whether the HSCs that were recovered using the bone burr were 
functionally distinct from the HSCs isolated by flushing we performed competitive 
reconstitution assays on 300,000 flushed or burred bone marrow cells. Four of 6 
recipients of burred bone marrow cells and 7 of 7 recipients of flushed bone marrow cells 
became long-term multilineage reconstituted by donor cells (Figure 3.2F). There was no 
statistically significant difference between the levels of donor cells that arose from 
flushed versus burred bone marrow cells (Figure 3.2F). 
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No evidence for N-cadherin expression by HSCs in gene trap mice 
 We sought to confirm the lack of N-cadherin expression by HSCs using an 
independent approach. N-cadherinlacZ gene trap mice (Omnibank Sequence Tag OST 
49160, generated by Lexicon Genetics) have been generated by retroviral insertion of 
lacZ into the first intron of N-cadherin, along with a strong splice acceptor sequence (Luo 
et al., 2005). lacZ is expressed in these mice under the control of the N-cadherin native 
promoter and other regulatory elements, allowing N-cadherin expression to be visualized 
based on ß-galactosidase activity. ß-galactosidase expression in these mice matches the 
known pattern of N-cadherin expression in nervous system, heart, somites, and limbs 
(Luo et al., 2005). Myocardium sections from N-cadherinlacZ gene trap mice but not 
littermate controls showed clear ß-galactosidase activity throughout the myocardium 
(Figure 3.3) as reported previously (Luo et al., 2005). c-kit+Sca-1+lineage-Flk2- HSCs 
and CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs from Rosa mice (which 
ubiquitously express ß-galactosidase) showed ß-galactosidase activity (Figure 3.4A), but 
not HSCs from N-cadherinlacZ gene trap mice (Figure 3.4C) or littermate controls (Figure 
3.4B). Thus we were unable to detect N-cadherin expression by HSCs in N-cadherinlacZ 
gene trap mice. 
 In case N-cadherin expression is induced by activation, we also examined N-
cadherin expression by HSCs in culture and after mobilization by cyclophosphamide/G-
CSF. We cultured CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs from Rosa mice and 
from N-cadherinlacZ gene trap mice in liquid medium containing stem cell factor, 
thrombopoietin, insulin-like growth factor II, and acidic fibroblast growth factor 
(conditions that have been found to promote the maintenance of HSCs in culture) (Zhang 
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and Lodish, 2005) for 4 days and then stained with X-Gal.  Cells cultured from Rosa 
mice exhibited clear ß-galactosidase activity, but not HSCs from N-cadherinlacZ gene trap 
mice or littermate controls (Figure 3.5). We were similarly unable to detect ß-
galactosidase expression by CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs from the 
bone marrow or spleen of N-cadherinlacZ gene trap mice or littermate controls that had 
been treated with cyclophosphamide/G-CSF, but readily detected ß-galactosidase activity 
in HSCs from Rosa mice (Figure 3.5B). Finally, we also failed to detect N-cadherin 
staining on CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs from the spleen of 
cyclophosphamide/G-CSF mobilized mice using either the YS or GC-4 antibodies. Thus 
we were unable to detect N-cadherin expression by cultured HSCs or by mobilized HSCs. 
 
N-cadherin expressing bone marrow cells do not have HSC activity 
  Using the YS anti-N-cadherin antibody and the GC-4 anti-N-cadherin antibody, 
we sorted bone marrow cells into N-cadherin+ and N-cadherin- fractions (Figure 3.6A), 
then injected each fraction into irradiated mice in competitive reconstitution assays. The 
doses of cells were initially selected based on the fractions of N-cadherin+ and N-
cadherin- bone marrow cells that were contained in 200,000 whole bone marrow cells, as 
has been done in prior studies of marker expression by HSCs (Kiel et al., 2005). For 
example, in one experiment N-cadherin+ bone marrow cells that stained positively using 
the YS antibody represented 2% of bone marrow cells. As a result, we injected 4,000 N-
cadherin+ bone marrow cells or 196,000 N-cadherin- bone marrow cells into irradiated 
mice. Most (13/17) of the mice injected with N-cadherin- bone marrow cells became 
long-term multilineage reconstituted by donor cells, whereas none (0/17) of the mice 
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injected with N-cadherin+ cells became long-term multilineage reconstituted by donor 
cells (Figure 3.6A-C). We were thus unable to detect HSC activity among N-cadherin+ 
cells. 
 While this suggested that most HSCs were N-cadherin-, it left open the possibility 
that a minority of HSCs were N-cadherin+ and that we did not inject enough cells to 
detect this subset of HSCs. To address this we performed an independent experiment 
using the GC-4 antibody in which we injected the number of cells that would be present 
in 300,000 bone marrow cells.  In this experiment around 5% of bone marrow cells 
stained with GC-4, so we injected 15,000 N-cadherin+ bone marrow cells or 285,000 N-
cadherin- bone marrow cells into irradiated mice. To be certain that we did not miss any 
activity in the N-cadherin+ fraction, we included a second group of mice that was 
injected with 45,000 N-cadherin+ bone marrow cells.  Mice injected with N-cadherin- 
bone marrow cells always (12/12) became long-term multilineage reconstituted by donor 
cells, whereas none (0/13) of the mice injected with either dose of N-cadherin+ bone 
marrow cells became long-term multilineage reconstituted by donor cells (Figure 3.6A-
C). We thus failed to detect any HSC activity among N-cadherin+ bone marrow cells. 
 
N-cadherin expressing bone marrow cells have little progenitor activity in culture 
To test whether N-cadherin+ bone marrow cells have any progenitor activity we 
plated N-cadherin+ and N-cadherin- bone marrow cells in cytokine-supplemented 
methylcellulose medium and assayed the colony-forming ability of each fraction (Table 
3.1). When highly purified HSCs (such as CD150+CD48-CD41-c-kit+Sca-1+lineage- 
cells) are sorted into methylcellulose culture, more than 90% of the single cells form 
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colonies and the vast majority of the colonies are either CFU-GEMM (that contain 
granulocytes, erythrocytes, macrophages, and megakaryocytes) or CFU-GM (that contain 
granulocytes and macrophages) (Yilmaz et al., 2006b). Whether the YS or the GC-4 anti-
N-cadherin antibody was used to fractionate bone marrow cells, virtually all colony-
forming activity was in the N-cadherin- fraction of bone marrow cells, including all CFU-
GEMM and more than 99% of all CFU-GM (Table 3.1). We also sorted N-cadherin+ and 
N- cadherin- bone marrow cells into methylcellulose based on FDG staining of cells from 
N-cadherinlacZ gene trap mice. Again, virtually all colony-forming activity was in the N-
cadherin- fraction of bone marrow cells (Table 3.1). N-cadherin+ bone marrow cells 
rarely formed colonies in culture, particularly the types of colonies that are formed by 
HSCs. 
  
Osteoblast depletion does not necessarily lead to HSC depletion 
 The foregoing data suggest that N-cadherin is unlikely to act within HSCs to 
regulate their localization or function. However, this does not address the role of 
osteoblasts themselves in regulating bone marrow HSCs as they could still influence 
HSCs by other mechanisms.  To better understand the role that osteoblasts play in 
maintaining HSCs, we tested whether there was a quantitative relationship between 
osteoblast frequency and HSC frequency in the bone marrow. We examined biglycan-
deficient mice to test whether depletion of osteoblasts and osteoblast progenitors would 
reduce the number of HSCs, as would be expected if osteoblasts are quantitatively 
required for HSC maintenance. 
   
 95 
 Biglycan is an extracellular matrix proteoglycan that is most prominently 
expressed by osteoblasts and chondrocytes (Xu et al., 1998) (Figure 3.11A). biglycan–
deficient mice develop an osteoporosis-like phenotype, with less trabecular bone, fewer 
osteoblasts, and fewer osteoblast progenitors (Chen et al., 2002; Xu et al., 1998) (Figure 
3.11B-D). This is evident in 3 month-old mice, but worsens with age. We detected no 
statistically significant differences among biglycan–deficient mice and littermate controls 
of any age in the frequency of myeloid, erythroid, B, or T lineage cells in the bone 
marrow (Figure 3.12A) or spleen (Figure 3.12B). We also did not detect any differences 
in bone marrow cellularity (Figure 3.13A), or the number (Figure 3.13B) or type (Figure 
3.13C) of colony-forming progenitors in the bone marrow. The depletion of osteoblasts in 
biglycan–deficient mice did not lead to discernable hematopoietic defects. 
 We also directly assayed HSC frequency and function in these mice. We did not 
detect any differences among biglycan–deficient mice and littermate controls at 3, 9 to 
15, or 24 months of age in the frequency (Figure 3.13D) or absolute number (Figure 
3.13E) of CD150+CD48-CD41-c-kit+Sca-1+ HSCs in the bone marrow. To test HSC 
function, we transplanted 300,000 whole bone marrow cells from 3 month-old biglycan-
deficient mice or littermate controls into 3 to 6 month old biglycan-deficient or control 
recipients, along with 300,000 wild-type recipient bone marrow cells for radioprotection. 
Donor mice in these experiments were CD45.2+ while recipient mice were CD45.1+, 
irrespective of genotype. The biglycan-deficient bone marrow cells gave similar levels of 
long-term multilineage reconstitution as wild-type donor cells, whether they were 
transplanted into wild-type or biglycan-deficient recipients (Figure 3.13F).  These data 
indicate that biglycan deficiency had no effect on the level of reconstituting activity in 
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competitive reconstitution assays, irrespective of whether the donors, or the recipients, or 
both were biglycan-deficient. Thus we detected no effect of biglycan-deficiency on HSC 
frequency or function. 
 
HSCs in wild-type and biglycan-deficient bone marrow localize primarily to 
sinusoids 
 
 Using methods described previously (Kiel et al., 2005), we cut sections through 
the bone marrow of wild-type and biglycan-deficient mice and stained with SLAM 
family markers to localize HSCs. We observed no statistically significant differences 
among wild-type and biglycan-deficient mice in terms of the proportions of all bone 
marrow cells that were adjacent to, or within 5 cell diameters of, sinusoids or endosteum 
(Figure 3.14B). While not statistically significant, biglycan-deficient mice tended to have 
a lower proportion of bone marrow cells adjacent to, or within 5 cell diameters of, 
endosteum (Figure 3.14B), consistent with the reduced trabecular bone in these mice 
(Figure 3.11B, C). 
Most bone marrow HSCs appeared to localize to sinusoids. CD150+CD48-CD41-
lineage- cells are very highly enriched for HSCs (Kiel et al., 2005), and represented 
0.0042 to 0.0049% of cells in bone marrow sections in these experiments (Figure 3.14C). 
In both wild-type and biglycan-deficient mice, 58% of CD150+CD48-CD41-lineage- 
cells that we identified in sections were adjacent to sinusoids and almost all of these cells 
(92-95%) were within 5 cell diameters of a sinusoid. This suggests that HSCs are 
approximately 5-fold more likely than other bone marrow cells to be adjacent to 
sinusoids, consistent with our earlier observations (Kiel et al., 2005). Moreover, the fact 
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that nearly all HSCs are close to sinusoids suggests that nearly all HSCs are likely to be 
influenced by factors secreted by perivascular cells (Sugiyama et al., 2006). 
A smaller and potentially more variable proportion of HSCs localized to the 
endosteum. In wild-type mice we did not detect any CD150+CD48-CD41-lineage- cells 
at the endosteum while in biglycan-deficient mice 4 of 19 (21%) CD150+CD48-CD41-
lineage- cells localized to the endosteum. In our prior study (Kiel et al., 2005), we 
observed 14% of wild-type CD150+CD48-CD41-lineage- cells localized to the 
endosteum. Thus these results are consistent with our earlier study in suggesting that a 
minority of bone marrow HSCs are present at the endosteum at any point in time. We 
also did not detect many HSCs that were within 5 cell diameters of the endosteum: only 
8-21% of HSCs were visibly within 5 cell diameters of the endosteum in these 
experiments. Nonetheless, this suggests that HSCs are more likely than other bone 
marrow cells to be close to the endosteum, even in mice in which osteoblasts and 
trabecular bone have been depleted. These results are consistent with the possibility that 
the endosteum may represent a niche for a subset of HSCs despite the depletion of 
osteoblasts; however, most HSCs either do not require contact with cells at the 




 A recent model of the HSC niche holds that HSCs adhere to the surface of 
osteoblasts by N-cadherin-mediated homophilic adhesion, and that HSCs acutely depend 
upon this interaction for their maintenance. But while this model has received 
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considerable attention, no study has yet shown that N-cadherin-expressing bone marrow 
cells have HSC activity or that N-cadherin is required by HSCs for their maintenance. 
When we examined N-cadherin expression in very highly purified HSCs we were 
unable to detect N-cadherin expression by PCR (Figure 3.1A,B), by staining with the YS 
anti-N-cadherin antibody (Figure 3.1D), by staining with the GC-4 anti-N-cadherin 
antibody (Figure 3.1D), or by analyzing ß-galactosidase expression in N-cadherinlacZ gene 
trap mice (Figure 3.4C). This failure to detect N-cadherin expression did not depend on 
the use of SLAM family markers, as we were also unable to detect N-cadherin expression 
in c-kit+Sca-1+lineage-Flk2- cells. These results are consistent with earlier results from 
us and others that failed to detect N-cadherin expression by HSCs by microarray analysis 
(Ivanova et al., 2002; Kiel et al., 2005). 
Consistent with this, all of the HSC activity in long-term reconstitution assays 
came from the N-cadherin- fraction of bone marrow cells, irrespective of whether we 
used the YS or the GC-4 anti-N-cadherin antibodies (Figure 3.6). This did not simply 
reflect an inability of N-cadherin+ bone marrow cells to engraft in vivo, as N-cadherin+ 
bone marrow cells were rarely able to form primitive colonies in culture (Table 1). We 
were thus unable to detect primitive progenitor activity from N-cadherin+ bone marrow 
cells in vitro or in vivo. The only exception is that 3 of 30 irradiated mice that were 
injected with N-cadherin+ bone marrow cells became transiently multilineage 
reconstituted by low levels of donor cells (Figure 3.6B,C). This raises the possibility that 
a small subset of transiently reconstituting multipotent progenitors might express N-
cadherin, though it is also possible that N-cadherin- cells contaminated the N-cadherin+ 
fraction. 
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 Although these data indicate that HSCs are unlikely to be autonomously regulated 
by N-cadherin, it remains possible that osteoblasts play an important role in the 
maintenance of bone marrow HSCs through other mechanisms. But if HSCs do not 
adhere to the surface of osteoblasts using N-cadherin, how do osteoblasts influence HSC 
frequency? 
A first step is to determine whether there is a quantitative relationship between 
HSCs and osteoblasts in bone marrow. Although biglycan deficiency leads to progressive 
osteoblast depletion with age (Xu et al., 1998), we did not detect any effect of biglycan 
deficiency on hematopoiesis, or HSC frequency or function irrespective of age (Figure 
3.13). These data indicate there is not a quantitative relationship between HSCs and 
osteoblasts in the bone marrow: while modest increases in osteoblast numbers modestly 
increase HSC numbers (Calvi et al., 2003; Zhang et al., 2003), modest decreases in 
osteoblast numbers do not necessarily decrease HSC numbers. Osteoblasts are therefore 
not limiting for the creation of adult HSC niches. Nonetheless, osteoblasts were never 
completely eliminated from biglycan-deficient mice (Figure 3.7), so this study does not 
suggest that these cells are not involved in HSC maintenance. 
We also confirmed our observation that approximately 60% of bone marrow 
CD150+CD48-CD41-lineage- cells localize to sinusoids at any one time (Figure 3.14). 
Moreover, we extended this observation by finding that almost all bone marrow 
CD150+CD48-CD41-lineage- cells localize within 5 cell diameters of sinusoids (Figure 
3.14). This suggests that almost all bone marrow HSCs are present in or near perivascular 
environments. When combined with the observation that perivascular reticular cells are a 
major source of CXCL12, a factor that is required for HSC maintenance (Sugiyama et al., 
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2006), that endothelial cells can promote the maintenance of HSCs in culture (Li et al., 
2004; Ohneda et al., 1998), and that endothelial cell function is required for adult bone 
marrow hematopoiesis in vivo (Yao et al., 2005), these data suggest that at least some 
bone marrow HSCs are maintained in perivascular niches. 
A variety of other factors that regulate HSCs and hematopoiesis are also 
expressed around the vasculature in bone marrow (Kopp et al., 2005). It is also possible 
that mechanisms that have been suggested to regulate endosteal cells, such as 
sympathetic nervous system activity (Katayama et al., 2006), also regulate perivascular 
cells. Nonetheless, additional studies will be required to test whether perivascular cells 
act directly on HSCs to promote their maintenance. It is also important to bear in mind 
that some HSCs observed near sinusoids may be migrating through these environments 
(Wright et al., 2001), rather than being maintained there. 
It was recently observed that most bone marrow HSCs reside within relatively 
hypoxic environments (Parmar et al., 2007). Although it has not yet been determined 
which regions of the bone marrow are most hypoxic, it is conceivable that sinusoids are 
among the most hypoxic microenvironments. Sinusoids not only carry venous circulation, 
but it is slow venous circulation that is not designed to transport oxygen so much as to 
allow cells to enter and exit circulation. In contrast, a rich supply of arterial blood flows 
by and through the endosteum to nourish bone. This issue will require additional studies. 
While our data emphasize the potential role played by perivascular cells in the 
regulation of HSCs, they do not rule out a role for osteoblasts. We have observed a 
minority of CD150+CD48-CD41-lineage- cells that localize to the endosteum in this 
(Figure 3.14) and prior studies (Kiel et al., 2005). However, these cells are considerably 
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more likely than other bone marrow cells to localize to the endosteum (Figure 3.14B 
versus C). This is consistent with the suggestion that a subset of HSCs localizes to the 
endosteum (Arai et al., 2004; Kiel et al., 2005; Nilsson et al., 2001; Sugiyama et al., 
2006; Suzuki et al., 2006; Zhang et al., 2003) and that osteoblasts and osteoclasts may 
regulate the maintenance and migration of at least some HSCs (Adams et al., 2006; Arai 
et al., 2004; Calvi et al., 2003; Kollet et al., 2006; Zhang et al., 2003). Nonetheless, our 
data suggest that osteoblasts are unlikely to regulate HSCs by N-cadherin mediated 
homophilic adhesion. As with perivascular cells, in order to formally test whether there is 
an endosteal niche for HSCs it will be necessary to test whether endosteal cells act 
directly on HSCs to promote their maintenance through mechanisms that are required in 
vivo. 
Our demonstration that N-cadherin is not likely to regulate the adhesion of HSCs 
to osteoblasts, and the prior demonstration that Notch1/Jagged1 interactions are not 
required for HSC maintenance (Mancini et al., 2005) means that all of the mechanisms by 
which endosteal cells have been proposed to regulate HSCs involve secreted factors. This 
raises a number of questions. First, do these factors act directly on HSCs or do they act 
indirectly through third party cells? Endosteal cells may regulate HSC maintenance 
primarily by recruiting other bone marrow cells, like vascular cells (Tombran-Tink and 
Barnstable, 2004), raising the possibility that osteoblasts could promote HSC 
maintenance by recruiting vascular niches.  Second, if factors secreted from the 
endosteum act directly on HSCs, do they act only on the subset of HSCs that localizes to 
the endosteum or do they diffuse to other microenvironments? Third, are the HSCs that 
localize near sinusoids different from the HSCs that localize near the endosteum? So far 
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there is no evidence for this, as nearly all CD150+CD48-CD41-lineage- cells are 
quiescent (Kiel et al., 2005) and there is no evidence for a deeply quiescent subset of 
HSCs that goes months without dividing (Cheshier et al., 1999). Nonetheless, it remains 
possible that HSCs in different locations differ in other ways. Finally, it would be 
interesting to be able to test how often HSCs migrate between sinusoidal and endosteal 
environments. 
 Much remains to be learned regarding the identities of the cells that contribute to 
the maintenance of HSCs, and the mechanisms by which they contribute.  These 
mechanisms will likely be complex, involving multiple cell types and gene products, 
some of which act directly on HSCs and others that act indirectly through third-party 
cells. While the direct genetic experiments are conducted to elucidate these mechanisms, 
it will be important for working models of HSC niches to acknowledge this potential 
complexity. 
 
MATERIALS AND METHODS 
Mice 
C57BL/Ka-Thy-1.1 (Ly5.2) and C57BL/Ka-Thy-1.2 (Ly5.1) mice were housed in 
the Unit for Laboratory Animal Medicine at the University of Michigan. Adult mice were 
sacrificed between 8 and 10 weeks of age unless otherwise stated. For analysis of N-
cadherin expression in the forebrain, neonatal mice were sacrificed 1 to 4 days after birth. 
Experiments to characterize hematopoiesis in biglycan-deficient mice (an X-linked gene) 
were performed only on males.   
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Flow-cytometry and the isolation of HSCs 
Bone marrow cells were flushed from the long bones (tibias and femurs) with 
Hank’s buffered salt solution without calcium or magnesium, supplemented with 2% 
heat-inactivated calf serum (GIBCO, Grand Island, NY; HBSS+). Cells were triturated 
and filtered through nylon screen (45 um, Sefar America, Kansas City, MO) to obtain a 
single cell suspension.  For isolation of c-kit+Sca-1+lineage- cells, whole bone marrow 
cells were incubated with PE-conjugated monoclonal antibodies to lineage markers 
including B220 (6B2), CD3 (KT31.1), CD4 (GK1.5), CD8 (53-6.7), Gr-1 (8C5), Mac-1 
(M1/70), Ter119 and IgM in addition to FITC-conjugated anti-Sca-1 (Ly6A/E; E13-6.7) 
and biotin-conjugated anti-c-kit (2B8). c-kit staining was visualized using streptavidin 
APC-Cy7. Where indicated, an antibody against Flk2 (A2F10.1) was used to isolate 
Flk2- progenitors. For isolation of CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs, 
bone marrow cells were incubated with PE-conjugated anti-CD150 (TC15-12F12.2; 
BioLegend, San Diego, California), FITC-conjugated anti-CD48 (HM48-1; BioLegend), 
FITC-conjugated anti-CD41 (MWReg30; BD Pharmingen, San Diego, California), 
biotin-conjugated anti-Sca-1 (E13-6.7), and PE-Cy5-conjugated anti-c-kit (2B8) 
antibody, in addition to antibodies against the following FITC-conjugated lineage 
markers: Ter119, B220 (6B2), Gr-1 (8C5) and CD2 (RM2-5).  HSCs were sometimes 
pre-enriched by selecting Sca-1+ or c-kit+ cells using paramagnetic microbeads and 
autoMACS (Miltenyi Biotec, Auburn, CA).  Non-viable cells were excluded from sorts 
and analyses using the viability dye DAPI (1ug/ml).   
For isolation of bone marrow cells using the bone burr, bones were flushed with 
HBSS+, then the lumen of bones was briefly drilled with a high-speed micro-drill using a 
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0.5mm diameter steel bone-burr (Fine Science Tools, Foster City CA). The bones were 
then eluted a second time with HBSS+, triturated, and passed through a 27G needle 
several times prior to filtering through nylon mesh as above. 
Methods for staining bone marrow sections for the localization of HSCs are as 
described previously (Kiel et al., 2005).    
 
N-cadherin and Biglycan antibody staining 
 Cells were stained with antibodies against the extracellular domain of N-cadherin 
(YS, IBL, Japan; GC-4, SIGMA, St. Louis, MO) at 1:50-1:100 for 25 minutes on ice. 
Cells were then stained with APC or Cy5 conjugated secondary antibodies (Jackson 
Immunoresearch, West Grove, PA). Biglycan staining in sections was performed using a 
polyclonal antiserum provided by Dr. Larry Fisher (Bianco et al., 1990). 
 
Methylcellulose cultures 
 Sorted bone marrow cells were plated in wells of 96-well plates (Corning, 
Corning NY) containing 100ul 1.0% methylcellulose (Stem Cell Technologies, 
Vancouver, BC) as previously described. The methylcellulose was supplemented with 
1% penicillin/streptomycin (Gibco), 50ng/ml stem cell factor (SCF), 10ng/ml interleukin-
3 (IL-3), 10ng/ml interleukin-6 (IL-6) and 3U/ml erythropoietin (Epo). Colonies were 
maintained at 37oC in humidified incubators at 6% O2. Colony formation was scored after 
10-14 days of culture. 
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Long-term competitive repopulation assay 
Adult recipient mice (CD45.2) were irradiated with an Orthovoltage X-ray source 
delivering approximately 300 rad/min in two equal doses of 570 rad, delivered at least 2 
hr apart.  Cells were injected into the retro-orbital sinus of anesthetized recipients.  In 
addition to the sorted populations of CD45.1 cells, each recipient mouse received 
200,000 to 300,000 CD45.2 marrow cells for radioprotection.  Beginning at 4 weeks after 
transplant and continuing until at least 16 weeks following transplantation blood was 
obtained from the tail veins of recipient mice, subjected to ammonium-chloride 
potassium red cell lysis, and stained with directly conjugated antibodies to CD45.1 (A20, 
FITC), B220 (6B2), Mac-1 (M1/70), CD3 (KT31.1), and Gr-1 (8C5) to monitor 
engraftment.   
 
FDG staining 
Analysis of beta-galactosidase expression using fluorescein di-beta-D-
galactopyranoside (FDG; Molecular Probes, Invitrogen, Carlsbad CA) was carried out 
according to manufacturer’s instructions.  Bone marrow cells, previously stained with 
antibodies for the isolation of HSCs as described above and enriched for c-kit+ cells, 
were incubated for 1 to 5 minutes at 37oC in a hypotonic solution comprised of equal 
parts deionized H20 and PBS with 2mM FDG. After the incubation, cells were washed 
and analyzed by flow-cytometry. For these experiments, c-kit+Sca-1+lineage- HSCs 
were isolated using Sca-1-APC and c-kit-PE-Cy5 antibodies. ß-galactosidase activity in 
CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs was assessed by sorting these (FITC 
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negative) HSCs, then staining with FDG, and analyzing by flow-cytometry. In all cases, 
cells from a negative control littermate were stained and analyzed at the same time. 
 
X-Gal staining 
 For X-gal staining, slides were thawed at room temperature for 15 minutes, fixed 
in 0.25% glutaraldehyde in PBS at 4oC for 30min, rinsed in 0.1M phosphate buffer (PB) 
twice, incubated in X-Gal staining medium (0.1M PB containing 10 mM K3Fe(CN)6 and 
10 mM K4Fe(CN)6 along with the beta-galactosidase substrate X-gal (1 mg/ml; Molecular 
Probes)) at 37 °C for 4-12 hours, then rinsed three times in 0.1M PB at room temperature.  
Finally, the excess buffer was shaken off and the slides were mounted in 70% glycerol in 
PBS.  Positive (tissue isolated from ROSA mice) and negative controls (tissue isolated 
from wild-type littermate mice) were always stained and analyzed in parallel with slides 
from N-CadherinlacZ gene trap mice.  Images were gathered using an Olympus 
Florescence Microscope.   
 
Quantitative PCR 
2,000 to 10,000 HSCs or bone marrow cells were directly sorted into 400ul Trizol 
(Ambion, Austin, TX) containing 250ug/ml glycogen (Roche, Indianapolis IN). RNA 
was extracted according to manufacturer’s instructions. The extracted RNA (30ul 
volume) was treated for 20min at 37oC with RNase-free DNase-I (2U/ul; Ambion) in the 
presence of 2ul RNase inhibitor (10U/ul; Invitrogen). The RNA was then purified using 
an RNeasy Mini Kit (Qiagen, Valencia CA) according to manufacturer’s instructions and 
washed three times with 500ul RNase-free water. The RNA was used for making cDNA 
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by reverse transcription with 1ug random hexamer. The cDNA was extracted with 
phenol-chloroform and precipitated with 20ug glycogen. After dissolving the cDNA with 
RNase-free water, cDNA equivalent to 200 cells was used for each PCR reaction. The 
PCR reactions were performed using a LightCycler (Roche Diagnostic Corporation) 
according to manufacturer’s instructions. The RNA content of samples was normalized 
based on the amplification of hypoxanthine phosphoribosyl transferase (HPRT).  In 
addition to confirming the specificity of the PCR reactions by examining the melting 
curves of the products, PCR products were separated in 2% agarose gels to confirm the 
presence of a single band of the expected size. 
Primer sequences for amplification of N-cadherin were as described previously 
(Arai et al., 2004):  N-cadherin F-AGAGGGATCAAAGCCTGGGACGTAT and N-
cadherin R-TCCACCCTGTTCTCAGGGACTTCTC. Primer sequences for amplification 
of HPRT were as described previously (Kiel et al., 2005): HPRT F-
CCTCATGGACTGATTATGGACA and HPRT R-
ATGTAATCCAGCAGGTCAGCAA. 
 
Staining of bone marrow sections 
HSC localization in bone marrow sections was performed as previously described 
(Kiel et al., 2005) with minor modifications.  Freshly dissected undecalcified femurs 
from 9-15 month old wild-type and biglycan-deficient mice were embedded in 8% gelatin 
(Sigma) in phosphate buffer and snap frozen in N-methylbutane chilled in a slurry of 
ethanol and dry ice. Sections (5 µm) were cut using the CryoJane system (Instrumedics, 
Hackensack, New Jersey), a tungsten carbide blade (Diamond Knives, Wilmington DE) 
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and Bright Cryostat (Huntingdon, UK) at -24°C and placed on methacrylate coated 
slides. The sections were air-dried overnight at room temperature and subsequently fixed 
in -20°C acetone for 5 minutes. Slides were then blocked with 20% goat serum in 0.1M 
phosphate buffer (pH 7.4) for 40 minutes prior to antibody staining. Slides were first 
incubated in 0.03µg/µl 26D12 anti-CD150 antibody (DNAX, Palo Alto CA) for 2 hr and 
rinsed. Goat anti-rat IgG conjugated to Alexa555 (Molecular Probes) was added at 1/100 
dilution and rinsed. Slides were then incubated in 0.1µg/µl rat IgG (Sigma-Aldrich) for 
10 minutes and rinsed.  FITC-conjugated anti-CD48 and FITC-conjugated anti-CD41 
antibodies (each 1/100 dilution) as well as FITC-conjugated lineage markers including 
anti-B220 (stains B cells), CD2 (T cells), CD4 (T cells), CD8a (T cells), Gr-1 (myeloid 
cells) and CD11b (myeloid cells) antibodies (1/100 to 1/200 dilution), and biotinylated 
pan-endothelial cell antigen (MECA-32) at a 1/30 dilution were then incubated for 1 hour 
in 0.1µg/µl rat IgG and rinsed.  Pan-endothelial cell antigen was visualized with 
Alexa647-conjugated streptavidin (Molecular Probes) at a 1/200 dilution for 1 hour.  
Finally, slides were rinsed twice for 5 min each and mounted without drying using 
Prolong Antifade (Molecular Probes).  All antibody incubations took place in blocking 
buffer. All rinse steps were 2 times for 3 min each with blocking buffer unless otherwise 
indicated. All antibodies were purchased from Becton Dickinson unless otherwise noted. 
The nuclear dye DAPI was included in all stains to evaluate nuclear morphology and to 
exclude debris (lacking a nucleus), or dying cells (with fragmented nuclei). Microscopy 
was performed using an Olympus BX51 florescence microscope or an Olympus FV-500 
confocal microscope. 
   
 109 
For von Kossa staining of bone marrow sections, slides were equilibrated to room 
temperature, fixed in acetone at –20oC for 15 minutes, rinsed in water, incubated in 5% 
silver nitrate for 1 hour at room temperature in the dark, rinsed, incubated in 
photographic developer solution for 5 minutes, rinsed, incubated in 0.1% gold chloride, 
rinsed, fixed in 5% sodium thiosulfate for 5 minutes, rinsed, stained in Wright-Giemsa 
for 30 seconds and rinsed prior to imaging.  
For osteopontin staining of bone marrow, sections were fixed in acetone at –20oC 
for 5 minutes, washed in 0.1M phosphate buffer, incubated with primary osteopontin 
antibody (Chemicon, Billerica MA) for 2-3 hours at room temperature, then incubated in 
anti-rat IgG Alexa 555 (Molecular Probes, Carlsbad CA) for 2 hours at room 
temperature, stained with DAPI (Sigma-Aldrich, St. Louis MO) and mounted with Anti-
Fade (Molecular Probes).  The average number of nucleated bone-lining osteopontin+ 
cells within the medullary space of the bone was calculated per high power field in the 
distal third of the femur. 
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Table 3.1:  The N-cadherin+ fraction of bone marrow cells has little capacity to 





















that were in 
this fraction 
YS Ab N-cad+ 0.01±0.02% 0.03±0.08% 0% 0.05±0.11% 
 N-cad- 0.41±0.08% 99.97±0.08% 100% 99.95±0.11% 
GC-4 Ab N-cad+ 0.2±0.2% 0.7±0.4% 0% 0.8±0.6% 
 N-cad- 0.5±0.03% 99.3±0.4% 100% 99.2±0.6% 
      
N-cad+/+  FDG+ 0.53±0.19% 1.4±1.7% 0% 1.3±1.5% 
 FDG- 0.51±0.02% 98.6±1.7% 100% 98.7±1.5% 
N-cadlacZ FDG+ 0.56±0.31% 2.4±0.89% 0% 1.9±0.7% 
 FDG- 0.48±0.04% 97.6±0.89% 100% 98.1±0.7% 
 
N-cadherin+ or N-cadherin- bone marrow cells were sorted based on staining with the YS 
polyclonal antibody, the GC-4 monoclonal antibody, or based on FDG staining for ß-
galactosidase activity in N-cadherin+/+ wild-type (control) mice or N-cadherinlacZ gene 
trap mice. Cells were plated in methylcellulose medium supplemented with SCF, IL-3, 
IL-6, and Erythropoietin.  After 10 to 14 days the number and type of colonies was 
counted. The data represent 4-6 independent experiments in which an average of 16,000 
to 17,500 N-cadherin- bone marrow cells or 3,000 to 5,400 N-cadherin+ bone marrow 
cells were plated per experiment (based on antibody staining) and 2 independent 
experiments in which 18,000 to 27,000 FDG- bone marrow cells or 900 FDG+ bone 
marrow cells were plated per experiment.  There was no statistically significant 
difference in the colonies formed by the FDG+ fraction of cells from control wild-type 
mice as compared to N-cadherinlacZ gene trap mice, suggesting that the FDG staining in 
rare colony-forming progenitors may be attributable to background. The three columns 
on the right side of the table show the percentage of all CFU-C, CFU-GEMM, and CFU-
GM from bone marrow that fall into the N-cadherin+ or N-cadherin- fractions of cells. 








Figure 3.1: Failure to detect N-cadherin mRNA or protein expression by highly 
purified HSCs.   (A) N-cadherin could be readily amplified from three independent 
samples of neonatal forebrain cells but not CD150+CD48-CD41-c-kit+Sca-1+lineage- 
HSCs or c-kit+Sca-1+lineage-Flk2- HSCs by quantitative PCR, despite amplifying 
similar amounts of HPRT from the same samples. Data show the amplification of 
transcript against cycle number (left panel) as well as the melting curve, demonstrating 
specific amplification of HPRT in all samples but N-cadherin only in forebrain samples. 
These data are representative of three independent experiments using 4 to 5 
independently sorted HSC aliquots. 200 cell equivalents of cDNA were used per reaction. 
(B) PCR products were separated on a 2% agarose gel that revealed a product of the 
expected size for N-cadherin only in forebrain samples. Sequencing revealed that this 
product was N-cadherin but that bands of other sizes in other lanes were non-specific 
products. (C) Polyclonal (YS) and monoclonal (GC-4) anti-N-cadherin antibodies were 
used to stain neonatal forebrain cells. Staining was examined by flow-cytometry relative 
to control cells stained only with secondary antibodies. (D) We could not detect N-
cadherin staining above background with either the YS or GC-4 antibodies on 
CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs or c-kit+Sca-1+lineage-Flk2- HSCs. 
These data are representative of 3 to 9 independent experiments. 
 































Figure 3.2: Flushing with medium washes the vast majority of bone marrow cells 
and HSCs out of the bone marrow cavity.  Hematoxylin and Eosin stained sections 
through undecalcified, gelatin embedded femurs (A) or femurs that were “flushed” with 
medium to remove marrow cells (B) or subsequently “burred” (drilling through the 
marrow cavity) to remove residual cells (C).  Images show diaphysis sections (i) and 
epiphysis (ii) sections as well as higher magnification images (iii) (scale bar is always 
150 µm).  Only 1.6% of bone marrow cells were retained within the marrow cavity after 
flushing (arrowhead), and these residual cells were recovered by burring. D) The 
frequency of CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs did not differ among bone 
marrow cells recovered by flushing versus burring (p=0.83, n=3). E) Taken together, this 
means that 98.4% of HSCs were recovered by flushing the bone marrow cavity. F) When 
300,000 cells from either the flushed or burred fractions of bone marrow were injected 
into irradiated mice in competitive reconstitution assays, 7/7 recipients of flushed marrow 
cells and 4/6 recipients of burred marrow cells became long-term multilineage 
reconstituted by donor cells. There was no statistically significant difference in overall 
levels of donor cell reconstitution in these mice. Error bars represent standard deviation. 































Figure 3.3:  ß-galactosidase expression in the adult myocardium from N-
cadherinlacZ/+ gene trap mice.  Seven micron sections through the heart of an 8 week old 
N-cadherinlacZ/+ gene trap mouse were stained with X-Gal to visualize the ß-galactosidase 
expression pattern.  As expected, X-Gal staining (blue) was detected throughout the 


















































Figure 3.4:  N-cadherin is not detectably expressed by HSCs isolated from N-
cadherinlacZ/+ gene trap mice.  c-kit+Sca-1+lineage-Flk-2- HSCs or CD150+CD48-
CD41-c-kit+Sca-1+lineage- HSCs were isolated from Rosa mice (A), N-cadherinlacZ/+ 
gene trap mice (C) or N-cadherin+/+ (B) littermate controls and stained with FDG to 
measure ß-galactosidase activity by flow-cytometry. While most HSCs from Rosa mice 
exhibited FDG staining (A), no FDG staining was observed in HSCs from N-
cadherinlacZ/+ gene trap mice (C) above the background observed in negative control 
littermates (B). Flow-cytometry plots depict typical results from a single experiment, 
while mean±SD is presented for results from three independent experiments. 
 
 



























Figure 3.5: Mobilization or culture did not detectably increase N-cadherin 
expression by HSCs.   A) CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs from wild-
type (negative control) mice, N-cadherinlacZ/+ gene trap mice, or Rosa (positive control 
mice) were cultured in the presence of stem cell factor, thrombopoietin, insulin-like 
growth factor II, and acidic fibroblast growth factor for 4 days (Zhang and Lodish, 2005) 
and then subjected to X-Gal staining. All Rosa cells stained positively with X-gal but we 
did not detect staining by N-cadherinlacZ/+ cells or littermate control cells. B) 
CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs were isolated from the bone marrow or 
spleen of cyclophosphamide/G-CSF mobilized mice  (mice were treated with 
cyclophosphamide followed by five daily injections of G-CSF before being analyzed; see 
(Morrison et al., 1997) for details). FDG staining was detected from Rosa (positive 
control) cells but not from N-cadherinlacZ/+ cells or littermate (negative) control cells.  
Numbers represent the percentage (mean±SD) of CD150+CD48-CD41-c-kit+Sca-
1+lineage- HSCs with FDG expression above background. C) CD150+CD48-CD41-c-
kit+Sca-1+lineage- HSCs isolated from the spleens of cyclophosphamide/G-CSF 
mobilized mice were stained with antibodies against N-cadherin.  Secondary only 
controls are shown for comparison.  Numbers represent the percentage (mean±SD) of 
HSCs with staining above background.  Data were collected from 2 independent 
experiments. There were no statistically significant differences between controls and 
antibody stained samples or between wild-type controls and N-cadherinlacZ/+ samples 
(p>0.15). 
































Figure 3.6: All detectable HSC activity is contained within the N-cadherin- fraction 
of bone marrow cells.  (A) 1.5 to 6.8% of bone marrow cells stained positively for N-
cadherin, depending on the antibody used (mean±SD from 3-8 independent experiments). 
B) Bone marrow cells were fractionated into N-cadherin- and N-cadherin+ cells using 
either YS or GC-4 antibodies and injected into lethally irradiated mice. Cell doses were 
based on the fraction of N-cadherin- versus N-cadherin+ cells that were contained within 
200,000 (YS) or 300,000 (GC-4) bone marrow cells as indicated in the table (C). To 
ensure that we did not miss infrequent N-cadherin+ HSCs, we also tripled the dose of N-
cadherin+ bone marrow cells that was transplanted in one experiment (C). Recipient mice 
were monitored for engraftment by donor myeloid, B, and T-cells for 16 weeks after 
transplantation.  Recipients of N-cadherin- bone marrow cells almost always (YS) or 
always (GC-4) exhibited high levels of long-term multilineage reconstitution by donor 
cells, while recipients of N-cadherin+ donor cells never exhibited long-term multilineage 
reconstitution by donor cells. In panel B, each line represents a single mouse, and the 
black line at 0.3% represents the level of background below which donor cell engraftment 
could not be detected (shaded area). Data are from 3 to 4 independent experiments. 



































Figure 3.7: biglycan-deficient mice exhibit significant reductions in trabecular bone 
and osteoblasts relative to littermate controls.  Five micron sections through wild-type 
(Bgn+) and biglycan-deficient (Bgn-) femurs were stained with anti-Biglycan antiserum. 
Biglycan expression (red) was detected at the endosteal surface (arrowheads) and within 
the bone matrix through the epiphysis and diaphysis as well as in the non-ossified 
chrondrous regions (not shown) in wild-type tissue (A) but not in biglycan-deficient 
tissue (B).  Nuclei (blue) were stained with DAPI. This staining pattern is consistent with 
prior reports that Biglycan is preferentially expressed by osteoblasts in the bone marrow 
(Chen et al., 2004; Chen et al., 2002; Xu et al., 1998). 15 month-old biglycan-deficient 
mice exhibited less trabecular bone based on von Kossa staining (B) as well as fewer 
osteoblasts based on staining for Osteopontin (C). Counting of Osteopontin+ osteoblasts 
on endosteal surfaces revealed a significant reduction in biglycan-deficient mice (D). 
Note that all mice were male in this analysis. 






Figure 3.8: biglycan-deficient mice exhibit normal frequencies of hematopoietic cells 
in bone marrow and spleen throughout life.  No statistically significant differences 
were observed in the frequencies of Mac-1+Gr-1+ myeloid cells, Ter119+ erythroid cells, 
B220+surface IgM- B lineage cells, B220+sIgM+ B cells, or CD3+ T-cells from the bone 
marrow (A) or spleen (B) of biglycan-deficient (Bgn-, blue) mice as compared to 
littermate controls (Bgn+, red) at 3, 9 to 12 or 24 months of age. Data represent 2 to 7 














Figure 3.9: Normal hematopoiesis and HSC function despite osteoblast depletion in 
the absence of biglycan.  (A) Slightly fewer bone marrow cells were recovered per 
femur and tibia of biglycan-deficient (blue bars) mice as compared to littermate controls 
(red bars) at 3, 9 to 15 or 24 months of age, though in no case was the difference 
statistically significant (p=0.09 to 0.31; data from 5 independent experiments with 2 to 5 
mice per genotype per age). Numbers (B) and types (C) of colonies that formed in culture 
from biglycan-deficient (blue bars) mice and littermate controls (red bars) were similar at 
all ages. Frequency (D) and absolute number (E) of CD150+CD48-CD41-c-kit+Sca-1+ 
HSCs in bone marrow from control littermates (Bgn+, red bars) and biglycan-deficient 
(Bgn-, blue bars) mice at 3, 9 to 15, or 24 months of age (p=0.46-0.89). Data represent 
mean±SD from 2-5 animals of each genotype in 1-3 independent experiments per age 
group. (F) HSC engraftment and reconstitution in competitive repopulation assays was 
not affected by biglycan deficiency, irrespective of whether donors, recipients, or both 
were biglycan-deficient.  300,000 bone marrow cells from Bgn+ or Bgn- donors (along 
with 300,000 recipient bone marrow cells) were transplanted into Bgn+ or Bgn- recipients. 
No statistically significant differences were detected in the level of donor chimerism in 
any lineage in any treatment. The data represent the results obtained 16 weeks after 
transplantation from one of 2 independent experiments. A total of 12 to 17 recipients 
were analyzed for each treatment with 2-3 independent donors per genotype. 
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Figure 3.10: CD150+CD48-CD41-lineage- HSCs mainly localize to sinusoids in wild-
type and biglycan-deficient mice. (A) Sections through the bone marrow of 9 to 15 
month old wild-type and biglycan-deficient mice were analyzed by immunofluorescence 
for the localization of CD150+CD48-CD41-lineage- HSCs. Slides were also stained with 
an antibody against the pan-endothelial antigen MECA-32 and the nuclear dye DAPI.  
The localization of all bone marrow cells (B) and CD150+CD48-CD41-lineage- HSCs 
(C) was assessed for proximity to MECA-32+ sinusoidal endothelium or to endosteum. 
Arrow points to a CD150+CD48-CD41-lineage- cell adjacent to a MECA-32+ sinusoid 
(A). Data were obtained from 2-3 mice per genotype.  
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HEMATOPOIETIC STEM CELLS DO NOT DEPEND ON N-CADHERIN 
EXPRESSION FOR THEIR MAINTENANCE1 
 
 
SUMMARY   
According to the “osteoblastic niche” model, hematopoietic stem cells (HSCs) are 
maintained by N-cadherin-mediated homophilic adhesion to osteoblasts at the bone 
marrow endosteum. In contrast to this model we have been unable to detect N-cadherin 
expression by HSCs using several different techniques. It has nonetheless been suggested 
that HSCs express low levels of N-cadherin that are difficult to detect, but functionally 
important for HSC maintenance. To test this we conditionally deleted N-cadherin from 
HSCs and other hematopoietic cells in adult Mx-1-Cre+N-cadherinfl/- mice. N-cadherin 
deficiency had no detectable effect on HSC maintenance or hematopoiesis. N-cadherin 
deficiency did not affect bone marrow cellularity or lineage composition, the numbers of 
colony-forming progenitors, the frequency of HSCs, the ability of HSCs to sustain 
hematopoiesis over time, or their ability to reconstitute irradiated mice.  These results 
                                                
1 Submitted to Cell Stem Cell, May 2008 with authors listed as MJ Kiel, GL Radice and 
SJ Morrison. 
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demonstrate that N-cadherin expression by HSCs is not necessary for the function of 
HSC niches, an observation inconsistent with “osteoblastic niche” models. 
 
INTRODUCTION 
HSCs persist throughout adult life in the bone marrow where they continuously 
produce new blood cells to maintain the hematopoietic system. To understand the 
mechanisms that sustain HSCs it is necessary to identify the niche – the specialized 
microenvironment in which HSCs are thought to reside (Adams and Scadden, 2006; Kiel 
and Morrison, 2008).  
Osteoblasts have been widely suggested to contribute to the creation of HSC 
niches. Genetic manipulations that increase osteoblast numbers in mice also increase the 
number of HSCs (Calvi et al., 2003; Zhang et al., 2003). Osteoblasts have also been 
proposed to secrete factors that are necessary for HSC maintenance, including 
angiopoietin, thrombopoietin, and CXCL12 (Arai et al., 2004; Yoshihara et al., 2007), 
though none of these factors have yet been conditionally deleted from osteoblasts and 
each is also secreted by other cell types. Calcium ions from bone resorption (due to 
osteoblast and osteoclast activity) also regulate HSC localization and maintenance 
(Adams et al., 2006). These observations raise two general possibilities for how 
osteoblasts could contribute to HSC maintenance. One possibility is that osteoblasts 
produce extracellular factors that diffuse into the marrow, directly or indirectly regulating 
HSC niches that are near, but not at, the endosteum. A second possibility is that 
osteoblasts directly promote HSC maintenance by binding HSCs, creating “osteoblastic 
niches” at the endosteal surface. 
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The possibility of bone marrow HSC niches near, but not at, the endosteum has 
been raised by a number of recent observations (Kiel and Morrison, 2008). We have 
localized HSCs within the bone marrow using SLAM family markers that give high 
levels of stem cell purity and found that few HSCs localized to the endosteal surface 
(Kiel et al., 2007b; Kiel et al., 2005). Instead, most HSCs were present around sinusoids, 
some of which were close to the endosteum while others were more distant. It remains 
uncertain whether perivascular cells directly promote HSC maintenance; however, the 
observation that HSCs are considerably more likely than other hematopoietic cells to be 
adjacent to sinusoids (Kiel et al., 2007b) raises the possibility that there are perivascular 
niches. Consistent with this possibility, recent studies have suggested that perivascular 
cells, such as reticular cells and mesenchymal progenitors, express more CXCL12 and 
angiopoietin than osteoblasts (Sacchetti et al., 2007; Sugiyama et al., 2006). This raises 
the question of whether HSCs are maintained in direct contact with osteoblasts, or 
whether they are maintained in other microenvironments that are directly or indirectly 
influenced by factors secreted by endosteal cells. 
The widely discussed “osteoblastic niche” model has favored the idea that HSCs 
are maintained in direct contact with osteoblasts (Suda et al., 2005; Wilson and Trumpp, 
2006; Zhang and Li, 2008; Zhang et al., 2003). This model proposes that HSCs adhere to 
the surface of osteoblasts via N-cadherin mediated homophilic adhesion and that 
osteoblasts directly promote the maintenance of HSCs by mechanisms that involve cell-
cell contact, including Notch and N-cadherin activation (Haug et al., 2008; Wilson et al., 
2004; Zhang et al., 2003). However, genetic evidence supporting such mechanisms is 
lacking. Conditional deletion of Jagged1 and/or Notch1 (the ligand/receptor combination 
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proposed to regulate Notch signaling between osteoblasts and HSCs) does not affect HSC 
maintenance or function (Mancini et al., 2005). Moreover, conditional inactivation of all 
canonical Notch signaling by disruption of the CSL/Rbp-J transcriptional complex also 
does not affect the maintenance or function of adult HSCs (Maillard et al., 2008). It has 
not been tested whether N-cadherin deficiency affects HSC maintenance. 
Given the central role proposed for N-cadherin in the creation of osteoblastic 
niches, we recently tested whether HSCs express N-cadherin. We were unable to detect 
N-cadherin expression among highly purified HSCs by quantitative PCR, by staining 
with commercially available anti-N-cadherin antibodies, or in N-cadherin:LacZ genetrap 
mice (Kiel et al., 2007b). Published microarray analyses of HSCs from multiple 
laboratories also failed to detect N-cadherin expression (Ivanova et al., 2002; Kiel et al., 
2005). Only N-cadherin negative bone marrow cells had the capacity to give long-term 
multilineage reconstitution of irradiated mice (Kiel et al., 2007b), even when we used the 
commercially available anti-N-cadherin antibody that had been used to identify putative 
osteoblastic niches in bone marrow sections (Wilson et al., 2004; Zhang et al., 2003). 
This suggested that HSCs could not adhere to osteoblasts via N-cadherin and that the N-
cadherin+ cells imaged at the endosteum in prior studies could not have been HSCs. 
However, it was subsequently suggested that N-cadherin is expressed at very low levels 
on HSCs and that it remains functionally important for their localization within a 
quiescent osteoblastic niche despite being difficult to detect (Haug et al., 2008; Zhang 
and Li, 2008). 
To resolve this controversy it was suggested that N-cadherin should be 
genetically deleted from adult hematopoietic cells (Hooper et al., 2007). If N-cadherin is 
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not expressed by HSCs, then N-cadherin deficiency should not affect HSC maintenance. 
In contrast, if HSC niches are regulated by low levels of N-cadherin expression within 
HSCs then N-cadherin deletion should lead to the depletion of HSCs and to deficits in 
hematopoiesis. We have now addressed this by conditionally deleting N-cadherin from 
HSCs and other hematopoietic cells in adult Mx-1-Cre+N-cadherinfl/- mice. Despite 
efficiently deleting N-cadherin from HSCs, these mice exhibited no detectable effects of 
N-cadherin deficiency on HSC maintenance or hematopoiesis, either acutely after N-
cadherin deletion or months later. Bone marrow cells from these mice exhibited normal 
HSC frequency and a normal capacity to reconstitute irradiated mice. N-cadherin is 
therefore not required cell-autonomously to regulate HSC maintenance or function, 
casting doubt on widely published models of the osteoblastic niche. 
 
RESULTS  
N-cadherin is efficiently deleted after pIpC treatment 
Mice with germline N-cadherin deficiency (N-cadherin-/-) die by E11 due to 
severe developmental defects including cardiovascular failure (Radice et al., 1997). 
Therefore, to study the effects of N-cadherin deficiency on adult HSCs, we mated 
previously described N-cadherinfl mice (Kostetskii et al., 2005) with Mx-1-Cre mice 
(Kuhn et al., 1995) to conditionally delete N-cadherin from adult HSCs. Each of these 
strains were backcrossed for at least 6 generations onto a C57BL background. Mx-1-Cre 
expression is activated in HSCs, other hematopoietic cells, and some other tissues by 
administration of polyinosine-polycytidine (pIpC) (Hock et al., 2004; Kuhn et al., 1995; 
Yilmaz et al., 2006b).  
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To test the efficiency of N-cadherin excision within HSCs, we cultured individual 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs (1 cell/well) isolated from Mx-1-
Cre+N-cadherinfl/- mice after they had been treated with 7 doses of pIpC over 14 days. 
These cells include more than 95% of all long-term multilineage reconstituting cells in 
the bone marrow, and more than 40% of single cells within this population give long-
term multilineage reconstitution after transplantation into irradiated mice (Kiel et al., 
2005; Kiel et al., 2008; Yilmaz et al., 2006a).  Genomic DNA was extracted from 
individual myeloerythroid colonies formed by these HSCs and analyzed by PCR.  Of 
colonies cultured immediately after pIpC treatment, 53 of 54 showed complete 
recombination of N-cadherinfl (Figure 4.1A,B). Of colonies that arose from HSCs 
cultured 1 to 2 months following pIpC treatment, 72 of 73 showed complete 
recombination of N-cadherinfl (Figure 4.1A,B). This indicates that at least 98% of HSCs 
deleted N-cadherin upon pIpC treatment. The rare non-recombined cells did not appear to 
have a competitive advantage over N-cadherin deficient HSCs, as their frequency did not 
increase with time after pIpC treatment. 
 
N-cadherin deficiency does not alter hematopoiesis 
If N-cadherin is critical for HSC maintenance then N-cadherin deficiency should 
lead to defects in hematopoiesis.  We therefore tested whether acute or chronic loss of N-
cadherin affected hematopoiesis in Mx-1-Cre+N-cadherinfl/- mice. To test this we 
harvested the peripheral blood and bone marrow from Mx-1-Cre+N-cadherinfl/- mice or 
littermate controls (mice lacking Cre or bearing at least one wild-type allele of N-
cadherin) either immediately following pIpC treatment (2 weeks pIpC; Figure 4.1C-G) or 
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1-2 months following 2 weeks of pIpC administration (Figure 4.1H-L).  We did not 
detect any effect of N-cadherin deletion on white blood cell (WBC), erythrocyte (RBC) 
or platelet (Plts) concentration in the blood of Mx-1-Cre+N-cadherinfl/- mice as compared 
to littermate controls at either time point (Figure 4.1C, H).  We also did not detect any 
effect of N-cadherin deficiency on bone marrow cellularity (Figure 4.1D, I) or 
composition with respect to the erythroid (Ter119+ cells), myeloid (Mac-1+Gr-1+), B 
(B220+surfaceIgM±) or T cell (CD3+) lineages (Figure 4.1E, J).  Finally, we did not 
detect any effect of N-cadherin deficiency on the frequency (Figure 4.1F, K) or types 
(Figure 4.1G, L) of colony-forming progenitors in the bone marrow.  These results 
indicate that N-cadherin is not required within HSCs for hematopoiesis.       
 
N-cadherin deficiency does not alter HSC frequency or function in vivo 
To directly test whether N-cadherin deficiency affects HSC maintenance we 
examined the HSC content of bone marrow isolated from Mx-1-Cre+N-cadherinfl/- mice 
or littermate controls either immediately following pIpC treatment (Figure 4.2A-C) or 1-2 
months later (Figure 4.2D-F).  As previously reported for wild-type mice (Kiel et al., 
2007a; Kiel et al., 2005; Kiel et al., 2008), the vast majority of CD150+CD48-CD41-
lineage- cells from the bone marrow of Mx-1-Cre+N-cadherinfl/- mice or littermate 
controls were positive for the HSC markers Sca-1 and c-kit (Figure 4.2A, D).  We did not 
detect any difference in the frequency or absolute number of CD150+CD48-CD41-
lineage-Sca-1+c-kit+ HSCs in the hindlimb bone marrow of Mx-1-Cre+N-cadherinfl/- 
mice as compared to littermate controls (Figure 4.2B, E).  We were also unable to detect 
any difference in the frequency or absolute number of Flk2-lineage-Sca-1+c-kit+ HSCs 
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in Mx-1-Cre+N-cadherinfl/- mice as compared to littermate controls (Figure 4.3). Finally, 
when CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were individually cultured in 
methylcellulose, 83-89% of cells formed large myeloerythroid colonies irrespective of 
whether they were from Mx-1-Cre+N-cadherinfl/- mice or littermate controls (Figure 4.2C, 
F). We therefore could not detect any effect of N-cadherin deficiency on the frequency, 
absolute number, or colony-forming capacity of HSCs either immediately after N-
cadherin deletion or 1-2 months later. 
To test whether N-cadherin deficiency affects HSC function in vivo, we 
transplanted 1x106 bone marrow cells from non-pIpC-treated CD45.2+ Mx-1-Cre+N-
cadherinfl/- mice or CD45.2+ littermate controls into lethally irradiated CD45.1+ 
recipients along with 3x105 wild-type CD45.1+ bone marrow cells.  Four weeks 
following transplantation, we analyzed the blood of these recipients for engraftment by 
CD45.2+ donor cells and found that both Mx-1-Cre+N-cadherinfl/- cells and control cells 
had engrafted at similar levels, as expected (Figure 4.4A-C; 4 week time point). Starting 
6 weeks after transplantation, we administered pIpC for 2 weeks to all mice to delete N-
cadherin. If N-cadherin is required for HSC maintenance or function in vivo then we 
should have observed a loss of donor cells over time in the mice transplanted with Mx-1-
Cre+N-cadherinfl/- cells. We monitored the levels of donor cell reconstitution in all 
recipients for a total of 20 weeks after pIpC treatment but never observed a decline in 
donor myeloid (Mac-1+; Figure 4.4A), B (B220+; Figure 4.4B) or T cells (CD3+; Figure 
4.4C) in recipients of Mx-1-Cre+N-cadherinfl/- cells.  To ensure that N-cadherin had been 
efficiently deleted in this experiment, we performed PCR on genomic DNA from donor-
derived myeloid cells isolated from the peripheral blood of these recipients.  We observed 
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complete excision of N-cadherin from the myeloid cells collected from recipients of Mx-
1-Cre+N-cadherinfl/- cells but not recipients of control cells (Figure 4.4D).  These results 
indicate that N-cadherin is not required for the maintenance of HSC function in vivo and 
that N-cadherin-deficient HSCs are not at a competitive disadvantage relative to wild-
type cells. 
 
N-cadherin is not required for HSC reconstitution of irradiated recipients 
If N-cadherin is required for HSC homing or engraftment in the niche, then 
deletion of N-cadherin from HSCs prior to transplantation should cause an engraftment 
defect. To test this we treated Mx-1-Cre+N-cadherinfl/- mice or littermate controls with 
pIpC, then transplanted 1x106 bone marrow cells 2 months later along with 3x105 
recipient bone marrow cells into CD45.1+ recipient mice.  All of the recipients of both 
Mx-1-Cre+N-cadherinfl/- cells (n=12) and control cells (n=11) became long-term 
multilineage reconstituted by donor myeloid, B, and T cells (Figure 4.5A). The level of 
reconstitution by donor cells did not differ between recipients of Mx-1-Cre+N-cadherinfl/- 
cells and control cells in terms of all donor blood cells (CD45.2+, Figure 4.5B), donor 
myeloid cells (Mac-1+, Figure 4.5C), donor B cells (B220+, Figure 4.5D), or donor T 
cells (CD3+, Figure 4.5E). N-cadherin is therefore not required for the homing or 
engraftment of HSCs in vivo.    
 
DISCUSSION 
 The “osteoblastic niche” model proposes that HSCs are maintained in direct 
contact with osteoblasts via N-cadherin homophilic adhesion (Arai et al., 2004; Haug et 
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al., 2008; Suda et al., 2005; Wilson et al., 2004; Wilson and Trumpp, 2006; Zhang and 
Li, 2008; Zhang et al., 2003). According to this model, N-cadherin is postulated to be 
required within HSCs to maintain adhesion with the niche, to regulate quiescence, to 
regulate ß-catenin signaling, and to maintain HSCs in an undifferentiated state (Arai et 
al., 2004; Haug et al., 2008; Suda et al., 2005; Wilson et al., 2004; Wilson and Trumpp, 
2006; Zhang and Li, 2008; Zhang et al., 2003). Yet none of these predictions have been 
tested in N-cadherin deficient mice. Our data demonstrate that N-cadherin deletion in 
vivo from HSCs and other hematopoietic cells has no effect on hematopoiesis in the bone 
marrow (Figure 4.1), HSC frequency (Figure 4.2), HSC maintenance or function over 
time (Figure 4.4), or on the ability of HSCs to engraft and reconstitute irradiated mice 
(Figure 4.5). In no assay did N-cadherin deficient HSCs show a competitive disadvantage 
relative to wild-type HSCs. Our data thus demonstrate that N-cadherin is not required 
autonomously within HSCs to regulate their maintenance or function. 
 Other data have also been inconsistent with this model. HSCs were originally 
localized to the surface of osteoblasts based on staining for N-cadherin+ bromo-
deoxyuridine (BrdU) label-retaining cells (Zhang et al., 2003). However, in addition to 
being unable to detect N-cadherin expression within HSCs by several different 
techniques (Kiel et al., 2007b), we have also found that BrdU label-retention has very 
poor specificity and very poor sensitivity as an HSC marker: the vast majority of HSCs 
fail to retain BrdU for long periods of time and the vast majority of cells that do retain 
BrdU are not HSCs (Kiel et al., 2007a). When we localize highly purified HSCs within 
bone marrow sections using SLAM family markers, we find a minority of HSCs that 
localize to the endosteum (<20%) and a majority of HSCs (>60%) that localize to 
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sinusoids (Kiel et al., 2007b; Kiel et al., 2005). It thus remains possible that a subset of 
HSCs is maintained in niches that are at, or near, the endosteum by N-cadherin-
independent mechanisms but it seems unlikely that all HSCs depend on proximity to 
endosteal cells for their maintenance. Rather, our data (Kiel et al., 2007b; Kiel et al., 
2005) and the data of others (Sacchetti et al., 2007; Sugiyama et al., 2006) raise the 
possibility of perivascular niches for HSCs, though direct evidence that perivascular cells 
promote HSC maintenance is lacking. 
 A recent study from Li and colleagues (Haug et al., 2008) used an anti-N-cadherin 
antibody (MNCD2; (Matsunami and Takeichi, 1995)) that was not used in prior studies 
of HSCs to suggest that HSCs do express low levels of N-cadherin and that this can be 
used to resolve HSCs into two populations: an N-cadherinlow population that contains 
long-term multilineage reconstituting activity and an N-cadherinintermediate “reserve” 
population that resides within the osteoblastic niche. However, the N-cadherinlow staining 
could not clearly be distinguished from background fluorescence and the N-
cadherinintermediate population had little or no HSC activity in reconstitution assays. In our 
view, if cells fail to exhibit HSC activity in transplantation assays the simplest 
interpretation is that they are not HSCs. We have also independently tested the MNCD2 
antibody and fail to detect staining of HSCs (Figure 4.6). We do observe staining of bone 
marrow cells with this antibody, but the staining was not affected by N-cadherin deletion, 
suggesting that bone marrow staining is non-specific (Figure 4.6). We thus stand by our 
conclusion that HSCs do not express N-cadherin. 
 It remains possible that N-cadherin deficiency in osteoblasts could affect HSC 
maintenance or hematopoiesis, at least indirectly.  Expression of dominant negative N-
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cadherin in osteoblasts (that may affect other cadherins as well) leads to a reduction in 
trabecular bone and defects in osteoblast maturation (Cheng et al., 2000). Effects on 
hematopoiesis have not yet been tested in these mice, but it is possible that defects in 
osteogenesis could lead to changes in HSC frequency or hematopoiesis. Nonetheless, 
many direct and indirect mechanisms could potentially account for such effects so this 
would not provide evidence of an osteoblastic niche.      
Many potential models of the HSC niche remain compatible with existing data 
and there is little experimental basis on which to favor any specific model (Kiel and 
Morrison, 2008; Morrison and Spradling, 2008). One possibility is that HSCs reside in 
niches near the endosteum that are created through the combined action of factors 
secreted by endosteal, perivascular, and potentially other cells. Another possibility is that 
HSCs reside primarily in perivascular niches, at least some of which are close to the 
endosteum, and potentially influenced by factors secreted by endosteal cells. A third 
possibility is that there are spatially distinct niches in the bone marrow, some of which 
are close to the endosteum while others are not. These possibilities are not mutually 
exclusive and are not the only possibilities. Although some have recently proposed that it 
may be possible to distinguish between cells that reside in perivascular versus endosteal 
niches, there is little direct experimental support for this idea. Moreover, this model is 
conceptually problematic given that the endosteum is among the most highly 
vascularized sites in the bone marrow: HSCs cannot localize to the endosteum without 
being perivascular. To more clearly define the niche it will be necessary to genetically 
determine the physiologically important sources for factors that are required for HSC 
maintenance. 
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MATERIALS AND METHODS 
Mice 
C57BL/Ka-Thy-1.1 (CD45.2) and C57BL/Ka-Thy-1.2 (CD45.1) mice were 
housed in the Unit for Laboratory Animal Medicine at the University of Michigan. Both 
Mx-1-Cre mice and N-cadherinfl/- mice were backcrossed for at least six generations onto 
a C57BL background. In every experiment, littermate control mice were gender-matched 
and either lacked Mx-1-Cre or had at least one wild-type allele of N-cadherin.   
 
pIpC administration 
 pIpC was administered to mice as previously described (Yilmaz et al., 2006b).  
Briefly, pIpC was resuspended in Dulbecco’s phosphate buffered saline (D-PBS) at 2 
mg/ml and mice were injected with 25ug per gram of body weight every other day for 14 
days.     
 
Flow-cytometry and the isolation of HSCs 
Bone marrow cells were flushed from the long bones (tibias and femurs) with 
Hank’s buffered salt solution without calcium or magnesium, supplemented with 2% 
heat-inactivated calf serum (GIBCO, Grand Island, NY; HBSS+). Cells were triturated 
and filtered through nylon screen (45 um, Sefar America, Kansas City, MO) to obtain a 
single cell suspension.   
For isolation of Flk2-c-kit+Sca-1+lineage- cells, whole bone marrow cells were 
incubated with PE-conjugated monoclonal antibodies to lineage markers including B220 
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(6B2), CD3 (KT31.1), CD4 (GK1.5), CD8 (53-6.7), Gr-1 (8C5), Mac-1 (M1/70), Ter119 
and IgM in addition to FITC-conjugated anti-Sca-1 (Ly6A/E; E13-6.7) and biotin-
conjugated anti-c-kit (2B8). An antibody against Flk-2 (A2F10.1) was used to isolate 
Flk-2- progenitors. c-kit staining was visualized using streptavidin APC-Cy7.  
For isolation of CD150+CD48-CD41-c-kit+Sca-1+lineage- HSCs, bone marrow 
cells were incubated with PE-conjugated anti-CD150 (TC15-12F12.2; BioLegend, San 
Diego, California), FITC-conjugated anti-CD48 (HM48-1; BioLegend), FITC-conjugated 
anti-CD41 (MWReg30; BD Pharmingen, San Diego, California), biotin-conjugated anti-
Sca-1 (E13-6.7), and PE-Cy5-conjugated anti-c-kit (2B8) antibody, in addition to 
antibodies against the following FITC-conjugated lineage markers: Ter119, B220 (6B2), 
Gr-1 (8C5) and CD2 (RM2-5).  Sca-1 was visualized using streptavidin-conjugated APC-
Cy7.  HSCs were sometimes pre-enriched by selecting Sca-1+ or c-kit+ cells using 
paramagnetic microbeads and autoMACS (Miltenyi Biotec, Auburn, CA).  MNCD2 anti-
N-cadherin antibody was obtained from Linheng Li. Non-viable cells were excluded from 
sorts and analyses using the viability dye DAPI (1ug/ml).   
 
Long-term competitive repopulation assay 
Adult recipient mice (CD45.1) were irradiated with an Orthovoltage X-ray source 
delivering approximately 300 rad/min in two equal doses of 570 rad, delivered at least 2 
hr apart.  Cells were injected into the retro-orbital venus sinus of anesthetized recipients.  
Each recipient mouse received 3x105 CD45.1 marrow cells for radioprotection. 
Beginning 4 weeks after transplantation and continuing for at least 16 weeks, blood was 
obtained from the tail veins of recipient mice, subjected to ammonium-chloride 
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potassium red cell lysis, and stained with directly conjugated antibodies to CD45.2 (104, 
FITC), B220 (6B2), Mac-1 (M1/70), CD3 (KT31.1), and Gr-1 (8C5) to monitor 
engraftment. 
 
N-cadherin excision analysis 
Genomic DNA from individual CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSC 
colonies was isolated by phenol-chloroform extraction.  Glycogen (Roche, Indianapolis 
IN) was used to enhance the recovery of the DNA.  PCR products were separated using 
2% agarose gels to confirm the presence or absence of bands corresponding to wild-type, 
floxed or deleted alleles.  Primer sequences for amplification of N-cadherin alleles were 
as described previously (Kostetskii et al., 2005): N-cadherin NC23 5’-
GTATGGCCAAGTAATGGGGAC, N-cadherin L07 5’-




 Sorted bone marrow cells and twice-sorted HSCs were plated in individual wells 
of 96-well plates (Corning, Corning NY) containing 100ul 1.0% methylcellulose (Stem 
Cell Technologies, Vancouver, BC) as previously described. The methylcellulose was 
supplemented with 1% penicillin/streptomycin (Gibco), 50ng/ml stem cell factor (SCF), 
10ng/ml interleukin-3 (IL-3), 10ng/ml interleukin-6 (IL-6), and 3U/ml erythropoietin 
(Epo). Colonies were maintained at 37oC in humidified incubators at 6% O2. Colony 
formation was scored after 10-14 days of culture. 
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Figure 4.1: pIpC treatment of adult Mx-1-Cre+N-cadherinfl/- mice leads to efficient N-
cadherin deletion from HSCs without altering hematopoiesis. A) CD150+CD48-
CD41-lineage-Sca-1+c-kit+ bone marrow HSCs from pIpC-treated Mx-1-Cre+N-
cadherinfl/- mice or littermate controls were cultured in methylcellulose for 14 days, then 
genomic DNA was extracted from the colonies and examined for N-cadherin deletion. B) 
Virtually all of the colonies examined in 6 independent experiments from 15 Mx-1-
Cre+N-cadherinfl/- mice showed complete deletion.  Hematopoiesis was examined in Mx-
1-Cre+N-cadherinfl/- mice (black bars) or littermate controls (white bars) either 
immediately following 2 weeks of pIpC treatment (C-G) or 1-2 months following 2 
weeks of pIpC administration (H-L).  No statistically significant differences were 
observed in the concentration of white blood cells (WBC), erythrocytes (RBC) or 
platelets (Plts; C, H) from the blood of Mx-1-Cre+N-cadherinfl/- mice as compared to 
littermate controls.  We also did not observe any differences in bone marrow cellularity 
(D, I), composition (E, J), frequency (F, K), or types of colony-forming progenitors (G, 
L) in Mx-1-Cre+N-cadherinfl/- mice as compared to littermate controls.   Data are from 2 
to 6 mice per treatment in 2-3 independent experiments. All error bars represent SD. 


































Figure 4.2:  N-cadherin deletion does not affect HSC frequency or the ability of 
HSCs to form colonies in culture. The frequency of CD150+CD48-CD41-c-kit+Sca-
1+lineage- cells was examined by flow-cytometry in Mx-1-Cre+N-cadherinfl/- mice (black 
bars) or littermate controls (white bars) either immediately following pIpC administration 
(A-C) or 1-2 months later (D-F). No significant differences were observed in the 
frequency or absolute number of CD150+CD48-CD41-c-kit+Sca-1+lineage- cells 
contained within the bone marrow of Mx-1-Cre+N-cadherinfl/- mice as compared to 
littermate controls (B and E). We also did not detect any effect of N-cadherin deficiency 
on the frequency of Flk2-c-kit+Sca-1+lineage- cells (Figure 4.3). When individual 
CD150+CD48-CD41-c-kit+Sca-1+lineage- cells were cultured in methylcellulose, no 
significant differences were observed in the percentage of these cells that formed colonies 
or in the types of colonies they formed (C and F). The data are from 6 independent 
experiments with 1-2 mice per treatment per experiment. All error bars represent SD. 








Figure 4.3: N-cadherin deficiency does not affect the frequency of Flk2-c-kit+Sca-
1+lineage- cells in the bone marrow.  Representative flow-cytometry plots of bone 
marrow cells from Mx-1-Cre+N-cadherinfl/- mice (right) or littermate controls (left) after 2 
weeks of pIpC administration (A).  No significant difference was observed in the 
frequency of Flk2-c-kit+Sca-1+lineage- cells within the bone marrow of Mx-1-Cre+N-
cadherinfl/- mice as compared to littermate controls (B). These data are from 2 
independent experiments with 1-2 mice of each genotype per experiment. 






Figure 4.4: N-cadherin deficiency does not affect HSC maintenance or function in 
vivo. 1x106 bone marrow cells from CD45.2+ Mx-1-Cre+N-cadherinfl/- mice (black dots) 
or CD45.2+ littermate controls (white dots) were injected into lethally irradiated CD45.1+ 
wild-type recipients. pIpC was administered to all recipients for 2 weeks (shaded area) 
beginning at week 6.  Reconstitution by donor cells was then monitored for an additional 
20 weeks. We observed no decline in reconstitution by donor myeloid (Mac-1+, A), B 
(B220+, B), or T (CD3+, C) cells, indicating that N-cadherin deletion did not affect HSC 
maintenance, function, or the ability to compete with wild-type HSCs. Each line 
represents a single recipient mouse. Data from one representative experiment are shown. 
Two independent experiments with a total of 9 recipients per genotype gave similar 
results. D) After 28 weeks, donor myeloid cells were isolated from the blood of 
representative recipients and analyzed for N-cadherin deletion: recipients of Mx-1-
Cre+N-cadherinfl/- cells were reconstituted by N-cadherin deficient cells. 






Figure 4.5: N-cadherin deficiency does not affect the ability of HSCs to engraft or 
reconstitute irradiated recipients. pIpC was administered to Mx-1-Cre+N-cadherinfl/- 
mice or littermate controls. Two months later 1x106 bone marrow cells from CD45.2+ 
Mx-1-Cre+N-cadherinfl/- mice (black bars) or littermate controls (white bars) were 
injected into lethally irradiated CD45.1+ wild-type recipients along with 3x105 CD45.1+ 
bone marrow cells. All recipients became long-term multilineage reconstituted by donor 
cells (A, n=11-12 recipients per genotype).  The levels of reconstitution 12 weeks after 
transplantation are shown. N-cadherin deficiency did not affect the levels of 
reconstitution by all donor cells (CD45+, B) or by donor cells in the myeloid (Mac-1+, 
A), B (B220+, B) or T (CD3+, C) lineages. Four different control littermates and four 
different Mx-1-Cre+N-cadherinfl/- donors were separately transplanted into a total of 11-
12 recipients per genotype.  Error bars represent SD.  







































Figure 4.6: MNCD2 anti-N-cadherin antibody shows no staining of HSCs and the 
staining that is observed in whole bone marrow is unaffected by N-cadherin 
deletion. MNCD2 staining was compared to streptavidin-only negative control (first 
column) in whole bone marrow cells (A), CD150+CD48-CD41-Sca-1+c-kit+lineage- 
HSCs (B), and Flk2-lineage-Sca-1+c-kit+ HSCs (C). Staining above background was 
only observed in whole bone marrow (A). In all cases, staining was unaffected by N-
cadherin deficiency (third column shows Mx-1-Cre+N-cadherinfl/- mice after pIpC 
treatment). N-cadherin deficiency was confirmed by PCR in pIpC-treated mice (D). 
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HEMATOPOIETIC STEM CELLS DO NOT ASYMMETRICALLY 
SEGREGATE CHROMOSOMES OR RETAIN BROMO-DEOXYURIDINE1 
 
SUMMARY 
Stem cells are proposed to asymmetrically segregate chromosomes during self-
renewing divisions such that older (‘immortal’) DNA strands are retained in daughter 
stem cells while newly-synthesized strands segregate to differentiating cells (Cairns, 
1975; Conboy et al., 2007; Karpowicz et al., 2005; Potten et al., 1978; Shinin et al., 2006; 
Smith, 2005). Stem cells are also proposed to retain DNA labels, like bromo-
deoxyuridine (BrdU), either because they segregate chromosomes asymmetrically or 
because they divide slowly (Cotsarelis et al., 1990; Shinin et al., 2006; Tumbar et al., 
2004; Zhang et al., 2003). However, the purity of stem cells among BrdU label-retaining 
cells has not been documented in any tissue and the ‘immortal strand hypothesis’ has not 
been tested in a system with definitive stem cell markers. We tested these hypotheses in 
hematopoietic stem cells (HSCs), which can be highly purified using well-characterized 
markers. We administered BrdU to newborn, cyclophosphamide/G-CSF mobilized, and 
normal adult mice for 4 to 10 days, followed by 70-days without BrdU. In each case, less 
than 6% of HSCs retained BrdU and less than 0.5% of all BrdU-retaining hematopoietic 
                                                
1 Originally published in Nature 449:238-42, September 2007 with authors listed as MJ 
Kiel, S He, R Ashkenazi, SN Gentry, M Teta, JA Kushner, TL Jackson and SJ Morrison. 
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cells were HSCs, revealing poor specificity and poor sensitivity as an HSC marker. 
Sequential administration of chloro-deoxyuridine (CldU) and iodo-deoxyuridine (IdU) 
suggested that all HSCs segregate their chromosomes randomly. Division of individual 
HSCs in culture revealed no asymmetric segregation of label. HSCs therefore cannot be 
identified based on BrdU label-retention and do not retain older DNA strands during 
division, indicating these are not general properties of stem cells. 
 
INTRODUCTION 
 The ‘immortal strand hypothesis’ was proposed as a mechanism by which stem 
cells could avoid accumulating mutations that arise during DNA replication (Cairns, 
1975). While most cells segregate their chromosomes randomly (Armakolas and Klar, 
2006; Potten et al., 1978), it was argued that adult stem cells in steady-state tissues might 
retain older strands during asymmetric self-renewing divisions, segregating newly-
synthesized strands to daughters fated to differentiate (Figure 5.1a). Evidence has 
supported this model in some epithelial stem cells (Potten et al., 1978), neural stem cells 
(Karpowicz et al., 2005), mammary epithelial progenitors (Smith, 2005), and muscle 
satellite cells (Conboy et al., 2007; Shinin et al., 2006). A related idea is that adult stem 
cells in steady-state tissues might consistently retain DNA labels, either because 
chromosomes segregate randomly but stem cells divide more infrequently than other cells 
(Figure 5.1b) or because the older DNA strand is labeled and segregated asymmetrically 
(Figure 5.1c).  Tritiated thymidine (Cotsarelis et al., 1990) or histone (Tumbar et al., 
2004) label-retaining cells from the hair follicle are enriched for epithelial stem cells, 
though purity remains uncertain. Label-retaining cells have also been identified in the 
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hematopoietic system (Arai et al., 2004; Zhang et al., 2003), in mammary epithelium 
(Welm et al., 2002), in intestinal epithelium (Potten et al., 1978; Potten et al., 2002), and 
in the heart (Urbanek et al., 2006), but the purity of stem cells among these label-
retaining cells has not been tested. As a result, it remains uncertain whether label-
retention can identify stem cells with specificity or sensitivity. 
Under steady-state conditions in adult bone marrow, all HSCs divide regularly but 
infrequently (Cheshier et al., 1999) to sustain hematopoiesis as well as to maintain nearly 
constant numbers of HSCs. As a result of this observation, as well as the observation that 
HSC divisions yield asymmetric outcomes in culture (Takano et al., 2004), it has been 
proposed that adult HSCs divide asymmetrically (Takano et al., 2004), though the rarity 
of HSCs in vivo and their relative quiescence has made it impossible to confirm this 
directly. Nonetheless, if BrdU label-retention and/or asymmetric chromosome 
segregation are general properties of adult stem cells, then either or both of these 
characteristics should be evident in HSCs, depending on experimental conditions. 
 
RESULTS AND DISCUSSION 
To test the rate at which HSCs go into cycle we administered BrdU to mice for 1, 
4, or 10 days, then sorted HSCs onto microscope slides and stained with an anti-BrdU 
antibody.  HSCs were sorted as CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells (Figure 
5.2a). This population contains all of the detectable HSC activity in bone marrow and 
47% of single cells from this population give long-term multilineage reconstitution in 
irradiated mice (Kiel et al., 2005). After 1 to 10 days of BrdU, 51 to 94% of whole bone 
marrow cells and 6.5 to 46% of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs 
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became BrdU+ (Figure 5.2c,d). We calculated the rate at which HSCs went into cycle 
(Cheshier et al., 1999) as 6.0% per day (Figure 5.2e). Consistent with this, only 3.2% of 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells were in S/G2/M phase of the cell cycle 
at any one time (Figure 5.3). These results are similar to a prior study that identified 
HSCs with somewhat different markers (Cheshier et al., 1999). 
The linearity of BrdU incorporation over time (Figure 5.2e) suggests that most 
HSCs divide at a similar rate. If a minority of HSCs divided more rapidly, significantly 
more than 6.0% of HSCs should have incorporated BrdU after one day; however, we did 
not observe this (Figure 5.2d).  If a minority of HSCs were more deeply quiescent than 
most other HSCs, these HSCs should remain BrdU negative even after long periods of 
BrdU. This also has not been observed as more than 99% of HSCs are labeled after six 
months of BrdU (Cheshier et al., 1999). Therefore, there is no evidence for more rapidly 
dividing or more slowly dividing subsets of long-term self-renewing HSCs under steady-
state conditions, though we cannot exclude the possibility that a minority of HSCs divide 
somewhat more slowly than 6% per day. 
To evaluate BrdU label-retention, we administered BrdU for 10 days, followed by 
a 70 day chase without BrdU, like prior studies in the hematopoietic system (Arai et al., 
2004; Zhang et al., 2003). Given that 6.0% of HSCs entered cycle each day and 46% of 
HSCs were labeled after 10 days of BrdU (Figure 5.2d), we modeled the fraction of 
HSCs that would be expected to retain BrdU over time (Figure 5.4a; see Materials and 
Methods section for explanation). 
If HSCs follow the immortal strand model they should lose their BrdU only one 
division after BrdU is discontinued as the labeled chromosomes are segregated to 
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differentiating daughter cells (Figure 5.1a), and only 0.6% of HSCs would be expected to 
retain BrdU after 70 days without BrdU (Figure 5.4a). If HSCs segregate chromosomes 
randomly, then BrdU would be lost stochastically over time and the fraction of BrdU+ 
HSCs after a 70 day chase would depend upon the threshold of BrdU required for 
detection. If the threshold is equivalent to 0.5N labeled chromosomes (one quarter of the 
genome), this level of BrdU dilution could be achieved in cells that had divided 1 or 2 
times after BrdU was discontinued (depending on whether they had divided once or twice 
in the presence of BrdU), and only 1.4% of HSCs would be expected to retain BrdU after 
the 70 day chase (Figure 5.3a). In contrast, if the threshold of detection is equivalent to 
0.0625N labeled chromosomes, this could be achieved on average in cells that had 
divided 4 or 5 times after BrdU was discontinued, and 19.8% of HSCs would be expected 
to retain BrdU after the 70 day chase (Figure 5.4a). These calculations thus predict that 
few (<20%) HSCs should retain BrdU after a 70-day chase, irrespective of how 
chromosomes are segregated. 
To test this we administered BrdU for 10 days then stained whole bone marrow 
cells and CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs after 40, 70, and 120 days of 
chase. After 70 days of chase, 0.4±0.1% of bone marrow cells and 4.6±0.9% of HSCs 
were BrdU+ (Figure 5.4c). This demonstrates, as predicted (Figure 5.4a), that few HSCs 
retain BrdU. Moreover, only 2.0±1.0% of HSCs were BrdU+ after 120 days of chase, 
demonstrating that the frequency of BrdU-retaining HSCs continues to decline over time 
rather than identifying a deeply quiescent subset of HSCs that retains BrdU indefinitely. 
Although BrdU label-retaining cells were 10-fold enriched for HSCs, the rarity of HSCs 
means that only 0.08% of BrdU+ bone marrow cells were HSCs (0.0066% x 4.6%/0.4%). 
   
 154 
BrdU label-retention is therefore a very insensitive and non-specific marker of HSCs as 
the vast majority of HSCs did not retain detectable BrdU, and only rare BrdU label-
retaining cells were HSCs. Very similar results were obtained when we used flow-
cytometry to detect BrdU incorporation (Figure 5.5) or when HSCs were isolated using 
different surface markers (c-kit+Flk-2-lineage-Sca-1+ cells; Figure 5.7). These data are 
most consistent with random chromosome segregation by HSCs and the failure to detect 
BrdU after approximately 3 divisions in the absence of BrdU (Figure 5.4a). 
According to the immortal strand model, stem cells can incorporate BrdU into 
DNA strands that become the ‘older’ strands during symmetric cell divisions and these 
labeled DNA strands would be retained indefinitely by stem cells that resume asymmetric 
divisions (Figure 5.1c).  To test this, we administered BrdU to newborn mice for 10 days 
or to cyclophosphamide/G-CSF treated mice for 4 days. The absolute number of HSCs 
expands dramatically in both newborn (Bowie et al., 2006) and cyclophosphamide/G-
CSF mobilized mice (Morrison et al., 1997) (indicating symmetric divisions), before 
stabilizing to steady-state levels as mice enter adulthood or G-CSF is discontinued. After 
10 days of BrdU in neonatal mice, 93±3.7% of bone marrow cells and 80±11% of 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were BrdU+. Seventy days later, 0.1% 
of bone marrow cells and 6.4±2.5% of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs 
were BrdU+ (Figure 5.4d). After 4 days of BrdU in mobilized mice, 94±3% of 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were BrdU+. Seventy days later, 0.1% 
of bone marrow cells and 2.1±1.1% of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs 
were BrdU+ (Figure 5.4d). Thus even when BrdU was administered to symmetrically 
dividing HSCs, only 2 to 6% of HSCs retained the label and only 0.2% to 0.4% of BrdU-
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retaining bone marrow cells were HSCs. We were unable to identify any context in which 
BrdU label-retention identified HSCs with sensitivity or specificity, and none of these 
results were consistent with the immortal strand hypothesis. 
To address the possibility that the HSCs in the above experiments might have 
continued to divide symmetrically after BrdU was discontinued we also administered 
BrdU to mice from 20 to 29 days postnatally. HSCs are thought to transition from rapidly 
dividing cells with a fetal phenotype to relatively quiescent cells with an adult phenotype 
between 21 and 28 days postnatally (Bowie et al., 2006). We obtained similar results with 
only 6.5±1.1% of HSCs retaining BrdU after a 70-day chase. There was therefore no 
period during neonatal development when BrdU could be administered in a way that 
resulted in retention within significant numbers of HSCs. 
To test the immortal strand model directly, we treated mice with 10 days of CldU 
then 10 days of IdU. If HSCs segregate older and younger DNA strands asymmetrically, 
then HSCs should rarely incorporate both CldU and IdU under steady-state conditions 
because newly synthesized (labeled) DNA strands should be segregated to differentiating 
daughter cells after each division (Figure 5.6a). In contrast, if HSCs segregate older and 
younger DNA strands randomly then CldU-labeled HSCs should have the same chance of 
incorporating IdU as unlabeled cells and approximately 25% (50% x 50%) of HSCs 
should be double labeled (Figure 5.6b). 
After 10 days of CldU followed by 10 to 11 days of IdU we observed that 14% of 
HSCs incorporated only CldU, 32% of HSCs incorporated only IdU, and 27% of HSCs 
incorporated both CldU and IdU (Figure 5.6c; Figure 5.8). The frequency of CldU+IdU+ 
cells (27%) was therefore similar to the product of the frequencies of total CldU+ cells 
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and total IdU+ cells (41% x 59%=24%) indicating that CldU+ cells had a similar 
probability of incorporating IdU as other cells.  We repeated this experiment by 
administering CldU to mice for 60 days followed by 15 days of IdU, and found the 
frequency of CldU+IdU+ cells (63%) was again similar to the product of the frequencies 
of total CldU+ cells and total IdU+ cells (73% x 84%=61%). These results were not 
significantly affected by a slow clearance of CldU from mice, as CldU was cleared in less 
than 1 day after being discontinued from the drinking water (Figure 5.9). These 
observations directly contradict a key prediction made by the immortal strand hypothesis 
but are as would be expected by random chromosome segregation. 
The foregoing experiments left the formal possibility that if HSCs divide by a 
combination of symmetric and asymmetric divisions in vivo we might underestimate the 
frequency of HSCs that retain older DNA strands. To address this we examined the 
division of individual HSCs in culture that were isolated from mice treated for 10 days 
with BrdU. Single CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were sorted into 
cultures under conditions in which half of HSC divisions give asymmetric outcomes 
(daughter cells with different developmental potentials) (Takano et al., 2004). After 2 to 3 
days of culture we observed a total of 346 colonies in which HSCs had divided once (2 
daughter cells) or twice (3 or 4 daughter cells). Either all daughter cells were BrdU+ (162 
colonies; 46%) or all daughter cells were BrdU- (184 colonies) (Figure 5.4f) as would be 
expected by random chromosome segregation given that 46% of HSCs incorporate BrdU 
in vivo after 10 days (Figure 5.2d). We observed no colonies after 1 or 2 rounds of 
division that contained a mixture of BrdU+ and BrdU- cells. These in vitro experiments 
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on individual HSCs thus failed to detect any asymmetric segregation of labeled 
chromosomes. 
Our results were not confounded by effects of BrdU/CldU/IdU on HSC 
proliferation, survival, or DNA repair. The cell cycle status (Figure 5.3) and frequency 
(data not shown) of HSCs was not affected by these treatments. BrdU/CldU/IdU 
incorporation from DNA repair was not detectable (Figure 5.3). 
Our results indicate that BrdU label-retention is neither a sensitive nor a specific 
marker of HSCs. Nonetheless BrdU label-retention could be a better marker of stem cells 
in other tissues. Moreover, histone-GFP (Tumbar et al., 2004) may do a better job of 
marking stem cells, including HSCs, because it can be selectively expressed in subsets of 
progenitors and may be retained with different kinetics than BrdU. Our data demonstrate 
the need to test the sensitivity and specificity of BrdU and other label-retention markers 
before assuming they mark stem cells with fidelity. 
Our data also demonstrate that the immortal strand model (Cairns, 1975) does not 
apply to HSCs and cannot be considered a general model of stem cell division. Our data 
do not address whether stem cells from other tissues asymmetrically segregate 
chromosomes or whether HSCs segregate a limited number of chromosomes 
asymmetrically (Armakolas and Klar, 2006). Nonetheless, asymmetric chromosome 
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MATERIALS AND METHODS 
BrdU/CldU/IdU administration 
All experiments employed C57BL/Ka-CD45.2:Thy-1.1 mice. For experiments in 
adult mice, BrdU (Sigma, St. Louis, MO) was administered when the mice were 8 to 10 
weeks of age. Mice were given an intraperitoneal injection of 100 mg of BrdU/kg of body 
mass in Dulbecco’s phosphate buffered saline (DPBS; Gibco, Carlsbad, CA) and 
maintained on 1 mg/ml of BrdU in the drinking water for 1 to 10 days. Amber bottles 
containing BrdU water were changed every 1 to 3 days. For retention studies, BrdU water 
was replaced with regular water and the mice were maintained for 40 to 120 days before 
analysis. 
 BrdU injections into neonatal mice were performed as described (Taylor et al., 
2000).  Beginning within 3 days after birth, neonatal mice were injected subcutaneously 
with 50 mg BrdU/kg body weight twice daily for 10 days. Mice were weighed every two 
days and the dose of BrdU was adjusted. 
 To assess BrdU retention following cytokine mobilization, adult mice were 
injected with cyclophosphamide (200 mg/kg; Bristol-Myers Squibb, New York) and then 
on each of 4 subsequent days with 250 µg/kg per day of human G-CSF (Amgen, 
Thousand Oaks, CA) (Morrison et al., 1997). On the fourth day of G-CSF injection, a 
single intraperitoneal injection of 100 mg BrdU/kg of body mass was given and the mice 
were put on 1 mg/ml BrdU water for 4 additional days. The mice were then returned to 
regular water for 70 days before analysis. 
 For 5-chloro-2-deoxyuridine (CldU) and 5-iodo-2-deoxyuridine (IdU) 
experiments, mice were given an intraperitoneal injection of 100 mg of CldU/kg of body 
mass in DPBS and maintained on 1 mg/ml of CldU (Sigma) in the drinking water for 10 
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days. Mice were then given an intraperitoneal injection of 100 mg of IdU/kg of body 
mass in DPBS, and switched to 1 mg/ml of IdU (Sigma) in the drinking water for 10 to 
11 days before being sacrificed. 
 
BrdU segregation in cultured HSCs 
              Single CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were sorted from 
BrdU-treated mice into a V-bottom 96-well plate containing Stempro-34 medium 
(Invitrogen) supplemented with 2 mM L-glutamine, 50 µM 2-mercaptoethanol (Sigma), 
murine IL-3 (10 ng/ml), murine SCF (100 ng/ml) and murine Tpo (100 ng/ml; all 
cytokines from R&D Systems) with 10% charcoal absorbed fetal bovine serum (Cocalico 
Biologicals, Inc., Reamstown, PA) and cultured for 2 to 3 days in low oxygen chambers 
(Morrison et al., 2000). For analysis, plates were centrifuged at 500xg for 10 minutes, 
then cells from each colony were pipetted onto individual wells of Teflon printed glass 
slides and allowed to dry overnight prior to staining for BrdU and DAPI. 
 
BrdU staining 
Slides were thawed at room temperature for 15 minutes, fixed in 70% ethanol at –
20°C for 30 minutes, rinsed in 0.1M phosphate buffer (PB) twice, incubated in 2N HCl 
with 0.8% Triton in PB for 30 minutes, incubated in 0.1M Sodium Borate (pH 8.5) for 15 
minutes, then rinsed in 0.1M PB at room temperature, at 37oC, and at room temperature 
again.  The slides were then incubated with 0.3% Triton in 0.1M PB supplemented with 
5% Goat Serum for 1 hour at 4°C.  Slides were incubated at 4oC overnight with the 
primary anti-BrdU antibody that specifically recognizes BrdU and CldU but does not 
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recognize IdU (clone BU1/75, Accurate Chemical and Scientific Corp.).  Slides were 
then rinsed in 0.1M PB twice and incubated with Alexa488-conjugated goat anti-rat IgG 
(Invitrogen-Molecular Probes, Carlsbad, California) for 2 hours at room temperature.  
Slides were rinsed in 0.1M PB twice and incubated with DAPI for 1 hour at room 
temperature.  Finally, slides were rinsed three times in 0.1M PB, the excess buffer was 
shaken off and the slides were mounted in 70% glycerol in PBS.  Images were gathered 
using an Olympus BX-51 florescence microscope equipped with a Cooke Pixelfly CCD 
camera.  In some experiments, BrdU incorporation was measured by flow-cytometry 
using an antibody directly conjugated to allophycocyanin (APC; APC BrdU flow kit, BD 
Pharmingen). Sorted samples were fixed and permeablized according to manufacturer’s 
instructions, incubated in 2N HCl for 30 minutes at room temperature, neutralized in 
Sodium Borate (pH 8.5), washed in 0.5% Triton in DPBS, stained with anti-BrdU APC 
and resuspended in DAPI (10 μg/ml) prior to FACS analysis.  All flow-cytometry was 
performed on a FACSVantage SE-dual laser, three-line flow-cytometer (Becton-
Dickinson). 
 
Analysis of cell cycle distribution and cell death in HSCs 
Cell cycle distribution was analyzed by Hoechst 33342 (Invitrogen-Molecular 
Probes, Carlsbad, California) staining. CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs 
were sorted and resorted into ice-cold 70% ethanol and stored at –20oC overnight.  Cells 
were resuspended in PBS containing 0.02 mg/ml Hoechst 33342, incubated for 30 
minutes and analyzed by flow-cytometry using a UV laser. 
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For activated caspase-3 staining, frozen slides bearing sorted CD150+CD48-
CD41-lineage-Sca-1+c-kit+ HSCs or sections through E11 mouse forebrain were thawed 
at room temperature for 10 minutes, fixed at room temperature in 10% buffered neutral 
formalin (VWR, West Chester, Pennsylvania) for 10 minutes, rinsed in 0.1M PB twice, 
and blocked with 0.3% Triton in 0.1M PB supplemented with 5% Goat Serum for 1 hour 
at 4°C.  Slides were then incubated with anti-activated caspase-3 antibody (BD 
Pharmingen, San Diego, California) at room temperature for 2 hours.  Slides were then 
rinsed in 0.1M PB twice and incubated with Alexa488-conjugated goat anti-rabbit IgG 
(Invitrogen-Molecular Probes, Carlsbad, California) for 1 hour at room temperature.  
Slides were rinsed in 0.1M PB twice and incubated with DAPI for 30 minutes at room 
temperature.  Finally, slides were rinsed three times in 0.1M PB, the excess buffer was 
shaken off and the slides were mounted in 70% glycerol in PBS.  To test for the 
incorporation of BrdU due to DNA repair, BrdU was administered to adult mice for 12 
hours followed by irradiation with 100 rad from a Gammacell40 Extractor (MDS 
Nordion, Ottawa, ON, Canada) followed by 48 hours of further BrdU administration. 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were then sorted onto slides and 
stained for BrdU as described above.  
 
Mathematical models of BrdU uptake and retention 
To model the uptake and retention of BrdU in a population of stem cells we 
assumed that for days 0 through T the stem cells are exposed to adequate BrdU so that 
cells incorporate BrdU when they divide. Based on our data a random 6.0% of HSCs 
enter cycle each day. At day T, the BrdU supply is removed and the level of BrdU 
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incorporated into the chromosomes decreases for every cell division after day T.  The rate 
at which BrdU is diluted from cells during this chase period depends upon how the cells 
segregate their chromosomes. If chromosomes segregate randomly, then irrespective of 
whether stem cells divide asymmetrically or symmetrically with respect to daughter cell 
fate, BrdU labeled chromosomes will stochastically become diluted over time: on average 
the BrdU label will be diluted by half during each round of division and multiple 
divisions will be required to dilute the BrdU label to the point that it is no longer 
detectable by immunohistochemistry. This is modeled as case 1 below for asymmetrically 
dividing cells. In contrast, according to the immortal strand model (Cairns, 1975), stem 
cells divide asymmetrically under steady-state conditions and BrdU is preferentially 
incorporated into newly synthesized DNA strands that are asymmetrically segregated into 
differentiating daughter cells with each round of division. Under these assumptions, 
modeled as case 2 below, stem cells retain only the unlabeled older DNA strands once 
BrdU is withdrawn. 
 
Case 1: Random segregation of chromosomes (see Figure 5.1b) 
BrdU Incorporation: When chromosomes are allowed to segregate randomly, BrdU could 
be incorporated into one or two DNA strands within each chromosome, depending on the 
number of times a stem cell divides during the period of BrdU incorporation and the way 
in which the chromosomes segregate. To model the rate of BrdU incorporation: 
 y0 = fraction of cells without BrdU  
 y1 = fraction of cells with one strand BrdU+ after only one division  
 y2 = fraction of cells with both strands BrdU+ after two or more divisions  
 α = the proliferation rate of stem cells (6.0% of HSCs enter cycle per day) 
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 Note as well that cell death was not incorporated into this model because we did 
not observe significant cell death or changes in HSC frequency during the experiments. 




















Equation 1: Cells leave the y0 population when they divide. 
Equation 2: Cells from the y0 population are added into the y1 population 
through the incorporation of BrdU into one of the DNA strands. Cells 
leave the y1 population when they divide. 
Equation 3: Cells from the y1 population are added into the y2 population 
through further incorporation of BrdU through cell division.
 
To determine the frequency of BrdU+ stem cells at any time after the addition of BrdU 
we solve the system of ordinary differential equations with all HSCs initially being 
unlabeled prior to BrdU administration. Note that similar equations have previously been 
used to model BrdU incorporation and depletion from other cells (Bonhoeffer et al., 
2000). 
 
The process by which cells lose the BrdU label: At day T (when BrdU is removed), we 
determine the total number of BrdU+ stem cells by adding the y1 and y2 populations. 
Cells in the y1 population have a BrdU level of 1, whereas y2 cells have a BrdU level of 
up to 2. To model the rate at which these cells lose BrdU during subsequent divisions 
after removing BrdU: 
 
y10 = fraction of cells, initially with one labeled DNA strand that undergo 0 divisions after day T  
y11 = fraction of cells, initially with one labeled DNA strand that undergo 1 division after day T  
 … 
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y1N = fraction of cells, initially with one labeled DNA strand that undergo N divisions after day T 
y20 = fraction of cells, initially with two labeled DNA strands that undergo 0 divisions after day T  
y21 = fraction of cells, initially with two labeled DNA strands that undergo 1 division after day T  
 … 
y2N=fraction of cells, initially with two labeled DNA strands that undergo N divisions after day T 
 
Cells move from y1(k-1) to y1k at the proliferation rate α (cells move in y2k similarly). The 







































With each cell division, the cell's BrdU level is decreased by 
half. For instance, cells in y10 have BrdU level 1, cells in y11 
have half as much BrdU on average, cells in y12 have one 
quarter as much BrdU on average, etc. Similarly, cells in y20 
have BrdU level 2, cells in y21 have BrdU level 1, cells in y22 
have BrdU level 0.5, etc. We can determine the total fraction of 
cells that have a BrdU level that is above a minimum detection 
level (which can be set at any desired level in the simulations) 
by adding all relevant populations at any time after day T.
This set of ordinary differential equations is solved for initial conditions that are 
determined by the observed results of the BrdU incorporation at time T.  In this way, it is 
possible to plot the frequency of BrdU+ HSCs over time, depending on whether it takes 
1, 2, 3, or 4 rounds of division to dilute BrdU to the point at which it is no longer 
detectable (Figure 5.4a). Note that 1 round of division corresponds to a 2-fold dilution of 
BrdU while 4 rounds of division correspond to 16-fold dilution.  Our empirical data 
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suggest that approximately 3 rounds of division are required to dilute BrdU to the point 
that it is no longer detectable in HSCs. 
 
Case 2: Asymmetric chromosome segregation (immortal strand model; Figure 5.1a) 
BrdU Incorporation: Under this model, only one strand of DNA within each chromosome 
in stem cells can contain BrdU irrespective of how long BrdU is administered (though the 
proportion of labeled stem cells will increase over time). 
The equations for Case 2 are: 
 y0 = fraction of cells without BrdU  
 y1 = fraction of cells with one strand BrdU+ (after one or more divisions)  
 α  = proliferation rate of stem cells 













Equation 4: Cells leave the y0 population when they divide. 
Equation 5: Cells from the y0 population are added into the y1 
population through the incorporation of BrdU into one of the 
DNA strands. 
As before, in order to determine the proportion of cells within each population at the end 
of day T we solve the system of ordinary differential equations with initial conditions 
corresponding to the case where initially all HCSs are unlabeled prior to BrdU 
administration.  Cells in population y0 do not contain any BrdU, while those in y1 have a 
BrdU level of 1. 
 
The process by which cells lose BrdU label: We take all cells containing BrdU at day T 
(all cells in population y1 and monitor BrdU loss through cell division in the absence of 
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BrdU). In this case, the asymmetric segregation of chromosomes means that all dividing 
stem cells will lose all of the BrdU label in a single division in the absence of BrdU. 
Therefore, the fraction of stem cells that remain BrdU+ at time T, simplifies to the 
fraction of BrdU+ HSCs that do not divide after removing BrdU: 
y10 = fraction of cells, initially with one labeled strand that undergo 0 divisions after day T 
 
Cells move from y10 (and lose their BrdU label) at the proliferation rate α. The equations 





















This differential equation with initial condition y10(0) = y1(T) determines the fraction of 
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Figure 5.1: Contrasting predictions regarding stem cell labeling based on the 
immortal strand model versus random chromosome segregation. a) According to the 
immortal strand model (Cairns, 1975), stem cells divide asymmetrically under steady-
state conditions and BrdU is incorporated into newly-synthesized DNA strands that are 
asymmetrically segregated into differentiating daughter cells with each round of division, 
such that stem cells retain only the unlabeled older DNA strands. b) In contrast, if 
chromosomes segregate randomly, then BrdU labeled chromosomes will be stochastically 
diluted over multiple rounds of divisions. c) By the immortal strand model, if stem cells 
divide symmetrically then BrdU can be incorporated into DNA strands that become the 
‘older’ strands once stem cells resume asymmetric division. Under these circumstances 
the BrdU+ older strands would be retained indefinitely in stem cells. d) In contrast, if 
chromosome segregation is random then BrdU+ chromosomes are stochastically diluted 
over time after BrdU is discontinued. 
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Figure 5.2: 6.0% of HSCs stochastically enter cell cycle each day. a) HSCs can be 
isolated by flow-cytometry as CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells that 
represent only 0.0066±0.0003% (0.007% x 94%) of bone marrow cells but which contain 
all detectable HSC activity and which are very highly enriched for HSCs (nearly 50% of 
single cells give long-term multilineage reconstitution in irradiated mice(Kiel et al., 
2005)). b) BrdU incorporation into HSCs evaluated by immunofluorescence after sorting 
HSCs onto microscope slides (DAPI is a nuclear stain). The percentage of BrdU+ bone 
marrow cells (c) and CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs (d) after various 
periods of BrdU administration (3 independent experiments with 3 to 4 mice per 
experiment and 200 to 400 bone marrow cells or 100 to 400 HSCs counted per mouse). e) 
The percentage of HSCs that enter cycle each day (6.0%) can be derived by plotting the 
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Figure 5.3: Administration of CldU and IdU does not affect HSC proliferation or 
cell death and BrdU incorporation during DNA repair is negligible. a) Cell cycle 
distribution (based on DNA content) of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs 
isolated from a mouse that did not receive CldU or IdU (left) or from a mouse that 
received 4 days of CldU followed by 4 days of IdU (right) (two independent 
experiments). In separate experiments, the frequency of HSCs was not affected by these 
treatments as CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells represented 
0.0070±0.0011% of bone marrow cells in mice treated with BrdU or CldU or IdU for 10 
days and 0.0066±0.0014% of bone marrow cells in controls. b) Activated caspase-3 
staining of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs sorted onto a microscope 
slide following 10 days of CldU administration and 10 days of IdU administration. 
Arrowheads identify activated caspase-3+ cells in a section through embryonic day 11 
mouse forebrain (positive control), but no activated caspase-3+ HSCs were detected in 
either CldU/IdU-treated or control mice (200 to 300 HSCs examined per treatment; two 
independent experiments). c) BrdU was administered for 12 hours followed by gamma 
irradiation with 100 rad and then 48 hours of further BrdU administration.  No BrdU+ 
HSCs were detected in negative control mice (no BrdU). Among mice treated with BrdU 
for 60 hours, 17.4±1.6% of HSCs from non-irradiated mice were BrdU+ and 18.6±4.5% 
of HSCs from irradiated mice were BrdU+ (250 to 600 HSCs analyzed per treatment; 3 
independent experiments).  Since DNA damage would be expected in all cells that 
receive this dose of irradiation(Taniguchi et al., 1993), this demonstrates that the amount 
of BrdU that is incorporated as a result of DNA damage repair is negligible and cannot be 
detected by immunofluorescence in these assays. Our failure to detect BrdU 
incorporation from DNA repair is consistent with prior studies that found that nucleotide 
incorporation as a result of DNA repair is negligible relative to DNA replication, even 
over many years (Spalding et al., 2005). 
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Figure 5.4: Few HSCs retain BrdU and the vast majority of BrdU-retaining bone 
marrow cells are not HSCs. a) Model predicting the fraction of HSCs that retain BrdU 
over time after administering BrdU 10 days, depending on whether chromosomes 
segregate asymmetrically or randomly and on the threshold of BrdU that can be detected 
by immunofluorescence (0.5N, 0.25N, 0.125N, or 0.0625N labeled DNA). b) 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs sorted onto a microscope slide 
following 10 days BrdU administration and 70 days chase (without BrdU). Arrowheads 
identify BrdU+ cells. c) The frequency of BrdU+ bone marrow cells and HSCs after 10 
days BrdU administration and 40, 70, or 120 days chase. d) The frequency of BrdU+ bone 
marrow cells and HSCs after 10 days BrdU administration to neonatal mice followed by 
70 or 120 days chase; or after 4 days BrdU administration to cyclophosphamide/G-CSF 
treated mice followed by 70 days chase. All data are based on 3 to 5 independent 
experiments with 3 mice per experiment and 400 to 700 bone marrow cells or 300 to 400 
HSCs counted per mouse. 
 




Figure 5.5: Few HSCs retain BrdU, and the vast majority of BrdU label-retaining 
bone marrow cells are not HSCs even when BrdU incorporation is measured by 
flow-cytometry. In case flow-cytometric detection of BrdU was more sensitive than 
immunofluorescence microscopy, we repeated all of the experiments using this approach. 
The percentage of BrdU+ whole bone marrow cells (a) or CD150+CD48-CD41-lineage- 
HSCs (b) in negative control mice (no BrdU), or after 10 days of BrdU administration, or 
after an additional 70 days of chase (without BrdU). Note that fewer HSC markers were 
used to free up a fluorescence channel to detect BrdU by flow-cytometry; however, this 
should not introduce significant impurities as 45% of CD150+CD48-CD41- cells give 
long-term multilineage reconstitution in irradiated mice (Kiel et al., 2005).  Only 1.9% of 
HSCs detectably retained BrdU after 70 days chase and less than 0.04% of BrdU+ bone 
marrow cells were HSCs (0.0066% x 1.9%/0.36%). The data are based on 3 independent 
experiments in which 6,000 to 60,000 bone marrow cells or 400 to 1200 HSCs were 
analyzed per experiment. 

































Figure 5.6: HSCs segregate chromosomes randomly in vivo and in vitro. a) By the 
immortal strand model, stem cells sequentially exposed to CldU (10 days) then IdU (10 
days) would not incorporate both labels, with the exception of rare cells in S/G2/M phase 
of their first division after switching from CldU into IdU (expected frequency <<3%). b) 
In contrast, if chromosome segregation is random then CldU+ stem cells would have the 
same probability of incorporating IdU as unlabeled cells (expected frequency of 
CldU+IdU+ HSCs approximately 25%). c) CldU was administered to mice for 10 days 
followed by IdU for 10 to 11 days and CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs 
were stained. d) Examples of HSCs that incorporated neither label, only CldU, only IdU, 
or both labels (data are based on two independent experiments with 2 or 3 mice per 
experiment and 100 to 250 HSCs per mouse). HSCs from BrdU-treated mice divided 
once (d) or twice (e) in culture to form daughter cells. f) The progeny of these HSCs were 
either all BrdU+ or all BrdU-. We detected no clones in which label was asymmetrically 
segregated to a subset of daughter cells. 
 





























Figure 5.7: HSCs identified as c-kit+Flk-2-lineage-Sca-1+ cells also cannot be 
reliably identified based on BrdU label-retention.   a) In case the isolation of HSCs 
using different markers would identify a population that is more consistently marked by 
BrdU label-retention, we isolated c-kit+Flk-2-lineage-Sca-1+ cells, which represent 
around 0.02% of bone marrow cells (2.0% x 1.0%; a), and which are highly enriched for 
HSCs (Christensen and Weissman, 2001). b) c-kit+Flk-2-lineage-Sca-1+ cells were 
isolated from mice that had been administered BrdU for 10 days followed by a 70 day 
chase without BrdU.  Cells were sorted onto microscope slides and stained with DAPI (to 
identify nuclei) and BrdU. c) The frequency of BrdU+ c-kit+Flk-2-lineage-Sca-1+ cells 
after 10 days of BrdU administration or after an additional 70 days of chase in normal 
young adult mice or neonatal mice was very similar to what we observed when HSCs 
were isolated as CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells (Figure 5.4c, d). The 
frequency of BrdU+ c-kit+Flk-2-lineage-Sca-1+ cells after 4 days of BrdU administration 
followed by 70 days of chase in cyclophosphamide/G-CSF treated mice was also similar 
to what we observed in CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs (Figure 5.4d). 
These results were based on two independent experiments in which 6 mice and 200 to 
300 cells per mouse were analyzed per experiment.   
 
 































Figure 5.8: CldU+ and IdU+ cells can be distinguished by antibody staining. CldU 
and IdU staining of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs from control mice 
that were administered neither label (left column), only CldU (middle column), or only 
IdU (right column).  These controls were performed side-by-side with all CldU/IdU 
samples using the same staining conditions. IdU staining was only observed in samples 
from mice administered IdU and CldU staining was only observed in samples from mice 
administered CldU. 
 















Figure 5.9: CldU persists in mice for less than a day after administration is 
discontinued. To test whether the CldU/IdU double labeling of HSCs might simply have 
reflected a slow clearance of CldU from mice after its administration was discontinued 
(such that dividing HSCs were inadvertently exposed to both CldU and IdU) we 
sequentially administered CldU and IdU to mice for only 1 day each (a). If significant 
residual CldU remained in the mice for at least a day during IdU administration, all IdU+ 
HSCs should also be CldU+ in this experiment.  In contrast, if CldU is cleared from mice 
within hours of being discontinued, then only a minority of IdU+ HSCs should also be 
CldU+. b) The frequency of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs that 
stained only with CldU, or only with IdU, the total frequencies of CldU+ or IdU+ cells, 
and the frequency of CldU+IdU+ HSCs. Nearly two-thirds of IdU+ HSCs (6% IdU-only+ 
versus 9% total IdU+) were able to incorporate IdU without incorporating CldU over this 
brief period of administration, indicating that CldU does not persist in mice for longer 
than 8 hours after administration. The data are based on 3 separate mice analyzed in two 
independent experiments with 162 to 238 HSCs analyzed per mouse. The fact that some 
residual CldU remains in these mice during the first several hours of IdU administration 
can account for the consistent 2 to 3% increase in the frequency of CldU+IdU+ HSCs 
above that predicted by the product of single positive HSCs (27% observed versus 24% 
predicted with 10 day pulses (Figure 5.6c); 3% observed versus 1.3% predicted based on 
1 day pulses (panel b above)). 
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In this dissertation, I have presented evidence in favor of the existence of a 
perivascular niche for HSCs identified using markers of the SLAM-family of surface 
antigens.  Moreover, I have questioned the validity of some of the most widely cited 
evidence in favor of the existence of an osteoblastic HSC niche.   
Overall, many questions still remain relating to the role of the endosteum 
environment in the localization and maintenance of HSCs in the bone marrow. Some of 
the factors implicated in HSC maintenance by endosteal cells have not yet been tested for 
necessity in vivo. Evidence supporting a role for these factors in HSC maintenance is 
based upon experiments conducted in culture or on over-expression experiments in vivo. 
It will be important to test whether these factors are really required for HSC maintenance 
in vivo. Similarly, a fundamental question is whether there are redundant sources for 
critical growth factors in the bone marrow. It will ultimately be necessary to conditionally 
delete critical growth factors from specific stromal cell types to confirm that they are the 
physiologically important source for these factors.  It is clear that endosteal cells have 
important roles in the regulation of HSC maintenance and function.  However, answers 
                                                           
1 Originally published in Nature Reviews Immunology 8:290-301, April 2008 under the 
title “Uncertainty in the niches that maintain haematopoietic stem cells” with authors 
listed as MJ Kiel and SJ Morrison. 
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to these questions would provide insight into precisely how endosteal cells regulate HSCs 
and what fraction of the HSC pool depends on such mechanisms. 
With respect to whether there is a perivascular niche, multiple cell types in 
addition to endothelial cells themselves are located perivascularly and may contribute to 
the cell-extrinsic regulation of HSCs.  Mesenchymal progenitors, that localize 
perivascularly in the bone marrow (Shi and Gronthos, 2003), also appear capable of 
regulating HSC maintenance (Sacchetti et al., 2007). Cultured bone marrow stromal cells 
can form bony ossicles that become hematopoietic when transplanted subcutaneously in 
mice (Kaigler et al., 2005). These ectopic bone marrow compartments have cellular 
compositions similar to endogenous bone marrow. In contrast, transplantation of 
osteoblasts can form bone, but not hematopoietic bone. Rather, a recent study found that 
CD146-expressing mesenchymal progenitors, that reside perivascularly in the bone 
marrow, are uniquely capable of forming hematopoietic bone (Sacchetti et al., 2007). 
This suggests that self-renewing, perivascular mesenchymal progenitors can form HSC 
niches.  Additionally, these perivascular mesenchymal progenitors express factors that 
regulate HSC maintenance, including Angiopoietin and CXCL12. An interesting question 
concerns the relationship between these mesenchymal progenitors and the CXCL12-
expressing perivascular reticular cells (Sugiyama et al., 2006) – could these be the same 
cells? 
Additional cells that might have a role in the maintenance of HSCs also localize 
to the perivascular environment, including megakaryocytes. Megakaryocytes localize 
preferentially to sinusoids (Avecilla et al., 2004), and are often found adjacent to HSCs 
(Kiel et al., 2005). Mice with defects in megakaryocyte and platelet development also 
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have abnormalities in bone-marrow hematopoiesis (Shivdasani and Orkin, 1995; 
Vannucchi et al., 2002). Finally, there is considerable evidence of cross-regulation among 
megakaryocytes, endothelial cells, and osteoblasts (Avecilla et al., 2004; Kacena et al., 
2006; Kaigler et al., 2005), raising the possibility that all of these cells might work 
together to create HSC niches using a combination of direct and indirect mechanisms (see 
Figure 1.3). 
Does the perivascular environment actually promote the maintenance of HSCs, or 
are the HSCs around sinusoids in the process of migrating elsewhere? Significant 
numbers of HSCs enter and exit the circulation every day (Wright et al., 2001) and HSCs 
that are in the process of entering or exiting the bone marrow might be expected to be 
present around sinusoids. Additional studies will be required to genetically test whether 
perivascular cells maintain bone marrow HSCs using specific mechanisms. Moreover, it 
would be helpful to be able to image HSCs within the bone marrow to determine how 
long they spend in perivascular environments and whether they undergo self-renewing 
divisions in these locations. It is not clear whether this will be technically possible, but 
the ability to dynamically image the homing of hematopoietic progenitors to specialized 
regions of endothelium within the bone marrow of living mice is encouraging (Sipkins et 
al., 2005). The ability to perform live imaging of HSCs within the bone marrow (Suzuki 
et al., 2006) could also help to resolve the question of whether HSCs behave differently 
in different locations. 
If vascular niches have an important role in the maintenance and expansion of 
HSCs, an interesting question is whether all sinusoids can participate in the formation of 
vascular niches or whether only specialized domains within certain sinusoids are 
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competent to do so. If vascular structures can acquire competence to support HSCs and 
hematopoiesis in response to hematopoietic stress, it would suggest that the 
hematopoietic system has considerable plasticity with respect to the numbers and 
locations of stem cell niches. 
Whereas most evidence suggests important contributions by endosteal and 
perivascular cells to the maintenance of HSCs, it remains possible that there are crucial, 
but as yet undiscovered, roles for other cell types or other microenvironments in the 
maintenance of HSCs. Using SLAM family markers, 38% of HSCs in extramedullary 
tissues and 26% of HSCs in bone marrow were not detectably in contact with either 
sinusoids or endosteum (Kiel et al., 2005). It remains unclear whether these cells were 
migrating or whether they were present in distinct niches that we do not yet know how to 
identify. For example, it is possible that adipocytes secrete factors that regulate HSCs or 
hematopoiesis in the bone marrow (DiMascio et al., 2007). We remain at an early stage 
of elucidating the contributions of cells within the bone marrow and other tissues to the 
regulation of HSCs and hematopoiesis. 
A recent study suggests that HSCs often occupy hypoxic microenvironments in 
the bone marrow. The degree of blood perfusion in different regions of tissues can be 
tested by infusing brief pulses of Hoechst dye intravenously and then comparing the 
degree of Hoechst uptake by cells in different locations (Parmar et al., 2007). Cells in 
microenvironments that are well perfused by blood should be exposed to the highest 
concentrations of Hoechst dye, whereas cells in microenvironments that are poorly 
perfused should be exposed to much lower concentrations. Cells that stain with the lowest 
levels of Hoechst dye are therefore inferred to be in relatively hypoxic environments. 
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After intravenous infusion of Hoechst dye, HSCs were enriched among the bone-marrow 
cells that stained with the lowest levels of Hoechst by flow-cytometry (Durand et al., 
1990). At least certain regions of the endosteum appear to be hypoxic, though other 
regions of the bone marrow also contain hypoxic areas (Parmar et al., 2007). It remains 
unclear whether some perisinusoidal regions are hypoxic, a possibility given that 
sinusoids carry slow venous circulation that is not designed to transport oxygen so much 
as to allow cells to move in and out of circulation. Additional studies will be required to 
fully characterize the hypoxic regions within bone marrow and the manner in which they 
regulate HSCs. 
Recent evidence also indicates that HSC mobilization may be influenced by the 
sympathetic nervous system. Mice deficient in UDP-galactose ceramide 
galactosyltransferase, an enzyme that is required for normal peripheral nerve myelination 
and conduction, fail to mobilize hematopoietic progenitors in response to granulocyte 
colony stimulating factor (G-CSF) (Levesque et al., 2007). Pharmacological ablation of 
noradrenergic neurons also reduced the mobilization of hematopoietic progenitors, 
whereas ß2 adrenergic agonists enhanced mobilization (Katayama et al., 2006). These 
data indicate that the sympathetic nervous system regulates the localization of 
hematopoietic progenitors in the bone marrow. Since all of these treatments also had 
effects on osteoblast morphology, the sympathetic nervous system was interpreted to 
regulate an endosteal niche for HSCs. The sympathetic nervous system also regulates the 
vasculature (Katayama et al., 2006) and it was not tested whether there were effects on 
bone marrow vasculature in these mice. Additional work will be required to determine 
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which bone marrow cells mediate the effects of the sympathetic nervous system on 
hematopoietic progenitor mobilization. 
 
Drosophila spermatogenesis provides one paradigm for what a stem cell niche is, 
and how it works (Julien et al., 1995) (Figure 6.1). An average of 9 spermatogonial stem 
cells (blue) are arrayed around the hub, a cluster of 12 somatic cells (green) that produce 
a factor called Unpaired (Upd). Stimulation by Unpaired is required for the maintenance 
of spermatogonial stem cells, and Unpaired is concentrated in the extracellular matrix 
surrounding hub cells, so the stem cells can only be maintained immediately adjacent to 
the hub (Fuller and Spradling, 2007; Tulina and Matunis, 2001). The stem cells divide 
asymmetrically such that one daughter cell remains adjacent to the hub and retains stem 
cell identity, whereas the other daughter cell is displaced from the niche and is fated to 
differentiate (purple) by virtue of losing access to Unpaired (Kiger et al., 2001). The 
differentiating progeny continue to proliferate and differentiate into sperm. In this way, 
spermatogonial stem cells both sustain the stem cell pool and generate differentiated 
progeny. Since the niche is constrained by the need for contact with the hub, this 
physically limits the number of stem cells that can reside within the tissue and ensures 
that half of the progeny of stem cells are displaced from the niche and fated to 
differentiate. Nonetheless, if stem cells are ablated, the daughter cell that is normally 
destined to differentiate can reoccupy the open space in the niche to maintain 
homeostasis (Morrison and Kimble, 2006). 
The Drosophila germline is attractive in the simplicity of the mechanisms by 
which it maintains limited numbers of stem cells while also sustaining spermatogenesis. 
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Does the hematopoietic system employ analogous mechanisms to maintain proscribed 
numbers of HSCs while sustaining hematopoiesis? We might imagine that this is the 
case, though it need not be. As more and more niches are characterized in vertebrates and 
invertebrates we are sure to uncover new mechanisms and perhaps even new paradigms. 
For now, much less is known about HSC niches in two crucial respects. First, whereas we 
have single-cell resolution in the Drosophila germline, with the ability to reliably identify 
each stem cell and each supporting (hub) cell, HSCs are so rare, and hematopoietic 
tissues so vast, that it can be much more difficult to locate the actual stem cells. Second, 
the mechanisms that have been implicated in the regulation of the Drosophila germline 
are supported by genetic evidence showing necessity under physiological conditions in 
vivo (Brawley and Matunis, 2004). In the hematopoietic system, we draw more complex 
models but many elements of these models remain genetically untested. 
Despite the limitations in existing knowledge, both endosteal and perivascular 
cells appear to contribute to the maintenance, expansion, and localization of HSCs. One 
possibility is that perivascular and endosteal cells contribute to the formation of a 
common niche that is influenced by both cell types (Figure 6.2C). Alternatively, they 
may form spatially distinct niches (Figure 6.2A). If they do form distinct niches, are these 
niches functionally distinct in terms of their effect on HSCs (Figure 6.2B)? Finally, it is 
possible that there is less microenvironmental specialization than we imagine in the bone 
marrow, and that HSCs in a variety of locations have access to factors required for HSC 
maintenance (Figure 6.2D). For now, we can only speculate about the answers to these 
questions. 
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Another fundamental question is whether the mechanisms that are responsible for 
the maintenance of HSCs change after injury. It is striking that increased Jagged1–
Notch1 signalling (Calvi et al., 2003; Fuller and Spradling, 2007; Varnum-Finney et al., 
1998) and increased canonical WNT signalling (Reya et al., 2003; Stier et al., 2002) are 
sufficient to promote HSC expansion, though not under all circumstances (Scheller et al., 
2006; Willert et al., 2003). Yet the genes encoding Jagged1, Notch1 and ß-catenin are not 
necessary for the maintenance of adult HSCs in vivo (Kirstetter et al., 2006; Mancini et 
al., 2005) (Table 6.1). One possibility is that there are redundant signals that can promote 
HSC maintenance or expansion under physiological conditions, any of which is 
sufficient, but none of which is necessary. It is also possible that WNT signaling or Notch 
signaling is necessary for the response of HSCs to certain stresses but not under steady-
state conditions. The idea that different signals may regulate HSCs under different 
circumstances is also consistent with the observation that the cellular composition of the 
bone marrow, and the potential for extramedullary hematopoiesis change in response to 
stress. Going forward it will be important to distinguish between environmental 
mechanisms that maintain HSCs under steady-state conditions versus mechanisms that 
regulate HSC survival or expansion after injury. 
These questions also pose some conceptual issues. Are HSC niches set in number 
such that they specify the numbers of HSCs that can be present in tissues, or are many 
cells facultatively capable of creating HSC niches? Are niches transiently or permanently 
competent to support HSCs, and are they transiently or permanently occupied? What 
changes allow HSCs to expand in number during development (Cobas et al., 2004)? 
What changes allow HSCs to expand in number prior to mobilization (Bodine et al., 
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1993; Morrison et al., 1995)? What changes allow extramedullary tissues to maintain 
large numbers of HSCs and high levels of hematopoiesis after hematopoietic stresses? It 
seems as though there are cells in hematopoietic tissues that do not form HSC niches 
under steady-state conditions but that can acquire this potential in the context of 
hematopoietic stress. How is this regulated to prevent hematopoietic tissues from 
accumulating inappropriate numbers of niches and HSCs? Do these environmental 
mechanisms go awry in hematopoietic malignancies? 
Are all sinusoidal vascular environments and all endosteal environments equally 
capable of promoting the maintenance of HSCs (directly or indirectly), or are there 
specialized domains that are uniquely capable of regulating HSCs? If so, are these 
domains invariant, or constantly shifting under physiological circumstances? Could this 
have something to do with the frequent migration of HSCs under steady state conditions 
(Morrison et al., 1997)? Or could the frequent migration of HSCs mean that they require 
only periodic contact with supportive cells? If so, is it really meaningful to think in terms 
of specialized niches that maintain HSCs? 
At this point, there are more questions than answers. Nonetheless, progress is 
rapid and the answers that arise over the next several years will provide fundamental 
insights into the mechanisms used by mammalian tissues to regulate development, 
homeostasis, and regeneration after injury. 
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Table 6.1:  Factors proposed to be important in extrinsic control of HSCs but for 
which genetic evidence in vivo raises uncertainty. 
 
 
Factor Proposed action in HSC niche Genetic evidence against role in vivo 
Wnts Wnt signaling in HSCs was 
believed to promote symmetric 
HSC division and expansion 
(Reya et al. 2003, Willert et al. 
2003) 
beta-catenin, the downstream target of 
Wnts, is dispensible for proper HSC 
function and maintenance (Cobas et al. 
2004, Koch et al. 2007).   
Jagged-1, Notch 
ligands 
Interaction of Jagged-1 
expressed on osteoblasts with 
its receptor Notch-1 on the 
surface of HSCs was believed 
to regulate HSC number (Calvi 
et al. 2003, Stier et al. 2002) 
Conditional deletion of Jagged-1 or 
Notch-1 in either hematopoietic cells or in 
hematopoietic stromal cells does not 
impair HSC activity or hematopoiesis 
(Mancini et al. 2005) 
N-cadherin 
(Cdh2) 
Contact of HSCs with 
osteoblasts mediated via 
homophilic cell-cell interactions 
was proposed to retain HSCs at 
the endosteal surface and 
maintain their quiescence (Arai 
et al. 2004, Wilson et al. 2004, 
Wilson et al. 2006, Zhang et al. 
2003) 
Lack of expression of N-cadherin on the 
surface of in vivo reconstituting HSCs 
(Kiel et al. 2007). N-cadherin conditional 
deletion from HSCs has no effect on HSC 
maintenance or function (Chapter 4). 
 
Several reasons may reconcile these apparent discrepancies.  First, it is formally 
possible that these factors are sufficient but not necessary to produce the proposed effects 
on HSCs.  Second, it is possible that there are molecules with redundant function that 
mask the effect of loss of these factors in vivo.  Finally, it is possible that the effects of 
these factors are mediated indirectly or are context dependent and require, for example, 
stresses to the hematopoietic system before effects of loss of function can be seen.      
 
   




Figure 6.1: Spermatogenesis in Drosophila melanogaster provides a paradigm for 
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Figure 6.2: Possible relationships between endosteal and perivascular niches.  Both 
endosteal and perivascular cells have been hypothesized to contribute to the formation of 
hematopoietic stem cell (HSC) niches (Adams and Scadden, 2006; Kopp et al., 2005; Li 
and Xie, 2005; Suda et al., 2005; Wright et al., 2001).  A) One possibility is that there 
are spatially distinct endosteal and perivascular niches that have functionally redundant 
roles in the maintenance of HSCs.  B) Another possibility is that these niches are 
spatially and functionally distinct, regulating HSCs in different ways. Although it has 
been hypothesized that ‘activated’ HSCs localize to vascular niches there is no evidence 
to support this possibility at present as the HSCs identified using Signalling lymphocyte 
activation molecule (SLAM) markers (that are frequently observed adjacent to sinusoids) 
include few dividing cells (Kiel and Morrison, 2006).  C) Rather than multiple spatially 
distinct niches, it is possible that there is a single niche near the endosteum that is 
regulated by factors secreted by both endosteal and perivascular cells.  D) Finally, it is 
formally possible that there is little spatial specialization within the bone marrow in terms 
of the capacity to maintain HSCs and that much of the bone marrow is close enough to 
endosteal, perivascular, and other cell types to support HSC maintenance. However, the 
observation that HSCs are more likely than other bone marrow cells to localize near 
sinusoids and endosteum argues against this possibility (Kiel et al., 2007; Kiel et al., 
2005). 
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